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GENERAL INTRODUCTION, AIMS AND OUTLINE OF THE THESIS
1
Cognitive impairment and dementia
Dementia is a progressive and irreversible disease in which there is deterioration 
of cognitive function, characterized by memory loss and difficulties with thinking 
and problem-solving, severe enough to interfere with daily functioning. The prevalence 
of dementia is high and as people live longer, the burden of cognitive impairment 
in society becomes increasingly important. In the Netherlands, over 270,000 people 
are currently diagnosed with dementia and this number is expected to be doubled 
within twenty years [1]. Worldwide, around 50 million people have dementia and 
this number is projected to reach over 150 million in 2050 [2]. Thus, dementia 
presents society with a major health problem, and therefore, a better understanding 
of underlying mechanisms is of utmost importance and may eventually lead to 
personalized treatment of cognitive impairment and dementia. 
Cerebral small vessel disease
Cerebral small vessel disease (SVD) has been recognized as the most important 
vascular contributor to cognitive decline and the development of dementia [3, 4], 
and will be the topic of this thesis. SVD refers to a variety of pathological processes 
affecting the smallest cerebral blood vessels. Since in vivo assessment of these small 
vessels is not yet possible with conventional neuroimaging techniques, SVD is usually 
operationalized as a spectrum of radiological manifestations that are thought to 
result from SVD. These neuroimaging markers include white matter hyperintensities 
(WMH), lacunes and cerebral microbleeds (Box 1) [5], and are present in virtually 
every individual over 60 years of age, although at a highly variable degree [6, 7]. 
Temporal dynamics of cerebral small vessel disease
We can only start to understand the complexity of underlying mechanisms and 
consequences of SVD if we have proper understanding of the time course of the 
disease. Progression of SVD has been extensively studied over the years, however, 
studies investigating SVD progression have usually operationalized the change in 
SVD markers over time with the aid of neuroimaging at two time points. 
Consequently, SVD progression is usually considered a continuous process that 
linearly progresses over time, without actual proof of this assumption. In this 
thesis, I will elaborate on the dynamics of SVD progression over time using 
repeated neuroimaging assessments at three time points, further challenging the 
assumption of a continuous progressive nature of SVD markers. 
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Thus far, studies on SVD have mainly used conventional MRI, thereby visualizing 
only the tip of the “SVD” iceberg, since pathological changes of the white matter 
are not only limited to SVD visible on conventional MRI but may also occur in 
the normal appearing white matter (NAWM). More advanced neuroimaging 
techniques such as diffusion tensor imaging (DTI) can possibly provide additional 
information on the underlying mechanisms of SVD – i.e. before they become 
visible on conventional imaging – by the assessment of the microstructural 
organization of the white matter (Box 2) [27-30]. Previous studies have shown 
associations between changes in baseline DTI parameters – i.e. increased mean 
diffusivity (MD) and decreased fractional anisotropy (FA) – and WMH progression 
[31, 32]. However, the temporal course of DTI changes in NAWM regions later 
converting into WMH remains to be elucidated. 
The etiology of cerebral small vessel disease
The most common causes of SVD are hypertension and cerebral amyloid angiopathy 
(CAA) [8]. Hypertension causes arteriopathy that predominantly affects small 
perforating end-arteries in deep brain areas, whereas CAA is characterized by the 
deposition of amyloid beta (Aβ) within cortical arteries [9-13]. In parallel with this 
distribution of the underlying pathology, hypertensive arteriopathy is commonly 
associated with microbleeds in deep brain regions (e.g. basal ganglia, thalamus, and 
brainstem), whereas CAA is characterized by (micro)bleeds in a lobar distribution. 
Apart from hypertension, other major risk factors for SVD include aging and the 
presence of vascular risk factors. The presence of vascular risk factors has been 
associated with cognitive decline and dementia as well [14, 15]. Hypertension [16, 
17], diabetes mellitus [18], hypercholesterolemia [19, 20], obesity [21, 22], smoking 
[23], and lack of physical exercise [24-26] have all been related to an increased risk 
of cognitive impairment and dementia.  Yet, the underlying mechanisms of SVD 
and its progression remain poorly understood. In this thesis, I will use more 
advanced neuroimaging techniques and biomarkers in blood to further elaborate 
on the underlying mechanisms of SVD.
Box 1  Neuroimaging markers of cerebral small vessel disease
Neuroimaging markers of cerebral small vessel disease include white matter hyper-
intensities (WMH), lacunes and microbleeds. WMH are signal abnormalities in the white 
matter that appear as hyperintensities on fluid-attenuated inversion recovery (FLAIR) 
T2-weighted images. Lacunes of presumed vascular origin are cavities filled with 
cerebrospinal fluid (CSF), visible as round or ovoid subcortical hypointense areas of 
between 3 and 15 mm on FLAIR T2-weighted images. Microbleeds are defined as small 
hypointense areas of between 2 and 10 mm on T2*-weighted images.
Box 2  Microstructural integrity
Diffusion tensor imaging (DTI) is an imaging technique based on the diffusion of water 
molecules. In a free space (e.g. in the cerebrospinal fluid and to a lesser extent in the gray 
matter), diffusion of water molecules occurs randomly in a spherically symmetric 
pattern, which is also called isotropic diffusion. When the diffusion of water molecules 
is restricted by anatomical boundaries, the diffusion will be anisotropic instead of 
spherically symmetric. This is the case in the white matter, where diffusion of water 
molecules is restricted by axonal bundles and will occur along the direction of the white 
matter tracts. Hence, DTI theoretically provides information on the microstructural 
integrity of the white matter. Two important measures obtained from DTI are Mean 
diffusivity (MD), reflecting the overall magnitude of the diffusion, and fractional 
anisotropy (FA), reflecting the directionality of the diffusion. Damage to the white 
matter can lead to less anisotropic diffusion, which is typically reflected by an increase 
in MD and a decrease in FA [29, 30].
White matter hyperintensities Lacunes Microbleeds
CSF & Gray matter: 
Isotropic diﬀusion
White matter: 
Anisotropic diﬀusion
White matter damage: 
Less anisotropic diﬀusion
MD 
MD
FA & FA
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In addition to neuroimaging markers, perhaps biomarkers in blood, that reflect 
the SVD pathology, can also reveal insights on the etiology of SVD. Along with 
traditional vascular risk factors such as hypertension, Aβ has emerged as 
contributor to SVD. Aβ has previously been associated with AD and CAA, albeit in 
different forms. In Alzheimer’s Disease (AD), Aβ accumulates in the brain as senile 
plaques, predominantly composed of Aβ42 peptides. This is in contrast to CAA in 
which Aβ accumulates in the blood vessels, mostly composed of Aβ40 peptides. 
Several cross-sectional studies have suggested a role for circulating Aβ in SVD, 
reporting elevated plasma Aβ levels in participants with SVD [33-36]. However, 
since cross-sectional studies are limited in elaborating on causality, prospective 
studies are required to provide more insights on temporal precedence in the 
associations between plasma Aβ levels and SVD. In addition, neurofilament light 
chain (NfL) might provide additional information on the pathophysiological 
mechanisms of SVD, since NfL is an emerging blood marker for neuroaxonal 
damage. A role of serum NfL has been established in multiple neurological diseases 
affecting the elderly population, such as multiple sclerosis [37] and neurodegenerative 
disorders [38], including AD [39] and frontotemporal dementia [40]. However, 
a detailed account of the relationship between NfL in the blood and SVD burden 
and is lacking.
Cognitive consequences of cerebral small vessel disease
SVD has been associated with the development of cognitive impairment and 
dementia [3, 4, 41], as well as with gait impairment and an increased risk of 
parkinsonism [42], stroke [43], admission to a nursing home and even with an 
increased risk of mortality [44]. However, clinical symptoms in patients with a 
virtually identical SVD burden are often remarkably heterogeneous, both in 
nature and severity. Where SVD goes clinically unnoticed in the majority of 
patients, it leads to major cognitive deficits or dementia in others. In addition, the 
spectrum of cognitive symptoms attributable to SVD is more diverse than 
previously thought. SVD has previously mainly been associated with deficits in 
psychomotor speed and executive function [3, 43], but nowadays deficits in 
memory, attention, language and visuospatial abilities are also considered 
cognitive consequences of SVD [45, 46]. However, episodic memory deficits are not 
well understood by the location of SVD, since episodic memory performance is 
mainly supported by structures in the medial temporal lobes and especially the 
hippocampus [47, 48], which are typically unaffected by SVD [49]. Consequently, 
better understanding of the mechanisms by which SVD leads to cognitive deficits 
is needed. 
Box 3  Brain network characteristics and rich club organization
The connectivity of a brain network can be explored using graph theory, which conceptualizes 
the brain as a network with connections that mediate the interaction between brain regions 
[50, 51]. Figure A shows a schematic illustration of a structural brain network, consisting of 
nodes (brain regions) linked by edges (the connections between nodes). Several network 
measures of brain connectivity were calculated from these structural networks using the 
Brain Connectivity Toolbox [52], providing information on the organization and properties of 
these networks. These measures included: B) Network density, defined as the ratio between the 
number of existing connections and the total number of possible connections in a network; 
C) Node degree, representing the number of connections that link a node to the rest of the 
network; D) Node strength, representing the strength of the connections of a node. The total 
network strength is computed as the sum of all connection strengths in a network; E) Path 
length, defined as the shortest distance or minimum number of connections between two 
nodes. The global network efficiency is inversely related to the path length, reflected by the 
average efficiency for all nodes. Figure F shows the rich club organization of the network, 
referring to the presence of nodes that are both highly connected to the network and highly 
interconnected with each other, hence called rich clubs [55, 56]. Connections between the rich 
club nodes are referred to as rich club connections and are considered to play an important 
part in the integration of information. Connections to the rich club nodes are referred to 
as feeder connections and connections between the non-rich club nodes as peripheral 
connections.
Rich club connections
Feeder connections
Peripheral connections
Rich club
Non-rich club
Edge
Node
Node degree
Node strength Path length
Density
A. B. C.
D. E. F.
Rich club organization
Structural network
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Additional insights into the mechanisms by which SVD leads to cognitive deficits 
might be gained by taking into account remote effects of SVD, the interaction of 
SVD markers with hallmarks of AD and disruptions in network connectivity. The 
temporal interactions between SVD markers and hippocampal atrophy – either as 
a remote effect of SVD or a hallmark of AD – and their effect on cognitive decline, 
can be investigated using advanced statistical models. In addition, structural 
networks, constructed with the use of DTI (Box 3) [50-52], provide a measure of 
whole brain connectivity which might drive the associations between SVD and 
cognitive performance [53, 54]. Especially a set of centrally located and highly 
interconnected regions – also called rich clubs – are thought to play a pivotal role 
in maintaining global network function [55, 56]. In other words, due to their 
central role in brain networks and high connectivity with other nodes, damage to 
rich clubs or rich club connections might have a more widespread effect on 
network function compared with damage to peripheral nodes or peripheral 
connections in a network (Box 3, Figure F). Earlier cross-sectional studies in SVD 
have shown that SVD affects preferentially these rich club connections, thereby 
leading to cognitive impairment [57, 58]. The question remains how SVD affects 
progression of brain network impairments over time and whether this affects the 
rate of cognitive decline. Therefore, prospective studies are required to assess the 
temporal dynamics and the directionality of events.
Aim of this thesis and study design
The aim of this thesis is to gain insights into the time course, the etiology and the 
cognitive consequences of SVD. The studies presented in this thesis are based on 
the RUN DMC study, a prospective cohort study on the risk factors and clinical 
consequences of SVD in elderly with SVD using three neuroimaging and cognitive 
assessments over nine years (Box 4).
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Outline of this thesis
In Part II of this thesis, I will start with describing how SVD changes over time. 
In Chapter 2, I will review evidence on progression and regression of SVD markers 
from the existing literature and in Chapter 3 I will describe the temporal dynamics 
of SVD within the RUN DMC study. 
In Part III, I will use the insights on the time course of SVD to elaborate on the 
underlying mechanisms of SVD and its progression. I will start with describing 
changes in microstructural integrity preceding progression of white matter 
hyper intensities (Chapter 4). Thereafter, I will examine how amyloid beta levels in 
plasma are associated with severity and progression of SVD markers (Chapter 5). 
Additionally, I will assess the associations between neurofilament light chain levels 
in serum with severity (Chapter 6) and progression (Chapter 7) of SVD markers.
In part IV, I will elaborate on cognitive consequences of SVD. I will first provide 
a framework of mechanisms by which SVD can lead to clinical symptoms (Chapter 8). 
In Chapter 9, I will describe the cognitive consequences of regression of SVD 
markers over time. Thereafter, in Chapter 10, I will elaborate on the interaction of 
white matter hyperintensities with hippocampal atrophy and how this explains 
memory decline in elderly with SVD. In Chapter 11, I will investigate whether 
changes in rich club organization over time are associated with cognitive decline.
Finally, in Part V, I will summarize the main results of this thesis (Chapter 12) and 
will provide a discussion (Chapter 13) with general interpretation and clinical 
implications of these findings, together with some methodological considerations 
and future perspectives. 
Part II
Temporal dynamics of 
cerebral small vessel disease
Chapter 2
Disease progression and regression 
in cerebral small vessel disease
Published as:
van Leijsen EMC, de Leeuw FE, Tuladhar AM
Disease progression and regression in sporadic small vessel disease  
- insights from neuroimaging 
Clinical Science. 2017;131(12):1191-1206
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Introduction
Markers of cerebral small vessel disease (SVD) include, amongst others, white matter 
hyperintensities (WMH), lacunes of presumed vascular origin and microbleeds [5] 
and are present on neuroimaging in virtually every individual over 60 years of age 
[6], although in highly variable degree. SVD is considered the most important 
vascular contributor to the development of cognitive impairment and dementia 
[3, 4, 41], and is associated with an increased risk of stroke [43], admission to a 
nursing home and even with an increased risk of mortality [44]. 
Progression of SVD has been studied extensively over the years, usually by opera-
tionalizing the change in SVD markers over time with the aid of neuroimaging at 
two time points. Consequently, SVD progression is usually expressed as volume 
change or incidence per year, assuming rather linear, continuous progression 
over time.  More recently also a decrease in WMH volume [28, 59-62], number of 
lacunes [63, 64] and microbleeds over time [65, 66] has been reported, challenging 
the assumption of a continuous progressive nature of SVD markers. 
Comprehensive characterization of the time course of disease progression will 
result in better understanding of underlying mechanisms and clinical consequences 
of SVD. This might be particularly valuable in clinical trials that use SVD markers 
as outcome measure and as such may in time lead to personalized treatment 
approaches. It remains to be established whether progression is interrupted by 
regression or whether progression and regression occur in identifiable phases or 
simultaneously in different brain regions.
In this opinion review, we will summarize evidence on the progression and 
regression of SVD markers based on data from longitudinal neuroimaging studies, 
with an emphasis on WMH, lacunes and microbleeds. By reviewing studies on 
SVD progression we combine evidence on the time course of progression of various 
SVD markers over multiple time points in different cohorts. We will elaborate on 
the time course of SVD and discuss possible mechanisms and clinical implications 
of a dynamic time course of SVD.
Literature search
We identified articles by searching PubMed using the search terms as described in 
the Appendix to cover three main SVD markers: WMH, lacunes and microbleeds. 
We limited the search to full-text manuscripts published in English from January 
1st 1990 to October 10th 2016. We included serial magnetic resonance imaging 
studies (i.e. studies with at least two time points) on sporadic SVD in participants 
Abstract
Cerebral small vessel disease (SVD) is considered the most important vascular 
contributor to the development of dementia. Comprehensive characterization of 
the time course of disease progression will result in better understanding of 
etiology and clinical consequences of SVD. SVD progression has been studied 
extensively over the years, usually describing change in SVD markers over time 
using neuroimaging at two time points. As a consequence, SVD is usually seen as 
a rather linear, continuously progressive process. This assumption of continuous 
progression of SVD markers was recently challenged by several studies that showed 
regression of SVD markers. Here we provide a review on disease progression in 
sporadic SVD, thereby taking into account both progression and regression of SVD 
markers with emphasis on white matter hyperintensities, lacunes and microbleeds. 
We will elaborate on temporal dynamics of SVD progression and discuss the view 
of SVD progression as a dynamic process, rather than the traditional view of SVD as a 
continuous progressive process, that might better fit evidence from longitudinal 
neuroimaging studies. We will discuss possible mechanisms and clinical implications 
of a dynamic time course of SVD, with both progression and regression of SVD 
markers.
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25-fold across studies between 0.4 and 9.5 percent per year [60, 64, 67, 68, 71, 73, 
81, 83, 101, 102, 110, 118-122], with higher incidence in hospital-based cohorts 
(Table 2). The Age, Gene/Environment Susceptibility-Reykjavik Study, a large 
 population-based study, reported a yearly incidence of lacunes of 0.8% [102]. 
The Rotterdam Scan Study [60] and the Cardiovascular Health Study [87] reported 
higher incidence (3.5% and 2.9% per year, respectively). Incidence of lacunes was 
higher in the hospital-based LADIS and SCANS studies, reporting incidence of 
5.8% of 9.5% per year respectively [68, 119], probably due to the high proportion 
of participants with lacunes at baseline. In the RUN DMC study, 20.3% of the 
participants had incident lacunes over the course of nine years (2.3% per year) [110].
Predictors for incident lacunes were severity of WMH and presence of lacunes at 
baseline [119], history of stroke, atrial fibrillation and carotid atherosclerosis and 
presence of vascular risk factors such as hypertension and hypercholesterolemia 
[60, 81, 119, 121]. Incident lacunes were predominantly located in brain regions 
with contact or partial overlap with pre-existing WMH, suggesting that especially 
tissue adjacent to WMH is susceptible to further ischemia [123].
  
Incidence of microbleeds 
The yearly incidence of microbleeds ranged between 2.9 and 3.5 percent in popu-
lation-based studies and between 2.2 and 31.5 percent in hospital-based studies 
[65-67, 78, 85, 102, 110, 124-134] (Table 3). In participants with intracerebral 
hemorrhages or CAA the incidence was up to 41.8% per year [72, 135-137]. In the 
RUN DMC study, yearly incidence of microbleeds was 2.2% per year [110].
Major predictors for microbleeds incidence were age and presence of SVD at 
baseline: in the Rotterdam Study incidence was 7.6% in subjects aged 60 to 69 years, 
15.6% in those between 70 and 79 years, and 18.6% in subjects older than 80 years 
[132]. Subjects with microbleeds at baseline had higher risk for incident micro- 
bleeds as compared with participants without microbleeds at baseline [65]. 
Besides the number of microbleeds at baseline, presence of lacunes and baseline 
WMH severity also predicted incident microbleeds [78]. In addition, APOE genotype 
and vascular risk factors (i.e. smoking and blood pressure) were predictors of 
incident microbleeds [78]. Predictors of microbleeds differed across brain regions, 
suggesting differences in etiology for deep versus lobar microbleeds [9, 138]. 
Deep microbleeds were associated with cardiovascular risk factors such as hyper- 
tension and smoking [9] and therefore considered to be due to hypertensive 
arteriopathy. In contrast, lobar microbleeds are considered to be due to cerebral 
amyloid angiopathy (CAA), because of their association with known risk factors for 
CAA including APOE ε4 genotype [9, 139]. 
above the age of 50 years examining change of these markers over time. We also 
searched reference lists of identified papers for further relevant articles.
The search strategy yielded 204 articles for WMH, 194 articles for lacunes and 
167 articles for microbleeds. After screening the titles and abstracts and adding 
relevant literature from reference lists 74 articles (not mutually exclusive) fulfilled 
the inclusion criteria: 49 articles for WMH, 16 for lacunes and 22 for microbleeds 
(Flowchart in the Supplementary material).
Progression of SVD markers
Data on progression of SVD markers over time come from 41 hospital-based and 
30 population-based studies. We will discuss the findings from longitudinal neuro- 
imaging studies describing progression of WMH, lacunes and microbleeds over time.
WMH progression
Both population-based and hospital-based studies have shown that WMH volume 
increases over time, although the range of WMH progression of varies considerably 
across the studies (Table 1). Average increase of WMH volume varied over 20-fold, 
ranging between 0.1 and 2.2 ml/yr, depending on the study population [32, 59-62, 
67-110]. The range of WMH progression did not differ between population-based 
and hospital-based cohorts (Table 1), probably due to heterogeneity within these 
cohorts.
Predictors of WMH progression were age, baseline WMH severity, hypertension and 
current smoking [3, 60, 62, 94, 97, 111-115]. For example, the Rotterdam Study 
reported more WMH progression in the strata of higher age [60] and participants 
with uncontrolled untreated hypertension showed more WMH progression than 
people with uncontrolled, but treated hypertension [114]. Moreover, the Austrian 
Stroke Prevention Study reported an annual increase in WMH volume of 1.3 ml per 
year in those with confluent lesions and almost no progression in participants with 
punctuate lesions [97]. In the RUN DMC study, participants with moderate or severe 
WMH at baseline had a high likelihood of progression of their WMH, whereas 
participants with only mild WMH did not show progression, not even over a period 
of nine years [110]. Finally, the WMH penumbra - a region surrounding the WMH 
composed of normal appearing white matter but with lower structural integrity - 
has been reported to be at increased risk of becoming WMH over time [116, 117]. 
Incidence of lacunes
The incidence of lacunes varied notably between different hospital- and population- 
based studies. The proportion of participants with incident lacunes varied almost 
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Table 1  Characteristics of longitudinal changes of WMH by study population
Ref Population n (%) Age FU 
time
Nr of 
scans
Field 
strength
Identical MRI 
B & FU?
WMH  
assessment
Progression  
of WMH*
Regression  
of WMH**
Hospital-based studies
SVD
[110] SVD (RUN DMC) 276 (54.9%) 62.5 ± 7.7 8.7 3 1.5T No; FLAIR 
voxel size 
adjusted 
Semiautomated volumetrics - FLAIR/T1; 
FU FLAIR sequence resliced to B FLAIR
+0.54 ml/y 9.4 %; 
-0.1 ml/y ‡
[81]
[96]
[82]
SVD (LADIS)  (multicentre) 396 (62.0%)
394 (61.7%)
20 (3.1%)
73.6 ± 5.0
73.1 ± 5.0
74 ± 5
3.1
3
2.1
2
2
2
1.5 /
0.5T
1.5T
No; new MRI 
in 3 centers
Yes
Modified Rotterdam Progression scale - FLAIR
Modified Rotterdam Progression scale - FLAIR
Semiautomated volumetrics - FLAIR
VS
VS
+2.2 ml/y
-
- 
US
[100] Vascular disease (PROSPER) (multicentre) 554 (85.8%) 75.0 ± 3.2 2.8 2 1.5T Yes Semiautomated volumetrics - FLAIR +0.3 ml/y -
[79] SVD 88 (72.7%) 52 ± 8.5 2 2 1.5T Yes Automated volumetrics - FLAIR +0.2 ml/y -0.02 ml/y
Stroke
[68] Lacunar stroke (SCANS) 99 (81.8%) 70 ± 9.8 3 2-4 1.5T Yes Automated volumetrics - FLAIR +0.8 %/y † -
[59] Ischemic stroke 100 (100%) 67.5 ± 11.8 2.3 2 Yes Semiautomated volumetrics - FLAIR or T2 27%; 
+1.4 ml/y ‡ 
22%; 
-0.3 ml/y ‡
[75] Stroke or TIA (PROGRESS) (multicentre) 192 (85.3%) 60.8 ± 12.2 3 2 1.0 / 1.5T Yes Modified Scheltens scale - T2 +0.1 ml/y -
[71] Stroke or TIA (VITATOPS) (multicentre) 359 (76.2%) 64.3 ± 12.7 2.1 2 1.5T Yes Semiautomated volumetrics - FLAIR/T2 +0.05 ml/y ‡ -
[85] Stroke patients (CASISP) (multicentre) 584 (81.1%) 59.7 ± 9.8 1.2‡ 2 1.5T Yes ARWMC scale - FLAIR/T2 VS -
[88] Lacunar stroke (multicentre) 118 (42.0%) 63 ± 12 2 2 1.5 / 3.0T No; 3.0 to 1.5T 
& 1.5 to 3.0T
Modified Rotterdam Progression scale - FLAIR;
5 participants B 1.5T to FU 3.0T excluded
VS -
[105] Lacunar stroke 70 (72.2%) 68 ± 11 3.3 2 1.5T Yes Multispectral image analysis - FLAIR/T1/T2* +1.0 ml/y ‡ -
[69] Stroke patients (CATCH) 40 (71.4%) 61 ± 11 1.5 2 3.0T Yes Visual ROI comparisons - FLAIR +1.9 ml/y -
Memory clinic
[61] Memory clinic (Sunnybrook Dementia) 57
56
44
74.3 ± 8.3
67.9 ± 8.0
69.4 ± 7.0
1.7
1.8
2.0
2 1.5T Yes Semiautomated volumetrics - T1/PD/T2 AD +SVD: +1.0 ml/y
AD -SVD: +0.2 ml/y
Controls: +0.4 ml/y
US
[86] Memory clinic (ADNI) (multicentre) 193
397
229
74.6 ± 7.5
74.0 ± 7.5
75.1 ± 5.0
1.8
2.7
3.2
2 1.5T Yes Automated volumetrics - T1/T2/PD AD: +7.4 ˆ
MCI: +7.6 ˆ
NC: +4.9 ˆ
-
[89] Memory clinic 7
47
96
79.2 ± 3.5
75.7 ± 6.8
74.0 ± 7.0
3.7
3.5
4.3
2 1.5T Yes Semiautomated volumetrics - FLAIR/T1 AD: +1.6 ml/y
MCI: +1.7 ml/y
Controls: +0.7 ml/y
-
[32] Memory clinic 13
34
72
76.4 ± 8.7
74.7 ± 8.6
74.2 ± 6.6
3.3
2.9
4.1
2 1.5T Yes Semiautomated volumetrics - FLAIR/T1 AD: +1.2 ml/y
MCI: +0.5 ml/y
Controls: +0.4 ml/y
-
[78] Memory clinic 254 66 ± 10 1.9 2 1.0T Yes Modified Rotterdam Progression scale - T2* VS -
Other
[83] Atherosclerosis (SMART-MR) 565 (43.2%) 57 ± 9 3.9 2 1.5T Yes Automated volumetrics - FLAIR/T1 +0.6 ml/y ‡ -
[92] Artery stenosis (ROCAS) 208 (91.6%) 61 ± 9 2 2 1.5T Yes Semiautomated volumetrics - T1/PD/T2 +0.2 ml/y ‡ -
[101] Diabetes type 2 190 (86.8%) 62.7 ± 8.1 6 3 1.5T Yes Modified Rotterdam Progression scale - FLAIR VS -
[72] CAA patients 26 (36.6%) 69.1 ± 6.5 1.1‡ 2 1.5T Yes Semiautomated volumetrics - FLAIR or T2 +0.5 ml/y ‡ -
[76] Migraine patients 17 47.0 ± 11.2 3 2 3.0T Yes 3D slicer - FLAIR/T2/T1 +0.1 ml/y ‡ US
[95] Cirrhosis patients 19 (63.3%) 60 ± 9 0.8 2 1.5T Yes Semiautomated volumetrics - T2/FLAIR/T1 -0.6 ml ‡° -0.6 ml ‡°
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Table 1  Continued
Ref Population n (%) Age FU 
time
Nr of 
scans
Field 
strength
Identical MRI 
B & FU?
WMH  
assessment
Progression  
of WMH*
Regression  
of WMH**
Population-based studies
[67]
[60]
[94]
Population-based (Rotterdam Scan) 803 (75.6%)
668 (62.0%)
20
68.3 ± 6.2
71 ± 7
72
3.4
3.4
3.3
2
2
2
1.5T Yes
Yes
Yes
Automated volumetrics - T2/PD
Rotterdam Progression scale - T2/PD
Automated volumetrics - PD
+0.18 ml/y ‡
VS
+0.57 ml/y
-
US 
US 
[97, 
109]
Population-based (ASPS) 243 (47.7%) 60.2 ± 6.3 6.0 3 1.5T Yes Semiautomated volumetrics - PD +0.2 ml/y US
[87] Population-based (CHS) (multicentre) 1919 (32.6%) 74.0 5 2 1.5 / 0.35T Yes CHS scoring - PD VS -
[102] Population-based (AGES-Reykjavik) 1949  (33.3%) 74.6 ± 4.6 5.2 2 1.5T Yes Automated volumetrics - PD/T2/FLAIR/T1 +1.2 ml/y -
[107] Population-based 67 (57.3%) 81.7 ± 3.9 4.0 2 3.0T Yes Semiautomated volumetrics - FLAIR/T1 +0.2 %/y † -
[73, 
80]
Population-based (ARIC) (multicentre) 983 (50.4%) 61 ± 4 11‡ 2 1.5T Yes Semiautomated volumetrics  - FLAIR +0.5 ml/y -
[90] Population-based (3C) (multicentre) 1118 (62.1%) 72.0 ± 4.0 3.6 2 1.5T Yes Automated volumetrics - T2 +0.25 ml/y US
[74] Population-based (Framingham Heart) 1352 (26.4%) 54 ± 9 5 2 1.0 / 1.5T No; 1.0 or 1.5T Semiautomated volumetrics - T2 +0.2 ml/y -
[62] Population-based (Sydney Stroke) 51 (63.8%) 71.0 ± 5.9 3 2 1.5T Yes Semiautomated volumetrics - FLAIR +2.2 ml/y US
[106] Population-based 70 (50.7%) 79 4 2 1.5T Yes Manual grid volumetrics - T2 +0.27 ml/y 23 %
[91] Population-based (NCODE) 110 (79.9%) 70.7 ± 5.6 2.0 2 1.5T Yes Semiautomated volumetrics - T2/PD +0.6 ml/y -
[98] Population-based (OBAS) 104 85.1 ± 5.6 4.6 ≥3 1.5T Yes Semiautomated volumetrics - PD/T2 +1.0 ml/y -
[99] Population-based 117 69.1 ± 6.2 2.1 2 1.5T Yes Semiautomated volumetrics - PD +0.7 ml/y -
[93] Population-based 250 (85.0%) 84.4 ± 2.5 4 2 3.0T Yes Automated volumetrics - T1 +1.0 ml/y -
[70] Population-based (WHICAP) 303 (39.4%) 79.2 ± 5.3 4.6 2 1.5T Yes Semiautomated volumetrics - FLAIR +0.2 ml/y -
[108] Population-based 210 (71.9%) 70.9 ± 0.9 4 2 0.5T Yes Visual rating scale - FLAIR VS -
[84] Population-based 50 73.9 ± 6.6 3.7 2 1.5T Yes Semiautomated volumetrics - T2 +0.6 ml/y -
[77] Population-based (1914 cohort) 26 (3.7%) 80.7 ± 0.4 3.6 2 1.5T Yes Automated volumetrics - PD/T2 +1.3 ml/y -
[103] Population-based 14 (23.7%) 76 ± 5 2 2 0.6T Yes Scheltens scale - T2 VS 14 %
[104] Population-based 13 (56.5%) 79 5 2 0.02/ 0.5T No; 0.02 to 0.5T Scheltens scale - T2 VS -
Studies describing change in WMH volume over time, subdivided into hospital-based, population-based 
and case studies. *WMH progression is presented as the annual unadjusted change and expressed as 
mean volume change in ml/year. **If studies mentioned regression of WMH volume, it is reported in this 
column. When available, the percentage of the study population with WMH regression and volume of 
WMH decrease in ml/year are also reported. FU: mean follow-up duration in years; N: number of participants 
with available imaging data during the entire follow-up; Age: mean age at baseline in years; VS: Visual 
scale score: no quantitative WMH volume assessments available; US: unspecified; ‡ Median follow-up 
duration reported or median WMH volume change reported in ml/year; † WMH volume change is 
expressed as %TBV/year; ˆ  10-3 log-transformed volume/month; ° WMH volume change is expressed in ml 
and is not extrapolated to ml/year.
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WMH volume [28], which might be the reason that WMH regression is more often 
observed in stroke patients. This hypothesis is confirmed by Yao and colleagues 
who found that in patients with CADASIL new WMH were associated with subtle 
increased brain volume [142]. Fourth, factors influencing the blood-brain barrier 
might play a role in reducing WMH volume [28, 59]. After acute infarction the 
blood-brain barrier might be disturbed, causing leakage of cerebral fluid into the 
white matter, which might recover afterward [140, 141].
Vanishing lacunes
Only two studies reported a decrease in number of lacunes [64, 110]. On follow-up 
imaging in lacunar stroke patients, 94% of the lacunes visible at baseline imaging 
were completely or incompletely cavitated, most had reduction in diameter, and 
5 lacunes (6%) were not visible anymore. In the RUN DMC study cohort, 15 lacunes 
disappeared in 10 participants (3.6% of the total population that underwent 
follow-up imaging) over the course of nine years [110]. 
There might be several explanations for vanishing lacunes. It is possible that the 
brain tissue recovered after an acute lacunar infarction, without the formation of 
a lacune. Besides, it can be that lacunes are either collapsed into small lacunes 
that can be missed by brain imaging [64] or became incorporated into the ventricles. 
Also, since some primary studies were performed before the STRIVE criteria [5] 
were developed and reported, it is also possible that some lacunes were confused 
with enlarged perivascular spaces. Further, it is also possible that due to partial 
volume effects lacunes can be rated at baseline imaging but are not visible at 
follow-up imaging anymore.
Vanishing microbleeds
Although numerous studies have reported incident microbleeds over time, there 
are also some reports of a decrease in the number of microbleeds [65, 66, 78, 129, 
130]. However, most of these studies classified participants with vanishing micro- 
bleeds as “no incident microbleeds” [65, 78, 130] or mentioned less microbleeds 
at follow-up without further comment [129]. A study in patients with stroke 
or transient ischemic attack mentioned a decrease in number of microbleeds in 
14.5% of the patients and reported a dynamic temporal change of microbleeds 
during follow-up [66]. In the RUN DMC study, 42 microbleeds vanished in 16 
participants (6.1%) over the time course of nine years [110]. 
Vanishing SVD
Many studies have described overall net progression of SVD markers over time, 
but some studies also reported regression or vanishing of SVD markers over time. 
All longitudinal neuroimaging studies reporting regression of SVD markers are 
summarized in Table 1 for WMH, Table 2 for lacunes and Table 3 for microbleeds. 
We will discuss vanishing SVD for WMH, lacunes and microbleeds separately.
WMH regression
Some longitudinal population studies [28, 59-62, 82, 90, 94, 95, 97, 106, 109] 
reported regression of WMH in some participants, but reported negative volume 
changes without further comment [82, 94], attributed the reduction in WMH 
volume to measurement error or variability [62, 90, 97, 106, 109], or classified it as 
“no progression” without further explanation [60]. A recent longitudinal imaging 
study performed in a memory clinic population described progression, regression 
and stable WMH simultaneously in different brain regions in healthy elderly and 
Alzheimer’s Dementia patients [61]. Two other studies reported WMH regression 
in stroke populations: Wardlaw and colleagues noted reductions in WMH volume 
a year after stroke in a third of 200 patients with minor stroke [28] and a recent 
serial MRI study performed on ischemic stroke patients demonstrated both 
progression and regression, with WMH regression observed in 21.5% of stroke 
patients [59], mainly in per ventricular white matter, posterior horn, frontal sub 
cortical or parietal sub cortical areas. In the RUN DMC study decline in WMH 
volume was observed in 9.4% of the participants with symptomatic SVD [110]. 
Maillard and colleagues reported decrease in FLAIR signal intensity over time in 
areas of stagnant WMH [117], providing further evidence for regression of WMH. 
Significant WMH regression has also been demonstrated in case-studies reporting 
regression of WMH volume one year after cerebral infarction [140] or lacunar 
stroke [141].
The observed reductions in WMH volume may have several explanations: 
methodological, radiological or biological. First, WMH regression could be missed 
when using two neuroimaging assessments with a long interval: WMH decline 
within a certain time window can be compensated by WMH progression thereafter 
(or vice versa) in a cohort that on average showed progression. Second, it might be 
that changes in WMH volume could in part be explained by partial volume effects, 
leading to less accurate WMH volume estimations. Third, since the signal change 
on T2 or FLAIR is not just due to permanent myelin loss or axonal damage but may 
also be due to (reversible) shifts in water content [28], WMH can reduce or disappear 
on follow-up imaging. Recently developed WMH might also include areas of tissue 
edema and reduction in tissue edema at a later stage could then lead to reduced 
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Table 2  Characteristics of longitudinal changes of lacunes by study population
Ref Population n (%) Age FU 
time
Nr of 
scans
Field 
strength
Identical MRI   
B & FU?
Assessment  
of lacunes
Incident  
lacunes*
Vanishing 
lacunes**
Hospital-based studies
SVD
[110] SVD (RUN DMC) 276 (54.9%) 62.5 ± 7.7 8.7 3 1.5T No; FLAIR voxel 
size adjusted
STRIVE – Manually rated on FLAIR/T1;
FU FLAIR sequence resliced to B FLAIR
2.3 %/y 0.4 %/y
[81]
[119]
[120]
SVD (LADIS)
(multicentre)
396 (62.0%)
358 (56.0%)
387 (60.6%)
73.6 ± 5.0
74 ± 5
73.1 ± 5.0
3.1
3
3
2
2
2
1.5 / 0.5T No; new MRI in 
3 centers
Manually rated on FLAIR/T1/T2 6.1 %/y
5.8 %/y
6.2 %/y
-
-
-
Stroke
[68] Lacunar stroke (SCANS) 70 (57.9%) 70 ± 9.8 3 2-4 1.5T Yes STRIVE - Manually rated on FLAIR/T1/T2 9.5 %/y -
[71] Stroke or TIA (VITATOPS) (multicentre) 359 (76.2%) 64.3 ± 12.7 2.1 2 1.5T Yes Manually rated 3.3 %/y -
[64] Lacunar stroke 82 (59.4%) 63 ± 11 2.1 2 1.5 / 3.0T Yes Manually rated on FLAIR/T2 US 2.9 %/y
Other
[83] Atherosclerotic disease (SMART-MR) 565 (43.2%) 57 ± 9 3.9 2 1.5T Yes STRIVE – Manually rated on FLAIR/T1 2.2 %/y -
[101] Diabetes type 2 190 (86.8%) 62.7 ± 8.1 6 3 1.5T Yes Manually rated on T2/T1/FLAIR 3.7 %/y -
Population-based studies
[67]
[122]
[60]
Population-based (Rotterdam Scan) 803 (75.6%)
668 (62.0%)
668 (62.0%)
68.3 ± 6.2
71 ± 7
71 ± 7
3.4
3.4
3.4
2
2
2
1.5T Yes Manually rated on FLAIR/PD/T1 0.7 %/y
3.6 %/y
3.5 %/y
-
-
-
[121] Population-based (CHS) (multicentre) 1433 (24.3%) 74 5 2 1.5 / 0.35T Yes Manually rated on T2/T1 2.9 %/y -
[73] Population-based (ARIC) (multicentre) 810 (42.2%) 61.6 ± 4.2 10‡ 2 1.5T No Manually rated on T1/T2/PD;
FU scan best matched to B
1.6 %/y -
[102] Population-based (AGES-Reykjavik) 1949 (33.3%) 74.6 ± 4.6 5.2 2 1.5T Yes Manually rated on FLAIR/T2/PD 0.8 %/y -
[118] Population-based (PATH TLS) 375 (78.6%) 62.6 ± 1.5 4.0 2 1.5T No; new scanner Manually rated on FLAIR/T1 0.4 %/y -
Studies describing change in number of lacunes over time, divided into hospital-based and population- 
based studies. *Incidence of lacunes is expressed as percentage of participants with incident lacunes in 
%/year. **If studies mentioned vanishing lacunes it is reported in this column. When available, the 
proportion of the study population with vanishing lacunes is reported in %/year. FU: mean follow-up 
duration in years; N: number of participants with available imaging data during the entire follow-up; 
Age: mean age at baseline in years; US: unspecified; ‡ Median follow-up duration reported.
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Table 3  Characteristics of longitudinal changes of microbleeds by study population
Ref Population n (%) Age FU 
time
Nr of 
scans
Field 
strength
Identical MRI   
B & FU?
Assessment  
of microbleeds
Incident 
microbleeds*
Vanishing 
microbleeds**
Hospital-based studies
SVD
[110] SVD (RUN DMC) 264 (52.5%) 62.5 ± 7.7 8.7 3 1.5T No; MRI update 
identical T2*
STRIVE – Manually rated on T2* 2.2 %/y 0.7 %/y 
Stroke
[130] Lacunar stroke 96 64.5 ± 11.1 2.1 2 1.5 / 3.0T Yes STRIVE – Manually rated on T2* 8.6 %/y 2.9 %/y
[85] Stroke patients (CASISP) (multicentre) 500 (69.4%) 59.7 ± 9.8 1.2‡ 2 1.5T Yes MARS – Manually rated on T2* 11 %/y -
[131] Stroke patients 204 (73.6%) 68 2 2 1.5T Yes Manually rated on T2* 5 %/y -
[66] Stroke or TIA 224 (37.9%) 64.6 ± 11.3 2.3 2 1.5T Yes Greenberg – Manually rated on T2* 8.0 %/y 6.5 %/y 
[127] Stroke patients 508 (46.4%) 68.9 ± 11.5 3.7 2 1.5T Yes MARS - Manually rated on T2* 7.4 %/y 4.1 %/y
[126] Ischemic stroke 21 (43.8%) 65 ‡ 5.6 2 1.5T Yes MARS – Manually rated on T2* 4.1 %/y US
[128] Acute stroke 237 (13.6%) 64.0 ± 12.8 4 d 2 1.5T Yes Manually rated on T2* 12.7% ° 3 % °
[136] Primary ICH 63 (28.6%) 58.3 1.9‡ 2 1.5T Yes Manually rated on T2* 15.9 %/y ‡ -
[137] ICH patients (DECIPHER) 84 (42.0%) 58.0 ± 13.6 1 3 1.5 / 3.0T No; some on 
other scanner
Manually rated on T2* 33.3 %/y -
[135] Elderly with lobar ICH 34 (36.2%) 71.0 1.3 2 1.5T Yes Greenberg – Manually rated on T2* 38.5 %/y -
Memory clinic
[78] Memory clinic 254 66 ± 10 1.9 2 1.0T Yes Manually rated on T2* 6.3 %/y 1.1 %/y
[129] Memory clinic 26
23
33
78.9
75.5
71.2
1.1
1.1
1.2
2 1.5T Yes Manually rated on SWI MCI / D: 31.5 %/y
MCI: 0 %/y
Controls: 0 %/y
20 %/y
[134] AD, MCI & controls (AIBL) 123 (70.7%) 75 3 3 3.0T Yes Manually rated on SWI 9.7 %/y -
[124] MCI & controls 103 73 4 2-4 1.5T Yes Manually rated on SWI US -
Other
[133] Elderly with AF & controls 77 (31.7%) 69.2 + 9.3 2.6 3-5 1.5T No; 3 scanners Greenberg – Manually rated on T2* 5.5 %/y -
[72] CAA patients 26 (36.6%) 69.1 ± 6.5 1.1‡ 2 1.5T Yes Manually rated on T2* 41.8 %/y ‡ -
Population-based studies
[67]
[65, 
132]
Population-based (Rotterdam Scan) 803 (75.6%)
831
68.3 ± 6.2
68.5 ± 6.3
3.4
3.4
2
2
1.5T Yes Manually rated on T2* 2.9 %/y
3.0 %/y
-
0.2 %/y
[102]
[125]
Population-based (AGES – Reykjavik) 1949 (33.3%)
2635
74.6 ± 4.6
74.6
5.2
5.2
2
2
1.5T Yes Manually rated on T2* 3.4 %/y
3.5 %/y
-
-
Studies describing change in number of microbleeds over time, subdivided into hospital-based and 
population- based studies. *Incidence of microbleeds is expressed as percentage of participants with 
incident microbleeds in %/year. **If studies mentioned vanishing microbleeds it is reported in this 
column. When available, the proportion of the study population with vanishing microbleeds is reported 
in %/year.
FU: mean follow-up duration in years; N: number of participants with available imaging data during the 
entire follow-up; Age: mean age at baseline in years; MB: microbleeds; US: unspecified; d: days; ‡ Median 
follow-up duration reported; ° Incidence is expressed in % and is not extrapolated to %/y.
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likely to be detected using SWI compared to T2* images [145, 146]. Also, smaller 
voxel sizes and slice gaps improve detection of WMH, lacunes and microbleeds, 
due to a reduction of partial volume effects [145]. Therefore, there is a need for 
studies to directly assess the reproducibility of any longitudinal measurement of 
WMH, lacunes or microbleeds. Third, primary studies might be susceptible to bias. 
Dropout rates vary between 30 and 80%, as displayed in Tables 1 to 3. Although 
this is inevitable in longitudinal cohort studies, this attrition bias presumably 
leads to an underestimation of progression rates, since those without follow-up 
were often older with more severe SVD at baseline. Misclassification might also 
have occurred since regression of SVD was previously seen as measurement error. 
Many studies added participants with regression to the groups without progression 
and did not report SVD regression. The regression of SVD markers over time in 
this review might therefore be an underestimation of the true regression. 
Furthermore, the variability in data acquisition of SVD markers may confound 
the detection of MRI changes, thereby limiting the power to detect and follow the 
progression of imaging markers of SVD over time [145].
Due to these limitations, interpretation of results from the primary studies can 
be difficult and caution is warranted when results from the primary studies are 
combined. As most studies used identical MRI protocols at baseline and follow-up 
– or made adequate adjustments for longitudinal assessments – we feel that within 
studies the extent of progression and regression of SVD over time can be reliably 
reported.
Concluding remarks
Although SVD progression was traditionally seen as a continuous progressive 
process, it should rather be seen as a dynamic and highly variable process, 
sometimes with regression of SVD. Where previously regression of SVD markers 
was often attributed to measurement error or classified as ‘no progression’, 
SVD regression might instead be a true phenomenon with clinical implications. 
Further understanding of temporal dynamics of SVD can be obtained by 
performing serial imaging at both more and shorter time intervals. Studies using 
multiple (i.e. three or more) imaging assessments will allow disentangling of 
episodes with regression from those with progression and hence are necessary to 
elaborate on the course of SVD progression. Future studies are required to examine 
the associated factors and clinical significance of dynamical time course of SVD.
Vanishing microbleeds may depend on methodological issues or imaging artefacts 
[78, 130, 143]. It may be the result of a biological process, including physiological 
resorption [78, 129, 130, 143]. The disappearance of microbleeds may also be 
explained by clearance of hemosiderin-containing macrophages, if we consider 
the pathology of microbleeds as hemosiderin pigment accumulations in macrophages 
adjacent to ruptured atherosclerotic microvessels [66, 144].
Clinical implications
SVD is associated with poor clinical outcome. The association between SVD 
severity and progression with cognitive decline and dementia [3, 4, 41], incident 
stroke [43], gait dysfunction [98] and mortality [44] is well established.
If, and how, regression of SVD markers might affect clinical outcome remains to 
be established. There are two hypotheses how SVD regression might affect clinical 
outcome. First, WMH regression might co-occur with atrophy of the white matter, 
leading to impaired clinical outcome. Second, WMH regression might reflect 
resolution of transient white matter damage (i.e. before permanent axonal injury 
or demyelination has occurred), and might therefore account for recovery of clinical 
symptoms [28]. So far, studies on SVD dynamics could not find any significant 
associations between SVD regression and clinical outcome [59, 61]. Further studies 
are required to further explore the clinical significance of vanishing SVD.
Understanding the dynamic nature of SVD may be particularly valuable in clinical 
trials that use change of SVD markers as surrogate endpoints. Future therapeutic 
strategies that target vascular contributions to dementia, such as the use of 
anti- hypertensive treatments, may be particularly interested in dynamics and 
regression of SVD.
Limitations
Several methodological considerations need to be addressed. First, the studies 
included in this review are heterogeneous, as we included all longitudinal 
neuroimaging studies assessing SVD markers over time, irrespective of inclusion 
criteria or neuroimaging methodologies. Note that MRI technique varies largely 
across studies, with magnetic field strengths ranging from 0.02T in early studies 
to 3.0T in more recent studies, and varying voxel sizes and imaging parameters. 
Additionally, different methods for SVD assessment were used including visual 
scales and fully automatic quantitative volume measurements. Second, the repro-
ducibility of SVD markers is a major concern in cross-sectional and longitudinal 
observational studies, especially across centers [145]. For example, quantification 
of SVD markers depends on the choice of MR sequence; microbleeds are more 
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Lacunes
((Lacun* [tiab]) OR (deep infarct* [tiab]) OR (subcortical infarct* [tiab]) OR (deep 
stroke* [tiab]) OR (subcortical stroke* [tiab]) OR (silent stroke* [tiab]) OR (silent brain 
infarct* [tiab]) OR (small vessel infarct* [tiab]) OR (small vessel stroke* [tiab]) OR 
(lacunar stroke* [tiab]) OR (microinfarct* [tiab]) OR (microscopic infarct* [tiab])) 
AND ((cerebral small vessel disease [mh:noexp]) OR (small vessel disease* [tiab]) OR 
(lacun* [ti])) AND (MRI [mh]) AND ((longitudinal studies [mh]) OR (longitudinal* 
[tiab]) OR (follow-up studies [mh]) OR (incidence [mh]) OR (inciden* [tiab]) OR 
(disease progression [mh]) OR (progress* [tiab])) AND (1990/01/01 : 2016/10/10 [dp])
	194 articles
		After screening of titles and abstracts, 24 articles fulfilled  
the inclusion criteria
Microbleeds
((microbleed* [tiab]) OR (microhemorrhag* [tiab]) OR (microhaemorrhag* [tiab]) OR 
((“dot-like” [tiab]) AND (suscept* [tiab] OR hemosid* [tiab]))) AND ((cerebral small vessel 
disease [mh:noexp]) OR (small vessel disease* [tiab]) OR (cerebral hemorrhage [mh]) OR 
(microbleed* [ti])) AND (MRI [mh]) AND ((longitudinal studies [mh]) OR (longitudinal* 
[tiab]) OR (follow-up studies [mh]) OR (incidence [mh]) OR (inciden* [tiab]) OR 
(disease progression [mh]) OR (progress* [tiab])) AND (1990/01/01 : 2016/10/10 [dp])
	167 articles
		After screening of titles and abstracts, 24 articles fulfilled  
the inclusion criteria
Supplementary material 
Literature search methods and terms
We identified articles by searching PubMed using the search terms below to cover 
three main SVD markers: WMH, lacunes and microbleeds. The MeSH terms 
“cerebral small vessel disease” and “MRI” were used to ensure potentially relevant 
articles, and the MeSH terms “lacunar stroke” and “leukoaraiosis” were used 
where relevant. All terms except for “cerebral small vessel disease” were exploded. 
Inclusion criteria were: 1) longitudinal MRI on at least two time points; 2) sporadic 
SVD; 3) elderly above age of 50 years.
The search strategy yielded 204 articles for WMH, 194 articles for lacunes and 167 
articles for microbleeds. After screening the titles and abstracts and adding 
relevant literature from reference lists 71 articles (not mutually exclusive) fulfilled 
the inclusion criteria: 49 articles for WMH, 16 for lacunes and 22 for microbleeds.
The final search terms were as follows:
WMH
((White matter hyperintens* [tiab]) OR (white matter lesion* [tiab]) OR (white matter 
disease*[tiab]) OR (white matter change*[tiab])) AND ((cerebral small vessel disease 
[mh:noexp]) OR (small vessel disease* [tiab]) OR (leukoaraiosis [mh]) OR (leukoaraiosis* 
[tiab])) AND (MRI [mh]) AND ((longitudinal studies [mh]) OR (longitudinal* [tiab]) OR 
(follow-up studies [mh]) OR (incidence [mh]) OR (inciden* [tiab]) OR (disease progression 
[mh]) OR (progress* [tiab])) AND (1990/01/01 : 2016/10/10 [dp])
	204 articles
		After screening of titles and abstracts, 36 articles fulfilled  
the inclusion criteria
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Supplementary Figure  Flowchart of the literature search process
Records identified through 
PubMed search
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(n=204)
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PubMed search
for lacunes
(n=194)
Records identified through 
PubMed search
for microbleeds
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Studies included in this review (Tables 1 to 3)
(sporadic SVD; elderly over 50 years; longitudinal MRI)
(n=71)
Records after duplicates removed
(n=429)
Records screened
(n=429)
Records excluded
(no serial MRI and/or other than sporadic SVD)
(n=368)
Additional articles identified through 
other sources
(n=35)
Studies included in
WMH summary
(Table 1)
(n=49)
Studies included in 
lacunes summary
(Table 2)
(n=16)
Studies included in 
microbleeds summary
(Table 3)
(n=22)
Articles after screening
(n=61)
Articles assessed for 
eligibility
(n=96)
Articles excluded
(no serial MRI and/or other than sporadic SVD)
(n=25)
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Introduction
Markers of cerebral small vessel disease (SVD) are present on neuroimaging in 
virtually every individual over 60 years. They include white matter hyperintensities 
(WMH), lacunes and cerebral microbleeds [5]. SVD, and its progression, has been 
recognized as the most important vascular contributor to dementia [3, 4]. 
Therefore understanding of the time course of SVD progression will result in 
better understanding of both etiology and consequences of SVD.
Current knowledge regarding temporal dynamics of SVD is limited due to lack of 
studies with more than one follow-up assessment. Consequently, these studies 
could only report the average, presumably linear change in SVD severity [67, 68, 
82, 90, 97, 119, 125, 130]. Previous studies, however, have suggested that SVD 
progression may be a non-linear process accelerating over time [60, 61]. Recent 
studies suggest that SVD might exert its clinical effects by affecting remote brain 
structure and function [49, 147]. The temporal relation between changes in SVD 
and the subsequent atrophy of these remote brain structures is thus far unknown.
Recently, a decrease of WMH volume [28, 59-62] as well as a decrease in number of 
lacunes [63, 64] and microbleeds [65, 66] have been reported, further challenging 
the assumption of linear progression of SVD markers. Neither the time course, 
nor the magnitude of this “disappearing SVD” has been investigated.
In this study we investigated the temporal dynamics of SVD by three consecutive 
neuroimaging assessments over a period of nine years in participants with SVD, 
distinguishing progression from regression. As secondary analysis we investigated 
the temporal dynamics related to atrophy of remote brain structures. 
Methods
Study population
This study is part of the RUN DMC study that prospectively investigates risk factors 
and clinical consequences of SVD. The detailed study protocol has been published 
previously [148]. Of 503 baseline participants, 281 underwent repeated MRI 
assessment at three time points. Five participants were excluded because of 
insufficient scan quality, yielding a final sample of 276 participants for the present 
study (Supplementary Figure 1). 
Abstract
Objective: To investigate the temporal dynamics of cerebral small vessel disease 
(SVD) by three consecutive assessments over a period of nine years, distinguishing 
progression from regression.
Methods: Changes in SVD markers of 276 participants of the RUN DMC cohort 
were assessed at three time points over 9-years. We assessed white matter hyper-
intensities (WMH) volume by semi-automatic segmentation, and rated lacunes and 
microbleeds manually. We categorized baseline WMH severity as mild, moderate 
or severe according to the modified Fazekas scale. We performed mixed-effects 
regression analysis including a quadratic term for increasing age.
Results: Mean WMH progression over nine years was 4.7 ml (0.54 ml/yr; IQR 
0.95–5.5 ml), 20.3% of patients had incident lacunes (2.3%/yr) and 18.9% incident 
microbleeds (2.2%/yr). WMH volume declined in 9.4% of the participants during 
the first follow-up interval, but only for 1 participant (0.4%) throughout the whole 
follow-up. Lacunes disappeared in 3.6% and microbleeds in 5.7% of the participants. 
WMH progression accelerated over time: including a quadratic term for increasing 
age during follow-up significantly improved the model (p<0.001). SVD progression 
was predominantly seen in participants with moderate to severe WMH at baseline 
compared to those with mild WMH (OR 35.5; 95% CI 15.8-80.0; p<0.001 for WMH 
progression; OR 5.7; 95% CI 2.8-11.2; p<0.001 for incident lacunes and OR 2.9; 95% 
CI 1.4-5.9; p=0.003 for incident microbleeds).
Conclusions: SVD progression is non-linear, accelerating over time, and is a highly 
dynamic process, with progression interrupted by reduction in some, in a population 
that on average shows progression.
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MRI protocol
Images were acquired at three time points on 1.5-Tesla MRI (2006: Siemens, 
Magnetom Sonata; 2011 and 2015: Siemens, Magnetom Avanto) and included the 
following whole brain scans: 3D T1 MPRAGE imaging (voxel size 1.0×1.0×1.0 mm); 
FLAIR pulse sequences (baseline: voxel size 1.2×1.0×5.0 mm, interslice gap 1.0mm; 
follow-up: voxel size 1.2×1.0×2.5 mm; interslice gap 0.5 mm) and a transversal 
T2*-weighted gradient echo sequence (voxel size 1.3x1.0x5.0 mm, interslice gap 
1.0mm). Full acquisition details have been described previously [148]. The same 
head coil was used at all three time points. To minimize effects of changes in 
FLAIR sequence we resliced follow-up FLAIR images to match slice thickness of 
baseline images using linear interpolation.  
Brain volumetry
Grey matter (GM), white matter (WM) and CSF probability maps were computed 
using SPM12 (http://www.fil.ion.ucl.ac.uk/spm/) unified segmentation routines on 
the T1 MPRAGE images. Additionally, we used the WMH masks to correct the 
segmentation images, since several brain regions with WMH damage were 
initially misclassified. All WMH voxels were given mean WM intensity and these 
corrected T1 images were segmented using SPM12. All images were visually 
checked for co-registration and segmentation artefacts. GM, WM and CSF volumes 
(GMV, WMV and CSFV) were computed by summing all voxels belonging to that 
tissue class multiplied by voxel volume in ml. Intracranial volume (ICV) was 
determined by summing GMV, WMV and CSFV and total brain volume (TBV) by 
summing GMV and WMV. To account for inter-scan-effects we corrected for 
differences in ICV between baseline and follow-up. We normalized all volumes to 
baseline ICV to account for head size [149]. 
Small vessel disease
SVD was rated according to the STRIVE criteria [5]. WMH volumes were calculated 
by a semi-automatic WMH segmentation method, which has been described in 
detail elsewhere [150]. Segmentations were visually checked for segmentation 
errors by one trained rater, blinded for clinical data. WMH volumes were corrected 
for inter-scan-differences in ICV and then normalized to baseline ICV. Besides, we 
calculated WMH volumes for odd and even slices separately to determine the 
effects of change in slice thickness of the FLAIR sequence. 
We used the modified Fazekas scale to categorize WMH severity at baseline (mild: 
Fazekas 0-1; moderate: Fazekas 2; and severe: Fazekas 3) [151]. 
Standard Protocol Approvals, Registrations, and Patient Consents
The Medical Review Ethics Committee region Arnhem-Nijmegen approved the 
study and all participants gave written informed consent.
Figure 1  Temporal dynamics of WMH progression
Change in WMH volume (ml) over three time points by age at individual level (A). Acceleration of WMH 
volume change over two follow-up periods (ml/year) by age at individual level (B). Change in WMH 
volume (ml) over three time points by age at individual level stratified by baseline WMH severity 
(C). Baseline WMH severity was classified as mild (Fazekas 0-1; n=211), moderate (Fazekas 2; n=33), 
or severe (Fazekas 3; n=20). Smoothed curves using loess smoothing expresses average WMH change with 
increasing age.
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To identify differences in vascular risk factors in individuals with regression of 
SVD markers, we compared vascular risk factors for participants with and without 
regression of SVD markers and with those who remained relatively stable, by 
ANOVA followed by Bonferroni correction.
We created WMH probability maps stratified by baseline age and by baseline 
WMH severity. We repeated mixed-effects regression analysis stratified by baseline 
WMH severity to explore change in WMH within these groups separately. We 
calculated odds of SVD progression according to baseline Fazekas 0-1 versus 
Fazekas 2-3 by logistic regression analysis, adjusted for age and sex.
Statistical analyses were performed using SPSS Statistics version 20 and R 
Programming Language version 3.2.1.
Results
Baseline characteristics are presented in Table 1. Mean age at baseline was 62.5 ± 
7.7 years and 59.1% was male. Mean follow-up duration was 5.4 ± 0.2 years until 
first and 8.7 ± 0.2 years until second follow-up. Participants with moderate to 
severe WMH at baseline had lower MMSE scores (27.7±1.7 vs. 28.4±1.5; p<0.001) 
compared to participants with mild WMH. Steeper decline in MMSE score was 
seen in participants with WMH progression compared to participants whose 
WMH remained relatively stable (-0.95±2.5 vs. -0.32±1.8; p=0.031). Those lost to 
follow-up were significantly older and had more severe baseline SVD characteris-
tics compared to participants (Supplementary Table 1).
Temporal dynamics of SVD 
WMH probability maps are shown in Supplementary Figure 2 and Supplementary 
Video 1. Mean WMH progression was 0.54 ml/yr (median 0.24; IQR 0.11-0.64 ml/yr). 
Progression of WMH increased with baseline age (Figure 1A-B, Supplementary 
Video 2). In mixed-effects regression analysis, each year increase of age at baseline 
resulted in an increase in WMH as percentage of WM of 0.10% (95%CI: 0.07-13.7%). 
Including a quadratic term for increasing age during follow-up significantly 
improved the model (AIC base model 2995.2 versus AIC extended model 2932.9, 
likelihood ratio test, χ2 =64.3, df=1, p<0.001). Severity and progression of WMH 
were comparable for men and women.
Both number and location of lacunes and microbleeds were rated manually on 
FLAIR/T1-weighted and T2*-weighted MRI scans according to the STRIVE criteria 
[5] by two trained raters blinded for clinical data. Follow-up FLAIR images were 
resliced to match the baseline scans to prevent differences in partial volume 
effects between baseline and follow-up scans. Inter and intra-rater reliabilities 
were excellent.[152] Incidence was expressed as number of participants with new 
lacunes or microbleeds. We identified whether lacunes or microbleeds were truly 
incident or disappeared and in which time-period. To minimize risk of misclassifi-
cation due to co-registrations, we visually inspected all WMH segmentations and 
corrected lacune occurrence maps based on manual ratings.
Vascular risk factors
We assessed presence of hypertension, smoking, alcohol use, body mass index, 
diabetes and hypercholesterolemia, by standardized questionnaires, as described 
previously [148].
Statistical analysis
We calculated differences in baseline characteristics between participants and 
those without follow-up using univariate analyses. Differences in MMSE score 
between individuals with mild versus moderate or severe WMH at baseline and 
with or without WMH progression were examined using nonparametric tests.
We created WMH probability maps and distribution maps of lacunes. WMH decline 
was defined as more than 0.25 ml volume decline, as this was shown to be smallest 
change that could be confirmed visually [59]. We plotted change of WMH volumes by 
age at individual level using R package ggplot2 (version 2.1.0) [153]. R package lme4 
was used to perform linear mixed-effects regression analysis to analyze WMH 
change as function of baseline age and time (version 1.1-12) [154]. We used a random 
intercept and random slope model, which permits the estimation of an average 
slope across the whole cohort while allowing for inter-individual variability. By 
smoothed curves using loess smoothing we explored average WMH change with 
increasing age. To evaluate a possible quadratic relationship, indicating non-linear 
progression of SVD, we compared model fit between the full model and the full 
model with a quadratic term for increasing age during follow-up included, using a 
likelihood ratio test and we evaluated change in Akaike information criterion (AIC). 
To determine remote effects of SVD progression, we analyzed the relation between 
WMH progression in the first follow-up interval, and subsequent brain atrophy, by 
means of linear regression analysis. Multicollinearity between different SVD 
markers was investigated using regression analysis. 
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Fifty-six participants (20.3%) developed new lacunes over nine years (2.3%/yr; Table 2). 
The distribution of lacunes is shown in Supplementary Figure 2 and Supplementary 
Video 3. Incidence of lacunes was higher for the second follow-up period (3.5%/yr) 
than for the first follow-up period (2.7%/yr). 
Fifty participants (18.9%) developed new microbleeds over nine years (2.2%/yr) 
(Table 2). Incidence of microbleeds in the second follow-up period (4.2%/yr) was 
higher than in the first follow-up period (1.7%/yr). WMH progression in the first 
follow-up period was associated with brain atrophy in the second follow-up period 
(β=0.124; p=0.040) as well as with WM atrophy (β=0.149; p=0.013) but not with GM 
atrophy (β=0.045; p=0.461). Multicollinearity between SVD markers is shown in 
Supplementary Table 2.
Regression of SVD markers
We also observed regression of SVD markers. We observed decline in WMH volume 
in 26 participants (9.4%; median decline -0.5 ml; IQR: -0.9 to -0.3 ml) during the 
first follow-up period and in 5 participants (1.8%; median -0.5 ml; IQR: -0.9 to -0.4 
ml) during the second follow-up period. In one participant WMH volume declined 
over the course of nine years (0.4%; -0.4 ml). In 10 participants (3.6%) 14 lacunes 
could not be found at follow-up imaging (Table 2). In 15 participants (5.7%) 37 
microbleeds were no longer detectable after nine years of follow-up (Table 2). 
Examples of lacunes and microbleeds that were no longer visible on follow-up 
imaging are shown in Figure 2. There were no differences for any of the vascular 
risk factors between participants with and without regression of SVD markers, 
also compared with those who remained relatively stable over the nine year 
course (data not shown).
Heterogeneity in temporal dynamics of SVD
Mean WMH progression over nine years was 2.4 ml for participants with mild 
WMH at baseline, 12.0 ml for those with moderate WMH and 15.2 ml for those 
with severe WMH (Figure 1C, Figure 3, and Supplementary Video 4). From 
participants with mild WMH at baseline, six percent showed WMH progression 
beyond measurement error, compared with 75% of participants with moderate or 
severe WMH. Participants with moderate to severe WMH at baseline had 36 times 
higher risk of WMH progression compared to participants with mild WMH (OR 
35.5; 95% CI 15.8-80.0; p<0.001). Participants with moderate to severe WMH also 
more often developed incident lacunes (OR 5.7; 95% CI 2.8-11.2; p<0.001) and 
microbleeds (OR 2.9; 95% CI 1.4-5.9; p=0.003) compared to participants with mild 
WMH at baseline.
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Figure 2  Lacunes and microbleeds no longer visible on follow-up imaging
Examples of a lacune that is no longer detectable on follow-up imaging (A), which appears to be 
assimilated by the ventricle. Microbleeds (B) appear to have faded away over time. 
A. Lacunes    
B. Microbleeds 
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Discussion
In this study we showed the temporal dynamics of SVD, revealing both SVD 
progression and regression, using three imaging assessments over a period of 
nine years. We demonstrated that progression of all SVD markers occurred in a 
non-linear fashion, accelerating over time consistent with a quadratic course. In 
addition, we showed that participants with moderate or severe WMH had a high 
likelihood of progression of their SVD, whereas participants with mild baseline 
SVD showed mild progression over a period of nine years.
Our study demonstrates that SVD progression is not linear but accelerates with 
increasing age. While the average progression in our study is comparable with 
other studies [67, 68, 82, 90, 97, 119, 125, 130], the use of three imaging assessments 
allowed us to show that SVD progression accelerated over time, providing evidence 
for a non-linear process [60, 61]. Moreover, our results suggest that a quadratic 
course of SVD progression over time is plausible, since including a quadratic term 
improved the model. Although we would need more than three time points to 
further study exponential functions, our study indicates non-linear temporal 
dynamics of SVD progression. Our findings do not support the hypothesized 
ceiling effect in which WMH progression reaches a certain threshold at high age 
and high lesion volume [3], as we also saw WMH progression in those at high age 
and with high SVD lesion load. 
The relation between WMH progression and subsequent WM atrophy and TBV 
atrophy, suggests that SVD affects adjacent brain structures. WM atrophy might 
be the result of disconnected white matter tracts due to SVD, leading to axonal 
loss by anterograde or retrograde degeneration, and subsequently the loss of brain 
volume [4, 155]. The clinical observation that patients with similar SVD burden 
show heterogeneity in clinical symptoms might be explained by disconnection of 
WM tracts.
Imaging assessments at three time points also enabled us to identify regression of 
SVD markers followed by progression, in a cohort that on average showed 
progression. This observation provides further evidence that SVD does not 
gradually evolve but is a dynamic process, with progression interrupted by 
regression in some. Thus far only few other studies have reported a decline in 
WMH volume [28, 59-61], possibly because WMH decline within a certain time 
window was compensated by WMH progression thereafter (or vice versa). Two 
imaging assessments do not allow disentangling of episodes with regression from 
those with progression. 
Figure 3  WMH probability maps stratified by baseline WMH severity
Probabilities of presence of WMH stratified by baseline WMH severity, color-coded in percentage from 5 
to 75%. Baseline WMH severity is determined as mild (Fazekas 0-1; n=211), moderate (Fazekas 2; n=33) and 
severe (Fazekas 3; n=20). The overall 9-year change is shown in the right column. Probability maps 
through the whole brain can be seen in Supplementary Video 4.
Mild 
Moderate 
Severe
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Strengths of this study include the large cohort of participants with SVD and the 
long follow-up duration. Furthermore, imaging assessments at three time points 
allowed us to characterize change in SVD over time, including SVD regression. 
SVD was rated according to standardized procedures [5], minimizing risk of mis-
classification. Moreover, semi-automatic WMH quantification reduced risk of 
information bias [3]. Furthermore, brain volumes were determined with the 
newest segmentation routines of SPM12 and corrected for segmentation errors 
using WMH masks. Finally, our study has high external validity for patients with 
SVD in a general neurology clinic. 
A limitation of our study is change of MRI scanner between baseline and first 
follow-up. However, by taking into account the third MRI assessment we are able 
to capture most of this possible bias. A slight adjustment in FLAIR sequence 
between baseline and first follow-up may have caused an overestimation of 
incident lacunes. However, we limited the possible negative effects by reslicing 
follow-up to baseline FLAIR images before rating lacunes. Besides, changes in 
signal characteristics of normal brain tissue and WMH might have lead to 
artefactually higher rates of lesion development. However we considered this 
unlikely, since we also observed regression of SVD markers from the second to 
third time-period in a considerable proportion of participants. Further, due to 
low-resolution T2* sequences, we might have missed smaller microbleeds. 
However, since similar GRE sequences are applied for all time points, risk of mis-
classification will result in comparable systematic error for all time points. 
Inevitably, attrition bias may have occurred due to the very long-term follow-up, 
probably leading to an underestimation of progression of SVD, since those who 
dropped-out were older, and had more severe SVD.
Our study demonstrates that SVD progression is a non-linear, dynamic and highly 
variable process, predominantly seen in participants with moderate or severe 
WMH at baseline. And, equally important, those with mild WMH rarely show 
progression over a nine year course. Since SVD progression has been linked to 
cognitive decline and development of dementia, our findings on inter-individual 
variability in SVD progression might be a major step forward in developing 
personalized treatment approaches. The findings that progression of SVD is 
sometimes interrupted by regression and that SVD progression occurs in a 
quadratic way and hence is not gradually, linearly progressive as was previously 
thought, suggest a paradigm shift on how SVD processes should be considered. 
Future studies should elaborate on the clinical consequences of this non-linear 
dynamic time course of SVD progression. 
The observed decline in WMH may have several explanations. First, WMH decline 
in the first follow-up period could be explained in part by partial volume effects 
caused by slight adjustments in FLAIR sequences between baseline and first 
follow-up. However, we think this is unlikely because WMH volumes calculated 
from even and odd slices were identical and because we also found WMH decline 
between the second and third MRI assessment. Second, different orientation of 
participants in the scanner might also partly explain disappearing SVD, especially 
for smaller lesions. In order to prevent this, we classified WMH regression as more 
than 0.25 ml volume decline. Third, recently developed WMH might represent 
areas of tissue edema. Reduction in tissue edema at a later stage could lead to 
reduced WMH volume [28]. Fourth, improved control of vascular risk factors or 
factors influencing the blood-brain-barrier might play a role by reducing WMH 
volume [28, 59]. Disappearance of lacunes could be due to partial volume effects, 
due to “collapsing” lacunes or to incorporation of the lacune into the ventricle 
(Figure 2) [63, 64]. Disappearing microbleeds may be explained by partial volume 
effects as well as by clearance of hemosiderin-containing macrophages [66]. Our 
findings are in line with the latter hypothesis. In most cases microbleeds seemed 
to “fade away” between 2006 and 2011 and were no longer visible in 2015.
All SVD markers at baseline were important predictors for SVD progression, in a 
non-linear way and independent of age. Additional analyses on progression of SVD 
markers by distribution of microbleeds did not reveal significantly different 
progression for participants with strictly lobar compared to participants with 
deep microbleeds (data not shown), although this analysis might have been 
underpowered. Although we would require an even longer follow-up to exclude 
the possibility that all participants with mild baseline WMH will ultimately 
progress to severe WMH, our data show that even the oldest participants with mild 
baseline WMH rarely show progression over a time course of nine years. This 
suggests different progression curves for participants with mild versus severe 
baseline WMH, implying heterogeneity in etiology of mild versus severe SVD. 
Small WMH volumes, representing punctuate WMH or small periventricular caps, 
probably consist of enlarged perivascular spaces and subependymal gliosis [97]. On 
the contrary, confluent WMH represent a continuum of ischemic tissue damage, 
ranging from mild fiber loss to complete infarction and may have a more malignant 
course in terms of cognitive deterioration. These different etiologies call upon a 
different diagnostic and therapeutic approach. The correlation between WMH 
severity and progression and MMSE score underlines the clinical relevance of our 
findings on inter-individual variability in SVD progression.
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Supplementary material
Supplementary Figure 1  Flowchart
Design of the RUN DMC study. Imaging assessments were performed at three time points over the course 
of nine years at baseline in 2006, at first follow-up in 2011 and at second follow-up in 2015. Note that the 
93 participants who were unable to undergo first follow-up assessment in 2011 were again contacted for 
second follow-up assessment in 2015 (dotted lines). In total 281 participants underwent imaging 
assessments at all three time points, of whom 276 participants were included in the present study.
Supplementary Table 1  Baseline characteristics of participants compared with 
those lost to follow-up
Participants 
n=276
Lost to follow-up
n=227
Significance
Demographics
Age (years), mean (SD) 62.5 (7.7) 69.5 (8.5) p<0.001
Sex, male, n (%) 163 (59.1) 121 (53.3) p=0.207
Education >primary school, n (%) 259 (93.8) 32 (14.1) p=0.004
MMSE score, mean (SD) 28.6 (1.3) 27.6 (1.8) p<0.001
SVD Characteristics
WMH volume, ml, median (IQR) 2.3 (0.8-6.1) 7.7 (2.6-16.2) p<0.001
WMH volume, ml, Mean (SD) 5.8 (9.5) 11.9 (13.6) p<0.001
% WMH of WM, mean (SD) 1.3 (2.3) 2.9 (4.4) p<0.001
Participants with any lacunes, n (%) 55 (19.9) 77 (33.9) p<0.001
Total number of lacunes 117 135 p=0.038
Participants with any microbleeds, n (%) ^ 36 (13.1) 47 (20.9) p=0.022
Total number of microbleeds ^ 140 159 p=0.496
Territorial Infarcts, n (%) 23 (8.3) 34 (15.0) p=0.023
Modified Fazekas score
Mild WMH (0-1), n (%) 218 (79.0) 114 (50.2) p<0.001
Moderate WMH (2), n (%) 38 (13.8) 70 (30.8) p<0.001
Severe WMH (3), n (%) 20 (7.2) 43 (18.9) p<0.001
Brain volumes  
White matter volume, ml (SD)  465.6 (38.9) 441.5 (50.2) p<0.001
Grey matter volume, ml (SD)  620.7 (48.9) 588.7 (51.6) p<0.001
Vascular risk factors
Smoking, ever, n (%) 196 (71.0) 157 (69.2) p=0.696
Alcohol, glasses/week, mean (SD) 8.3 (9.0) 7.5 (9.7) p=0.367
Glucose lowering drugs, n (%) 23 (8.3) 43 (18.9) p=0.001
Hypertension, n (%) 190 (68.8) 179 (78.9) p=0.015
BMI, mean (SD) 27.1 (4.1) 27.2 (4.2) p=0.778
Lipid-lowering drugs, n (%) 118 (42.8) 119 (52.4) p=0.032
Data are represented as numbers (%), mean (SD) or median (IQR). Comparisons between participants and 
those lost to follow-up were performed by t-test, Chi-square or Mann-Whitney-U test. ^For ratings of 
microbleeds 4 participants were additional excluded based on missing T2*or scanartefacts at baseline.
Baseline (2006)
participants with MRI
n=503
49 participants deceased
Follow-up 1 (2011)
participants with MRI
n=361
Follow-up 2 (2015)
participants with MRI
n=296
Participants with MRI in
2006 & 2011 & 2015
n=276
43 participants deceased
20 participants excluded in the present study
- MRI assessment in 2015 but not 2011 n=15
- Insufficient scan quality n=5
Participants eligible for
follow-up 1 (2011)
n=454
93 participants without MRI in 2011
- Lost to follow-up n=2
- Unable to vsit research centre n=54
- MRI contra-indications n=37
Note: These 93 participants were again contacted
for second follow-up assessment in 2015.
115 participants without MRI in 2015
- Unable to vsit research centre n=65
- MRI contra-indications n=50
Participants eligible for
follow-up 2 (2015)
n=411
62 63
CHAPTER 3 NONLINEAR TEMPORAL DYNAMICS OF CEREBRAL SMALL VESSEL DISEASE
3
Supplementary Figure 2  Probability maps of white matter hyperintensities  
and lacunes
Probabilities of presence of WMH at three time points (A) and probabilities to increase over these three 
time points (B), color-coded in percentage from 5 to 75%. Probability maps through the whole brain can 
be seen in Supplementary Video 1. Panel C shows the distribution of lacunes at three time points. Whole 
brain distribution maps can be seen in Supplementary Video 2.
A. WMH probability maps    
B. WMH change probability maps    
C. Distribution maps of lacunes 
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Supplementary Videos
All Supplementary Videos are available at Neurology.org
Supplementary Video 1  WMH probability maps
Probability maps of WMH through the whole brain, color-coded in percentage from 5 to 
75%. This movie shows the probability of presence of WMH at three different time points 
(2006-2011-2015). 
Supplementary Video 2  WMH probability maps stratified by baseline age
Probability maps of WMH progression stratified by baseline age through the whole brain, 
color-coded in percentage from 5 to 75%. This movie shows the WMH increase after 9 years 
of follow-up for participants aged <60 years, between 60 and 70 years and over 70 years. 
Supplementary Video 3  Distribution maps of lacunes
This movie shows the distribution map of presence of lacunes in three different time points 
(2006-2011-2015) in green, with incident lacunes in red.
Supplementary Video 4  WMH probability maps stratified by baseline WMH severity
Probability maps of WMH progression stratified by baseline WMH severity through the 
whole brain, color-coded in percentage from 5 to 75%. This movie shows the probability of 
WMH increase over 9 years of follow-up for participants with mild (Fazekas 0-1; n=211), 
moderate (Fazekas 2; n=33) and severe (Fazekas 3; n=20) WMH at baseline.
Part III
The etiology of 
cerebral small vessel disease
Chapter 4
Progression of white matter hyperintensities 
preceded by heterogeneous decline of 
 microstructural integrity
Published as:
van Leijsen EMC, Bergkamp MI, van Uden IWM, Ghafoorian M, van der Holst HM, 
Norris DG, Platel B, Tuladhar AM, de Leeuw FE
Progression of white matter hyperintensities preceded by 
heterogeneous decline of microstructural integrity
Stroke. 2018;49:1386-1393
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Introduction
White matter hyperintensities (WMH) are part of the spectrum of cerebral small 
vessel disease (SVD) markers and are frequently observed on magnetic resonance 
imaging (MRI) scans in individuals >60 years of age [5-7]. WMH are associated with 
cognitive decline and the development of dementia [3, 43]. The pathophysiology of 
WMH remains poorly understood, in part because studies on WMH and its progression 
have mainly used conventional MRI, thereby unable to assess its earlier stages that 
perhaps were not yet visible. Imaging techniques such as diffusion tensor imaging 
(DTI) can possibly provide additional information on these earlier stages by the 
assessment of the microstructural organization of the white matter (WM) [27-30]. 
Previous longitudinal studies have shown changes in baseline DTI parameters, 
that is, decreased fractional anisotropy (FA) and increased mean diffusivity (MD) 
that predicted incident WMH at follow-up [31, 32].
However, the temporal course of DTI changes in normal appearing WM (NAWM) 
preceding conversion to WMH remains to be elucidated. This is especially 
important because there is increasing evidence that WMH progression accelerates 
over time [110]. Besides, progression was found most pronounced in participants 
with severe WMH [97, 110], suggesting differences in pathogenesis for mild versus 
severe WMH. More knowledge of the sequence of events that precedes the 
conversion of NAWM toward WMH might result in better identification of patients 
at risk for further WMH progression and the attendant clinical symptoms. This 
would especially be useful to identify in which individuals and at what moment 
preventive therapies could be beneficial.
In the present study we therefore examined whether and when progression of 
WMH was preceded by changes in FLAIR and DTI values, using neuroimaging 
assessments at 3 time points for 9 years in 266 participants with SVD. We also 
studied differences between those with mild versus severe WMH. Finally, we 
analyzed the degree of WMH progression during follow-up according to baseline 
FLAIR and DTI measures.
Materials and methods
Study population
The RUN DMC study is a prospective cohort study of elderly with SVD that 
investigates risk factors and clinical consequences of SVD. The detailed study 
protocol has been published previously [148]. Of 503 baseline participants, 281 
Abstract 
Background and Purpose: White matter hyperintensities (WMH) are frequently 
seen on neuroimaging of elderly and are associated with cognitive decline and the 
development of dementia. Yet, the temporal dynamics of conversion of normal 
appearing white matter (NAWM) into WMH remains unknown. We examined 
whether and when progression of WMH was preceded by changes in FLAIR and 
diffusion tensor imaging values, thereby taking into account differences between 
participants with mild versus severe baseline WMH.
Methods: From 266 participants of the RUN DMC study, we semi-automatically 
segmented WMH at 3 time points for 9 years. Images were registered to standard- 
space through a subject-template. We analyzed differences in baseline FLAIR, 
fractional anisotropy (FA) and mean diffusivity (MD) values and changes in MD 
values over time between 4 regions: (1) remaining NAWM; (2) NAWM converting 
into WMH in the second follow-up period; (3) NAWM converting into WMH in the 
first follow-up period; and (4) WMH.
Results: NAWM converting into WMH in the first or second time-interval showed 
higher FLAIR and MD values than remaining NAWM. MD values in NAWM 
converting into WMH in the first time-interval were similar to MD values in WMH. 
When stratified by baseline WMH severity, participants with severe WMH had 
higher FLAIR and MD, and lower fractional anisotropy values than participants 
with mild WMH, in all areas including the NAWM. MD values in WMH and in 
NAWM that converted into WMH continuously increased over time.
Conclusions: Impaired microstructural integrity preceded conversion into WMH 
and continuously declined over time, suggesting a continuous disease process of 
white matter integrity loss that can be detected using diffusion tensor imaging 
even years before WMH become visible on conventional neuroimaging. Differences 
in microstructural integrity between participants with mild versus severe WMH 
suggest heterogeneity of both NAWM and WMH, which might explain the clinical 
variability observed in patients with similar small vessel disease severity.
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Spatial normalization
The spatial normalization process is described in the online-only Data Supplement 
and a schematic overview of the spatial normalization process is displayed in 
Figure I in the online-only Data Supplement. 
Normalization of FLAIR values
To account for inter-individual differences in FLAIR intensities, we normalized 
the FLAIR values [32]. We calculated the mean (μFLAIR) and SD (σFLAIR) of FLAIR 
values in the NAWM for each participant and defined a z-score per voxel (). The 
same procedure was applied to follow-up FLAIR images.
Definition of regions
We created 4 masks for each participant: (1) remaining NAWM through all three 
MRI assessments; (2) NAWM converting into WMH in the second follow-up period 
(i.e. between 2011 and 2015; in other words converting into WMH after at least 5 
years); (3) NAWM converting into WMH in the first follow-up period (i.e. between 
2006 and 2011; in other words converting into WMH within 5 years); and (4) WMH 
at baseline (Fig. 1). For mask (1), we created a binary NAWM mask by subtracting 
the baseline and incident WMH masks from the baseline WM mask. Mask (2) was 
created by subtracting the mask with incident WMH voxels in the first time-period 
from the mask with incident WMH voxels over the entire follow-up. Mask (3) was 
created by subtracting the baseline WMH map from the first follow-up WMH map. 
For mask (4) we used the baseline WMH mask.
Statistical analysis
We used t-tests to compare mean baseline FLAIR, FA and MD values in (1) remaining 
NAWM with values in (2) NAWM voxels converting into WMH in the second 
follow-up period, (3) NAWM converting into WMH in the first follow-up period, 
and (4) WMH. We additionally compared baseline FLAIR, MD and FA values in 
NAWM converting into WMH and in WMH with values in remaining NAWM for 
all time points separately (i.e. 2006-2011; 2011-2015; and overall 2006-2015) in 
order to validate the results. Further, we stratified by the modified Fazekas scale 
(mild: Fazekas 0-1; and severe: Fazekas 2-3) [151] to evaluate whether changes in 
microstructural integrity preceding WMH progression differed between 
participants with mild versus severe baseline WMH. We used one-way ANOVA to 
investigate whether baseline FLAIR and DTI values in the previously mentioned 
four areas differed between participants with mild versus severe WMH. 
Additionally, we used repeated-measures ANOVA to investigate changes in MD 
values over time in the four areas. To investigate associations between baseline 
MD and FLAIR values and severity of WMH progression, we calculated quintiles of 
participants underwent repeated neuroimaging assessments at three time points 
(baseline in 2006, first follow-up in 2011 and second follow-up in 2015) [110]. Fifteen 
participants were additionally excluded because of insufficient scan quality, 
yielding 266 participants for the present study. The Medical Review Ethics 
Committee region Arnhem-Nijmegen approved the study and all participants gave 
written informed consent. The data that support the findings of this study are 
available from the corresponding author upon request.
Vascular risk factors
We assessed the presence of hypertension, smoking, alcohol use, diabetes mellitus 
and hypercholesterolemia at baseline by standardized questionnaires, as described 
previously [148]. We defined hypertension as use of antihypertensive agents and/or 
systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg [148].
Neuroimaging protocol
MR images were acquired at three time points on 1.5-Tesla MRI (2006: Siemens, 
Magnetom Sonata; 2011 and 2015: Siemens, Magnetom Avanto) and included the 
following whole brain scans: T1-weighted 3-dimensional MPRAGE (isotropic voxel 
size 1.0 mm3), FLAIR (2006: voxel size 0.5×0.5×5.0 mm, interslice gap 1.0 mm; 2011 
and 2015: voxel size 0.5×0.5×2.5 mm; interslice gap 0.5 mm) and DTI (2006: 
isotropic voxel size 2.5 mm3, 4 unweighted scans, 30 diffusion weighted scans at 
b=900 s/mm2; 2011 and 2015: isotropic voxel size 2.5 mm3, 8 unweighted scans, 60 
diffusion weighted scans at b=900 s/mm2). Full acquisition details have been 
described previously [110, 148].
Brain tissue segmentation and volumetry
We calculated grey matter (GM), white matter (WM) and CSF volumes using SPM12 
(http://www.fil.ion.ucl.ac.uk/spm/) unified segmentation routines on the T1 MPRAGE 
images [110]. Next, we created binary WM masks from the WM segmentation 
maps. WMH were segmented semi-automatically using FLAIR and T1 sequences 
[150]. All segmentations were visually checked for artefacts and segmentation 
errors, blinded for clinical data. WMH volumes were calculated in millilitres, 
corrected for interscan differences in ICV and normalized to baseline ICV. 
DTI processing
All diffusion weighted images were denoised using a Local Principal Component 
Analyses filter [156], and corrected for cardiac, head motion, and eddy current 
artefacts simultaneously using the ‘PATCH’ algorithm [157], as described previously 
[152]. Diffusion tensor and scalar parameters were calculated using DTIFIT from 
FSL’s FDT toolbox.
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Fazekas score 2-3 were similar to MD values in NAWM converting into WMH in 
the first time-period and to WMH in participants with Fazekas 0-1.
Changes in MD values over time
In Figure 3, changes in MD over time are shown for the 4 areas. The MD value in 
areas of remaining NAWM remained constant over time (Figure 3, diamonds). MD 
values in persisting WMH during the 9-year course continued to increase over 
time (circles in Figure 3; p<0.001 for all time-periods). Interestingly, MD values in 
baseline MD and FLAIR values and analyzed WMH progression according to these 
strata, by one-way ANOVA adjusted for age and sex, followed by a Bonferroni 
correction, and tested continuous linear trend per stratum. Statistical analyses 
were performed using Matlab version 2014b and SPSS Statistics version 20.
Results
Baseline characteristics of the study population are presented in Table 1. Mean age 
at baseline was 62.5 (SD7.8) years. Mean follow-up duration until first follow-up 
assessment was 5.4 (SD0.2) years and 8.7 (SD0.2) years until second follow-up 
assessment. Median WMH volume progressed from 2.2 ml (IQR 0.8–6.1 ml) at 
baseline to 2.8 ml (IQR 1.2–7.5 ml) at first follow-up and to 4.7 ml (IQR 2.0–11.5 ml) 
at second follow-up. We observed lacunes in 52 participants (19.0%) at baseline and 
incident lacunes in 20.3% of participants. Presence of lacunes was more frequent 
in participants with severe WMH compared with participants with mild WMH 
(49.1% versus 11.8%; p<0.001). Participants who had not completed follow-up 
assessment were significantly older at baseline, had more vascular risk factors, and 
more severe SVD characteristics (Supplementary Table 1).
Baseline FLAIR and DTI parameters in areas converting into WMH
In Figure 2A, differences in baseline FLAIR, MD and FA values are shown between 
the 4 areas. Compared with remaining NAWM areas through all 3 time points, 
NAWM areas converting into WMH in the second time-interval had higher 
normalized FLAIR intensity and higher MD, but similar FA values. NAWM areas 
converting into WMH in the first time-interval had higher normalized FLAIR 
intensity, higher MD, and lower FA values compared with remaining NAWM. In 
contrast, when compared with WMH, these NAWM areas converting into WMH in 
the first time-period had lower normalized FLAIR intensity and higher FA, but MD 
values were similar between areas of WMH and areas converting into WMH in the 
first 5 years. Comparable differences in baseline FLAIR and DTI values were observed 
between the 4 areas when the follow-up periods were investigated separately 
(Supplementary Table 2). 
Baseline FLAIR and DTI parameters by WMH severity
Figure 2B illustrates baseline FLAIR and DTI measures in the 4 areas stratified by 
baseline WMH severity. Participants with Fazekas 2-3 had significantly higher 
normalized FLAIR and MD and lower FA values than those with Fazekas 0-1, in all 
WM areas, including the NAWM (p<0.005 for all comparisons). MD values in 
NAWM converting into WMH in the second time-period in participants with 
Table 1  Characteristics of the study population
Study 
population 
(n=266)
WMH severity
Fazekas 0-1 
(n=211)
Fazekas 2-3 
(n=55)
Difference
Demographics
Age, years 62.5 ± 7.8 61.6 ± 7.4 66.2 ± 8.4 p<0.001
Male sex, no 157 (59.0) 129 (61.1) 28 (50.9) p=0.218
MMSE score 28.6 ± 1.3 28.7 ± 1.3 28.3 ± 1.5 p=0.037
Education, years 10.1 ± 1.5 10.2 ± 1.4 9.7 ± 1.8 p=0.027
Vascular risk factors
Hypertension, no 181 (68.0) 135 (64.0) 46 (83.6) p=0.006
Diabetes, no 28 (10.5) 21 (10.0) 7 (12.7) p=0.621
Hypercholesterolemia, no 112 (42.1) 89 (42.2) 23 (41.8) p=1.000
Smoking, ever, no 191 (71.8) 148 (70.1) 43 (78.2) p=0.313
Alcohol, glasses/week 8.3 ± 9.1 8.9 ± 9.3 6.1 ± 7.8 p=0.038
Body mass index, kg/m2 27.1 ± 4.1 27.2 ± 4.2 26.5 ± 3.8 p=0.220
Imaging characteristics
Total brain volume, ml 1087.1 ± 69.8 1095.8 ± 65.4 1053.7 ± 76.3 p<0.001
Grey matter volume, ml 621.2 ± 48.6 627.1 ± 46.4 598.6 ± 50.7 p<0.001
White matter volume, ml 465.8 ± 38.6 468.6 ± 37.4 455.1 ± 41.8 p=0.020
WMH volume, ml 2.2 (0.8–6.1) 1.4 (0.7–3.1) 14.8 (10.5–26.9) p<0.001
Lacunes, no 52 (19.5) 25 (11.8) 27 (49.1) p<0.001
Microbleeds, no 34 (12.8) 19 (9.0) 15 (27.3) p=0.001
NAWM MD, 10-3 mm2/s 0.85 ± 0.04 0.84 ± 0.03 0.88 ± 0.04 p<0.001
NAWM FA 0.35 ± 0.02 0.36 ± 0.02 0.34 ± 0.02 p<0.001
Data represent mean ± SD, number of participants (%) or median (IQR). Comparisons between participants 
with Fazekas 0-1 and Fazekas 2-3 were performed by t-test, Chi-square or Mann-Whitney-U test.
No: number of participants; MMSE: Mini-Mental State Examination; WMH: white matter hyperintensities; 
NAWM: normal appearing white matter; MD: mean diffusivity; FA: fractional anisotropy.
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NAWM converting into WMH within the first 5 years were similar to MD values in 
persisting WMH at baseline and continued to increase over time (Figure 3, 
triangles; p<0.005 for all repeated measures ANOVAs). MD values in NAWM 
converting into WMH between 5 and 10 years were slightly less elevated at baseline 
compared to WMH, but continuously increased over time (p<0.005 for all 
time-periods), reaching the level of MD in WMH areas at first follow-up in 2011 
(Figure 3, squares).
WMH progression according to baseline FLAIR and DTI parameters
We evaluated the progression of WMH at different levels of baseline FLAIR and DTI 
parameters by dividing the groups into quintiles. Cut-off values of quintiles were 
0.816; 0.833; 0.848 and 0.874 *10-3 mm2/s for MD values and 315; 322; 329 and 336 
for FLAIR values. The degree of WMH progression according to baseline MD and 
FLAIR strata in NAWM is presented in Figure 4. Higher baseline MD values in 
NAWM were associated with increased WMH progression over nine years (mean 
difference highest versus lowest quintile: 0.73ml/y; 95%CI 0.26-1.19; p<0.001 
Figure 2  Baseline FLAIR and DTI parameters in regions preceding WMH
Intensities of FLAIR, FA and MD values at baseline in a) remaining NAWM; b) NAWM converting into 
WMH in the second follow-up period; c) NAWM converting into WMH in the first follow-up period; d) 
WMH. Figure A: Overall baseline FLAIR intensities and FA and MD values (mean with 95%CI); statistical 
differences between the four areas are calculated by t-tests. Figure B: Baseline FLAIR intensities, FA and MD 
values (mean with 95%CI) stratified by baseline Fazekas scores (Fazekas 0-1: squares; Fazekas 2-3: diamonds); 
statistical differences between participants with Fazekas 0-1 and Fazekas 2-3 are calculated for the four 
areas separately, by one-way ANOVA. *p<0.05; **p<0.01; ***p<0.001.
Figure 1  Progression of white matter hyperintensities and definition of regions
Left: WMH progression during follow-up in a single representative patient: WMH at baseline (yellow), at 
first follow-up (green), and at second follow-up (blue). Right: Overview of the four masks included in 
analyses: a) remaining NAWM; b) NAWM converting into WMH in the second follow-up period; c) NAWM 
converting into WMH in the first follow-up period; d) WMH.
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these findings by adding an additional time point with a total follow-up of 9 years, 
which enabled us to distinguish between NAWM converting into WMH within 
the first and the second time-period. We observed that baseline MD values were 
higher in NAWM areas converting into WMH within 5 years than in NAWM areas 
that converted into WMH between 5 and 9 years. Besides, MD values continued to 
increase over time. The continuously ongoing decline of microstructural integrity 
within the WM underlines that WMH progression visible on conventional FLAIR 
imaging is only the “tip of the iceberg” with underlying loss of microstructural 
integrity that can only be visualized using more advanced neuroimaging techniques. 
adjusted for age and sex; overall p-trend<0.001). Higher FLAIR values at baseline 
were also associated with increased progression of WMH (mean difference highest 
versus lowest quintile: 0.47ml/y; 95%CI 0.03-0.91; p=0.025; overall p-trend<0.001). 
Discussion
In this longitudinal study with 3 imaging assessments during 9 years, we observed 
that impaired microstructural integrity in the NAWM preceded conversion into 
WMH and that WM microstructural integrity declined over time. Participants 
with severe baseline WMH showed more loss of structural integrity compared 
with participants with mild WMH in all areas of the WM, including the remaining 
NAWM. These results suggest that WMH progression is an ongoing process 
characterized by loss of WM microstructural integrity occurring years before 
WMH can be detected on conventional MRI.
These results are in line with 2 longitudinal studies showing changes in baseline 
DTI and FLAIR signal intensities that were related to incident WMH at follow-up, 
with mean follow-up durations of 3.5 and 3.7 years [31, 32]. Here, we extended 
Figure 3   Changes in microstructural integrity over time in regions  
preceding WMH
Change in MD values over the three time points in a) remaining NAWM (diamonds); b) NAWM converting into 
WMH in the second follow-up period (squares); c) NAWM converting into WMH in the first follow-up 
period (triangles); and d) WMH (circles).
Figure 4   Progression of white matter hyperintensities, according to baseline MD 
and FLAIR strata
WMH progression (in ml/y), stratified by baseline MD (top) and normalized FLAIR (bottom) quintiles.
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vascular risk factors according to current guidelines, until further data from 
randomized controlled trials are available.
Major strengths of this study include the longitudinal design of our study with 3 
neuroimaging assessments during 9 years, which enabled us to elaborate on the 
temporal dynamics of WMH progression. Furthermore, the availability of these 3 
time points enabled us to validate the findings in the other follow-up periods.
Several methodological issues and limitations deserve consideration. First, 
differences in MRI scanner and FLAIR sequences between baseline and first 
follow-up might be a potential source of bias because this might have led to 
differences in co-registrations of the FLAIR images and WMH masks to MNI space 
between baseline and first and second follow-up images. However, we consider 
this unlikely because we performed several analyses to estimate and minimize 
the effects of possible interscan effects. Co-registrations of all images to MNI space 
have been performed with great caution using an intermediate subject-template 
and the most robust and accurate registration routines [162]. Besides, in additional 
analyses we only used those WMH voxels that were classified as WMH both at 
baseline and at follow-up imaging, reducing the risk of bias because of possible 
overestimation of WMH at baseline. These analyses revealed similar results (data 
not shown). Moreover, we validated our findings by repeating analyses for all 
time-periods separately (Supplementary Table 2). The results for the first follow-up 
and the overall time-interval were comparable with the results for the second 
follow-up period in which scanner and sequence protocols remained identical. 
Hence it is unlikely that change in scanner between baseline and first follow-up 
biased the results. Second, so-called partial volume effects might have introduced 
a potential bias, that is, NAWM voxels around the border of existing WMH can 
contain a fraction of WMH signal intensity that affects measurements in that 
voxel. It is possible that this has led to an overestimation of intensities in the 
masks consisting of NAWM voxels that converted into WMH during follow-up 
when WMH progression occurred adjacent to already existing WMH. However, it 
cannot explain all differences, especially because also NAWM voxels remote from 
preexisting WMH were included in the masks. Third, because of the long-term 
follow-up of our study a proportion of the participants was unable to complete the 
entire follow-up. This attrition bias might have led to an underestimation of the 
effects because those lost to follow-up had more severe SVD already at baseline 
(Supplementary Table 1), and severity of WMH at baseline is associated with 
progression of WMH [60, 97, 110]. A fourth limitation might be that we would need 
even more advanced neuroimaging protocols to visualize the underlying 
mechanisms of final conversion of NAWM into WMH because MD values in NAWM 
Participants with severe baseline WMH showed higher normalized FLAIR and MD 
values and lower FA values than participants with mild baseline WMH in all areas, 
including the remaining NAWM. Differences between participants with mild 
versus severe baseline WMH have been reported before with respect to progression 
of their WMH, suggesting heterogeneity in pathogenesis of mild versus severe 
WMH [60, 97, 110]. Our observed differences in microstructural integrity between 
participants with mild and severe baseline WMH in both remaining NAWM and 
WMH confirm and extend this hypothesis. The observation of impaired micro-
structural integrity in remaining NAWM in participants with baseline Fazekas 2-3 
indicates that NAWM is not as normal one would expect from conventional MRI, 
and underlines the hypothesis of a continuous, ongoing disease of the WM in SVD. 
Moreover, it might be an explanation for the observation that WMH progression 
was most pronounced in participants with severe WMH at baseline [110].
The findings that the microstructural integrity within WMH was more impaired 
in participants with severe baseline WMH than in participants with mild baseline 
WMH and also continuously declined over time within WMH in both groups, 
suggest that not only NAWM, but also WMH is heterogeneous. This heterogeneity 
of microstructural integrity in WMH might explain clinical variances observed in 
subjects with similar SVD severity. For example, participants with impaired WMH 
microstructural integrity might have more severe clinical symptoms compared 
with participants with the same degree of WMH, but with higher microstructural 
integrity in their WMH. This hypothesis is supported by findings in patients with 
SVD, showing that patients with severe loss of microstructural integrity within 
their WMH showed decreased cognitive performance and had higher risk of 
parkinsonian signs, independent of WMH volume [158, 159].
Our findings can be clinically relevant because differences in microstructural 
integrity between remaining NAWM and incident WMH suggest that it would be 
possible to predict which NAWM voxels will convert into WMH, based on baseline 
FLAIR and DTI values. Our observation that impaired microstructural integrity at 
baseline was associated with more extensive WMH progression during 9 years 
implies that measures of microstructural integrity can possibly be used as 
biomarker for WMH progression as well as for personalized treatment approaches. 
Increasing evidence suggests that endothelial dysfunction might be an important 
factor in the pathogenesis of SVD because loss of WM microstructure has been 
associated with reduced endothelial function [160]. Although speculative, 
potential treatment strategies might target the brains’ microvascular endothelium 
with endothelin antagonists or nitric oxide donors [161], although randomized 
controlled trials are required. For now, we would argue a stringent control of 
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Supplementary material
Supplementary methods
Spatial normalization
A schematic overview of the spatial normalization process is displayed in Suppl. 
Fig. I. We created a T1-weighted subject-template from the T1-weighted scans of all 
three time points(1) using ‘buildtemplateparallel’, part of Advanced Neuroimaging 
Tools (ANTs) (http://stnava.github.io/ANTs/) [167], and registered the subject- 
template to atlas space (2) using ‘antsRegistrationSyN’ [167, 168]. All T1-weighted 
images were co-registered to the subject-template and subsequently to atlas-space 
(3) by ‘ApplyTransforms’ using the affine matrix and warp image from step (1) and 
(2), resulting in three T1-weighted images in atlas-space. 
The B0-images, along with the MD and FA maps, were registered to the T1-weighted 
images (4) using ‘epi_reg’, part of FMRIB’s Linear Image Registration Tool (FLIRT), 
FSL v5.0.9 (http://www.fmrib.ox.ac.uk/fsl/) [169, 170]. The FLAIR images, together 
with the binary WMH masks, were registered to the T1-weighted images using 
‘antsRegistrationSyN’ (5). All intermediate images were co-registered to the subject- 
template and subsequently to atlas-space, using ‘ApplyTransforms’. 
that converted into WMH within 5 years were similar to MD values in WMH. 
Otherwise, it might be that other processes such as secondary neurodegeneration, 
hypoperfusion, inflammation or small acute infarctions play a role in the final 
conversion into WMH. Studies with more follow-up ascertainments on shorter 
time-intervals may shed more light on the underlying processes of the final 
conversion into WMH. Because there is increasing awareness that SVD exerts its 
clinical effects by affecting remote brain structures [49, 147, 163, 164], future 
studies should also address the role of GM atrophy and how it is affected by WMH 
progression. In addition, it would be of interest to study to study changes in micro-
structural integrity preceding incident lacunes, since the presence of lacunes 
plays an important role in the development of cognitive deficits as well [165, 166].
In conclusion, WMH progression visible on conventional FLAIR imaging is only 
the “tip of the iceberg” with underlying loss of WM microstructural integrity that 
continuously declines over time. These findings indicate that microstructural 
measures derived from DTI can predict the development of WMH years before they 
are visible on conventional neuroimaging. Future studies should elaborate on the 
possibility to use these measures of microstructural integrity for personalized 
treatment approaches.
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Supplementary Figure 1 Schematic overview of the normalization process
Schematic overview of the spatial normalization process for three scans of the same subject. 1): Creation of 
subject-template using T1-weighted images. 2): Co-registration of T1-weighted images to the subject-tem-
plate and 3) atlas-space. 4): Co-registration of diffusion weighted (DTI) images to the T1-weighted images, 
together with the MD and FA images. 5) Co-registration of FLAIR images and WMH masks to the T1-weighted 
images. All images were subsequently co-registered via the subject-template to the atlas-space. 
Methodology is illustrated by color codes; i.e. red: buildtemplateparallel; light blue: antsRegistrationSyN 
for T1 (2) and FLAIR (5), and epi_reg for DTI (5); dark blue: ApplyTransforms.
2006 2011 2015
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Supplementary Table 1  Baseline characteristics of the study population versus 
those lost to follow-up
Study 
population 
(n=266) 
Lost to 
follow-up 
(n=237)
Significance, 
p-value
Demographics
Age, years 62.5 ± 7.8 69.2 ± 8.5 <0.001
Male sex, number of participants 157 (59.0) 127 (53.6) 0.177
MMSE score 28.6 ± 1.3 27.6 ± 1.8 <0.001
Education, years 10.1 ± 1.5 9.5 ± 2.0 <0.001
Vascular risk factors
Hypertension, number of participants 181 (68.0) 188 (79.3) 0.005
Diabetes, number of participants 28 (10.5) 47 (19.8) 0.002
Hypercholesterolemia, number of participants 112 (42.1) 125 (52.7) 0.020
Smoking, ever, number of participants 191 (71.8) 162 (68.4) 0.496
Alcohol, glasses/week 8.3 ± 9.1 7.5 ± 9.6 0.346
Body mass index, kg/m2 27.1 ± 4.1 27.2 ± 4.2 0.664
Imaging characteristics
Total brain volume, ml 1087.1 ± 69.8 1031.6 ± 81.0 <0.001
Grey matter volume, ml 621.2 ± 48.6 589.4 ± 51.8 <0.001
White matter volume, ml 465.8 ± 38.6 442.2 ± 50.2 <0.001
WMH volume, ml 2.2 (0.8 – 6.1) 7.3 (2.6 – 15.5) <0.001
Lacunes, number of participants 52 (19.5) 80 (33.8) <0.001
Microbleeds, number of participants 34 (12.8) 49 (20.7) 0.012
Data represent mean ± SD, nr of participants (%) or median (IQR). Comparisons between participants and 
those lost to follow-up were performed by t-test, Chi-square or Mann-Whitney-U test.
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Introduction
Cerebral small vessel disease (SVD) is frequently seen on neuroimaging of elderly 
as white matter hyperintensities (WMH), lacunes and microbleeds [5], and is 
recognized as the most important vascular contributor to the development of 
dementia [3, 4]. Hypertensive arteriopathy and cerebral amyloid angiopathy (CAA) 
are the most common causes of SVD [8], which are distinguished based on both 
the localization of the lesions and the distribution of neuroimaging characteristics, 
i.e. whereas CAA predominantly affects cortical arteries and hence is characterized by 
lobar microbleeds, hypertensive arteriopathy typically affects small perforating end 
arteries in deep brain areas and is characterized by deep microbleeds [9-11, 13].
Along with traditional vascular risk factors such as hypertension, amyloid β (Aβ) 
has emerged as contributor to SVD. Aβ has previously been associated with 
Alzheimer’s Disease (AD) and CAA, albeit in different forms. In AD, Aβ accumulates 
in the brain to form amyloid plaques, predominantly composed of Aβ42 peptides. 
This is in contrast to CAA in which Aβ accumulates in the blood vessels, mostly 
composed of Aβ40 peptides. Several cross-sectional studies have suggested a role 
for circulating Aβ in SVD, reporting elevated plasma Aβ levels in participants 
with SVD [33-36]. Prospective studies would help describe the associations between 
Aβ levels and SVD over time. One longitudinal study reported associations 
between plasma Aβ levels and WMH progression over time, although they did not 
find any cross-sectional associations [171]. Recent studies reported associations 
between plasma Aβ and hypertension [34, 36, 172, 173], suggesting that these 
etiologies might interact. It remains to be investigated whether plasma Aβ levels 
are differentially associated with CAA or hypertensive SVD.
In this study we investigated the association of baseline levels of plasma Aβ38, 
Aβ40 and Aβ42 peptides with both severity and progression of SVD markers, 
independent of hypertension. To assess whether plasma Aβ should be considered 
either a general SVD marker or specific for CAA, we examined Aβ levels by 
distribution of microbleeds.
Materials and Methods
Study population
The Radboud University Nijmegen Diffusion tensor and Magnetic resonance 
imaging Cohort (RUN DMC) study is a prospective cohort study of 503 non-demented 
elderly with SVD, that investigates risk factors and clinical consequences of SVD. 
Abstract
Background and purpose: Cerebral small vessel disease (SVD) is a frequent pathology 
in aging and contributor to the development of dementia. Plasma amyloid beta 
(Aβ) levels may be useful as early biomarker, but the role of plasma Aβ in SVD 
remains to be elucidated. We investigated the association of plasma Aβ levels with 
severity and progression of SVD markers.
Methods: We studied 487 participants from the RUN DMC study of whom 258 
participants underwent three MRI assessments over nine years. We determined 
baseline plasma Aβ38, Aβ40 and Aβ42 levels using ELISAs. We longitudinally 
assessed volume of white matter hyperintensities (WMH) semi-automatically, and 
manually rated lacunes and microbleeds. We analyzed associations between 
plasma Aβ and SVD markers by ANCOVA adjusted for age, sex and hypertension.
Results: Cross-sectionally, plasma Aβ40 levels were elevated in participants with 
microbleeds (mean 205.4 vs. 186.4 pg/ml; p<0.01) and lacunes (194.8 vs. 181.2 pg/
ml; p<0.05). Both Aβ38 and Aβ40 were elevated in participants with severe WMH 
(Aβ38 25.3 vs. 22.7 pg/ml; p<0.01; Aβ40 201.8 vs. 183.3 pg/ml; p<0.05). Longitudinally, 
plasma Aβ40 levels were elevated in participants with WMH progression (mean 
194.6 vs. 182.9 pg/ml; p<0.05). Both Aβ38 and Aβ40 were elevated in participants 
with incident lacunes (Aβ38 24.5 vs. 22.5 pg/ml; p<0.05; Aβ40 194.9 vs. 181.2 pg/ml; 
p<0.01), and Aβ42 in participants with incident microbleeds (62.8 vs. 60.4 pg/ml; 
p<0.05).
Conclusions: Plasma Aβ levels are associated with both presence and progression 
of SVD markers, suggesting that Aβ pathology might contribute to the development 
and progression of SVD. Plasma Aβ levels might thereby serve as inexpensive and 
non-invasive measure for identifying individuals with increased risk for 
progression of SVD.
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SVD markers
We assessed grey matter (GM), white matter (WM) and CSF volumes using SPM12 
(http://www.fil.ion.ucl.ac.uk/spm/) unified segmentation routines on the T1 MPRAGE 
images corrected for WMH, as has been described in detail elsewhere [110]. 
We calculated intracranial volume (ICV) by adding GM, WM and CSF volumes.
WMH volumes were calculated by a semi-automatic WMH segmentation method, 
which has been described previously [150]. Segmentations were visually checked 
for segmentation errors by one trained rater, blinded for clinical data. WMH 
volumes were corrected for inter-scan-differences in ICV and then normalized to 
baseline ICV. Because of its easy to use applicability we additionally used a 
modified Fazekas scale to categorize WMH severity at baseline (mild: Fazekas 0-1; 
moderate to severe: Fazekas 2-3) [151]. 
Both number and location of lacunes and microbleeds were rated manually on 
FLAIR/T1-weighted scans and T2*-weighted MRI scans according to the STRIVE 
criteria [5] by two trained raters blinded for clinical data. Intra and inter-rater 
agreement was good (weighted kappa 0.87 and 0.95 respectively for lacunes and 
0.85 and 0.86 for microbleeds) [152] We also assessed the distribution of micro - 
bleeds, distinguishing lobar from deep microbleeds, since lobar microbleeds 
are considered a hallmark of CAA and deep or infratentorial microbleeds are 
hypothesized to result from hypertensive or atherosclerotic microangiopathy 
[9-11]. Incidence was expressed as number of participants with any new microbleeds 
or lacunes at nine-year follow-up. Baseline and follow-up scans were checked 
side-by-side to verify incidence of microbleeds or lacunes.
Vascular risk factors
We assessed presence of hypertension, smoking, alcohol use, diabetes and hyper-
cholesterolemia at baseline by standardized questionnaires, as described previously 
[148]. We defined hypertension as the use of antihypertensive agents and/or systolic 
blood pressure greater than or equal to 140 mm Hg and/or diastolic blood pressure 
greater than or equal to 90 mm Hg [148].
Statistical analysis
We assessed associations between plasma Aβ38, Aβ40 and Aβ42 levels and SVD 
markers by one-way ANOVA, followed by a Bonferroni correction in order to correct 
for multiple comparisons. In cross-sectional analyses we examined differences 
in plasma Aβ levels for participants with or without microbleeds or lacunes at 
baseline. In longitudinal analyses we assessed differences in plasma Aβ levels for 
participants with or without incident microbleeds or lacunes during follow-up. 
The detailed study protocol including the inclusion and exclusion criteria has 
been published previously [148]. In short, all consecutive patients referred to the 
Neurology department who underwent diagnostic neuroimaging were selected for 
participation. Inclusion criteria were age between 50 and 85 years and SVD on 
neuroimaging. SVD was defined as the presence of any WMH or lacunes of presumed 
vascular origin on brain imaging [174].
Of 503 participants, twelve were excluded based on quality of plasma analyses: five 
participants because their Aβ levels for at least one out of three Aβ peptides were 
below detection limits and seven participants because the coefficients of variation for 
Aβ measures were higher than 10%. Four participants were additionally excluded 
because of insufficient scan quality, yielding a final sample of 487 participants for 
the present study. Of these, 258 participants underwent repeated MRI assessment 
at three time points (baseline in 2006, first follow-up in 2011 and second follow-up in 
2015) and could be included for longitudinal analyses. The Medical Review Ethics 
Committee region Arnhem-Nijmegen approved the study and all participants gave 
written informed consent. The data that support the findings of this study are 
available from the corresponding author upon request.
Plasma analyses
We collected blood samples from all participants at baseline in 2006. EDTA plasma 
was separated from whole-blood samples (10 ml blood with EDTA acting as anti-
coagulant) by routine methods. These samples were stored at -80°C and were only 
thawed immediately before Aβ quantification. We determined plasma levels of 
Aβ1-38, Aβ1-40 and Aβ1-42 isoforms (hereafter called Aβ38, Aβ40 and Aβ42) 
by enzyme-linked colorimetric immunosorbent assay (ELISA; EUROIMMUN AG, 
Lübeck, Germany). No samples needed further dilution. Details on the assay 
procedure have been described earlier [175]. The operators were trained with a 
 familiarization panel immunosorbent assay (ELISA; EUROIMMUN AG, Lübeck, 
Germany) to get acquainted with the assay protocol and sample manipulation. 
Neuroimaging protocols
Images were acquired at three time points on 1.5-Tesla MRI (2006: Siemens, 
Magnetom Sonata; 2011 and 2015: Siemens, Magnetom Avanto) and included the 
following whole brain scans: T1-weighted 3D MPRAGE, FLAIR and T2*-weighted 
gradient echo sequence. Full acquisition details have been described previously 
[110, 148].
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Results
Demographics, imaging characteristics and plasma Aβ levels of the study population 
are shown in Table 1. At baseline, 81 participants (16.6%) had microbleeds, 132 
(27.1%) lacunes and 163 (33.5%) had moderate to severe WMH. We observed incident 
microbleeds in 49 participants (19.0%), incident lacunes in 62 (24.0%) and WMH 
progression in 34 participants (13.2%) over the follow-up of almost nine years. 
We used linear regression analyses to examine associations between plasma Aβ 
levels and both WMH severity at baseline and WMH progression over time. 
We used four models to investigate the associations between plasma Aβ levels and 
SVD markers: Model 1: unadjusted; Model 2: adjusted for age and sex. In Model 3 
we additionally adjusted for hypertension to examine whether the associations 
between plasma Aβ levels and SVD markers were independent of hypertension 
status. In Model 4 we additionally adjusted for total brain volume or atrophy to 
examine whether the associations were independent of neurodegeneration. In 
analyses on longitudinal data we also adjusted for follow-up duration and baseline 
severity of SVD in Models 2, 3 and 4. 
We additionally analyzed the associations between the ratios of plasma Aβ38/
Aβ40, Aβ38/Aβ42 and Aβ42/Aβ40 and SVD markers, as ratios might enhance our 
understanding of underlying mechanisms. To further investigate the role of hyper- 
tension, we investigated whether plasma Aβ levels were associated with hypertension 
status, by one-way ANOVA followed by Bonferroni correction. 
To quantify the strength of the associations between plasma Aβ levels and SVD 
markers, we analyzed Aβ levels in quintiles of their distribution and tested 
continuous linear trend per stratum. We analyzed odds ratios (OR) of presence of 
microbleeds and lacunes by quintiles of Aβ using logistic regression analyses, 
adjusted for age and sex. We calculated WMH volumes by quintiles of Aβ levels and 
displayed median, 25th, and 75th percentile values as box, and lower and upper 
adjacent values as whiskers.
To assess whether plasma Aβ should be considered either a general SVD marker or 
a specific marker for CAA, we also analyzed the relation between plasma Aβ levels 
and microbleeds, stratified by their location (i.e. lobar vs. deep or infratentorial) by 
one-way ANOVA, followed by a Bonferroni correction.
Statistical analyses were performed using SPSS Statistics version 20.
Table 1  Characteristics of the study population
Baseline (n=487) 
Demographics
Age, years 65.7 ± 8.7 
Male sex, nr of participants 278 (57.1) 
MMSE score 28.1 ± 1.7 
Education > primary school, nr of participants 438 (89.9)
Imaging characteristics 
Microbleeds, nr of participants 81 (16.6)
Lacunes, nr of participants 132 (27.1)
WMH volume, ml 3.5 (1.2 – 10.8) 
Total brain volume, ml 1061.6 ± 80.4 
White matter volume, ml 455.0 ± 46.3 
Grey matter volume, ml 606.7 ± 52.6 
Plasma Aβ levels
Aβ38, pg/ml 23.5 ± 5.6
Aβ40, pg/ml 189.5 ± 38.4
Aβ42, pg/ml 60.9 ± 6.1
Aβ38/Aβ40 ratio 0.13 ± 0.02
Aβ38/Aβ42 ratio 0.39 ± 0.09
Aβ42/Aβ40 ratio 0.34 ± 0.13
Vascular risk factors
Hypertension, nr of participants 356 (73.1)
Smoking, ever, nr of participants 343 (70.4)
Alcohol, glasses/week 7.9 ± 9.4
Body mass index 27.1 ± 4.1
Glucose-lowering drugs, nr of participants 64 (13.1)
Lipid-lowering drugs, nr of participants 231 (47.4)
Data represent mean ± SD, nr of participants (%) or median (IQR). Hypertension is defined as usage of 
antihypertensive agents and/or blood pressure equal or higher than 140 systolic or 90 diastolic.
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Compared to participants who completed follow-up (n=258), those lost to follow-up 
were older, more often had hypertension or diabetes, and had more severe SVD 
characteristics at baseline (Supplementary Table 1). 
Plasma Aβ38 and Aβ40 levels, but not Aβ42 levels, were elevated in participants 
with microbleeds or lacunes, although only the associations with Aβ40 remained 
significant after adjustments for age, sex, hypertension and total brain volume 
(Table 2). Additional analyses separating participants with 1 versus >1 microbleeds 
or lacunes revealed similar results (data not shown). A similar pattern was observed 
for WMH severity: plasma Aβ38 and Aβ40 levels were positively associated with 
WMH volume (Table 2). Additional adjustments did not change these associations. 
Higher Aβ38/Aβ42 ratios and lower Aβ42/Aβ40 ratios were observed in participants 
with presence of SVD markers, but, except for the association between Aβ38/Aβ42 
ratios and WMH, the significance of these associations was lost after adjustment 
for age, sex and hypertension (Supplementary Table 2). Plasma Aβ38, Aβ40 and 
Aβ42 levels were elevated in participants with hypertension (Supplementary Table 3).
Figure 1 illustrates a linear increase in the prevalence of microbleeds, lacunes and 
WMH volume with higher plasma Aβ40 quintiles (p-trend ≤0.001), but not with 
Aβ38 or Aβ42 quintiles. Participants with highest quintile of plasma Aβ40 levels 
had both higher risk of microbleeds (OR 3.3, 95%CI 1.5-7.3, p=0.003 unadjusted; OR 
2.2, 95%CI 0.95-5.0, p=0.066 age and sex adjusted) and higher risk of lacunes (OR 
3.5, 95%CI 1.7-6.9, p<0.001 unadjusted; OR 2.2, 95%CI 1.1-4.6, p=0.029 age and sex 
adjusted). WMH volume was also higher in highest quintile of plasma Aβ40 
(median: 7.2 ml) compared to the lowest quintile (median: 1.9 ml). 
Longitudinally, plasma Aβ40 levels were elevated in participants with incident 
lacunes and were positively associated with WMH progression, although these 
associations were no longer significant after additional adjustments (Table 2). 
Plasma Aβ38 levels were elevated in participants with incident lacunes during 
follow-up and plasma Aβ42 levels were elevated in participants with incident 
microbleeds (Table 2). These associations remained significant after additional 
adjustments for age, sex, follow-up duration, hypertension, total brain atrophy 
and presence of SVD at baseline.
Elevated plasma Aβ40 levels were associated with higher odds of incident lacunes 
(p-trend=0.002; highest quintile OR 3.0, 95%CI 1.2-7.5, p=0.016 unadjusted; OR 2.5, 
95%CI 0.97-6.3, p=0.058 adjusted) and WMH progression (highest quintile median 
2.3 ml; lowest quintile median 1.3 ml; p=0.006) over the follow-up (Figure 2). 
Elevated plasma Aβ38 levels were associated with higher odds of incident lacunes 
Figure 1   Associations between baseline plasma Aβ levels and presence  
of SVD markers
Associations between quintiles of plasma Aβ levels (left: Aβ38; middle: Aβ40; right: Aβ42) and 
microbleeds, lacunes (odds ratios) and WMH volumes (ml). Odds ratios (OR) are analyzed by logistic 
regression analyses, adjusted for age and sex. Box-and-whisker plots display median, 25th, and 75th percentile 
values as box, and lower and upper adjacent values as whiskers. P-trends for continuous linear trend per 
stratum are displayed in the upper left  corners.
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Figure 2   Associations between baseline plasma Aβ levels and progression  
of SVD markers 
Associations between quintiles of plasma Aβ levels (left: Aβ38; middle: Aβ40; right: Aβ42) and incident 
microbleeds, incident lacunes (odds ratios) and WMH progression (ml/y). Odds ratios (OR) are analyzed by 
logistic regression analyses, adjusted for age, sex, follow-up duration and baseline SVD severity. Box-and-
whisker plots display median, 25th, and 75th percentile values as box, and lower and upper adjacent 
values as whiskers. P-trends for continuous linear trend per stratum are displayed in the upper left 
corners.
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WMH and lacunes in all groups [33]. In the population-based Rotterdam Scan 
Study elevated plasma Aβ40 and Aβ42 levels were associated with the extent of 
WMH and the presence of lacunes in APOE ε4 carriers only [35]. Unfortunately, we 
do not have data on APOE genotype for our participants. More recently, associations 
between elevated plasma Aβ38, Aβ40 and Aβ42 levels and markers of SVD have 
been reported in two subsamples of the same population-based study [176]. Our 
results showing elevated plasma Aβ levels in participants with SVD strengthen 
the evidence for an association between plasma Aβ and SVD cross-sectionally.
The longitudinal design of our study enabled us to elaborate on the directionality 
of the associations between plasma Aβ levels and cerebrovascular pathology. In 
our study, progression of WMH and incident microbleeds and lacunes were 
associated with elevated plasma Aβ levels of one or more of the peptides. In 
contrast, the Three-City Dijon Study showed that decreased plasma Aβ40 and 
Aβ42 levels were associated with WMH progression over time, but did not find 
cross-sectional associations of plasma Aβ with SVD markers [171]. Discrepancies in 
these results might be explained by the different study populations with variation 
in SVD burden, different assay designs, or how the analysis of the samples was 
done. Especially, the multicenter design might have complicated longitudinal 
SVD assessment [145]. Interestingly, in our study associations were different for 
different Aβ peptides: elevated Aβ42 levels were associated with incident 
microbleeds whereas elevated Aβ38 and Aβ40 levels were associated with WMH 
progression and incident lacunes. This might be explained by the characteristics 
of the different Aβ peptides as the Aβ42 peptide is known to have more tendency 
to aggregate compared to the Aβ38 and Aβ40 peptides [177, 178]. Enhanced 
accumulation of Aβ42 in the media of arterioles [179] might weaken the vessel 
walls and ultimately lead to hemorrhages [180], although experimental studies 
would be required to investigate the underlying mechanisms. Altogether, our 
findings that elevated plasma Aβ levels were not only associated with severity of 
SVD cross-sectionally but also predicted the progression of SVD over time, suggest 
that amyloid β pathology - either neurodegeneration or CAA - might contribute to 
the development and progression of SVD. 
Several mechanisms could explain the associations between plasma Aβ levels and 
SVD. First, plasma Aβ might enhance endothelium-dependent vasoconstriction, 
leading to cerebral hypoperfusion which in turn might result in WMH and 
lacunes [181-183]. Second, an inverse relation could also explain our findings, i.e. 
that cerebral hypoperfusion – or reduced cerebral blood flow – promotes 
overproduction of Aβ and its secretion into the circulation [184]. Our findings 
showing associations between plasma Aβ levels and progression of SVD markers 
(p-trend=0.045; highest quintile OR 2.9, 95%CI 1.2-7.3, p=0.022 unadjusted; OR 2.5, 
95%CI 0.98-6.4, p=0.054 adjusted) and elevated plasma Aβ42 levels with higher 
odds of incident microbleeds (p-trend=0.041; highest quintile OR 2.2, 95%CI 
0.78-5.9, p=0.140 unadjusted; OR 2.2, 95%CI 0.76-6.2, p=0.146 adjusted).
Additional analyses on plasma Aβ levels by spatial distribution of microbleeds 
(Table 3) revealed significantly elevated plasma Aβ40 levels in participants with 
both lobar and deep microbleeds (n=17). This was not found for plasma Aβ38 and 
Aβ42 levels.
Discussion
Our study shows that elevated plasma Aβ levels were associated with neuroimaging 
markers of SVD, including microbleeds, lacunes and WMH cross-sectionally, and 
with progression of SVD longitudinally over a follow-up of almost nine years. 
These findings suggest a relationship between amyloid β pathology and the 
development and progression of SVD.
Our cross-sectional findings that plasma Aβ levels are elevated in participants 
with SVD are in line with results from previous cross-sectional studies. The 
Swedish BioFINDER study reported associations between elevated plasma Aβ40 
and Aβ42 levels and WMH and microbleeds [34] and the ADNI study reported 
elevated Aβ40 levels in participants with lacunar infarctions [36]. Another study 
in elderly with CAA, Alzheimer’s Disease (AD) and mild cognitive impairment 
(MCI) reported associations between elevated plasma Aβ40 levels and increased 
Table 3  Plasma Aβ levels by distribution of microbleeds
No microbleeds Distribution of microbleeds
No microbleeds
(n=406)
Strictly lobar
(n=45)
Strictly deep
(n=19)
Lobar & deep
(n=17)
Plasma Aβ levels
Aβ38, pg/ml 23.2 ± 5.5 24.9 ± 6.6 24.6 ± 5.4 26.5 ± 5.5
Aβ40, pg/ml 186.4 ± 36.1 201.2 ± 46.0 206.4 ± 51.4 215.5 ± 39.3 a
Aβ42, pg/ml 60.8 ± 5.9 60.7 ± 6.8 62.3 ± 8.3 62.0 ± 5.6
Plasma Aβ levels are expressed as mean ± SD (in pg/ml) and stratified by distribution of microbleeds. 
Statistical differences in plasma Aβ levels vs. group without microbleeds, analyzed by one-way ANOVA 
followed by Bonferroni correction. a p<0.05 unadjusted.
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Several limitations deserve consideration. First, since we only collected plasma 
samples at baseline we were not able to perform repeated plasma Aβ measurements. 
As a consequence, we could not assess the influence of changes in plasma Aβ levels 
over time on progression of SVD markers. Second, we do not have information on 
APOE genotype, which precluded us from studying the interaction between APOE 
status, plasma Aβ levels and SVD markers. Third, attrition bias might have led to 
an underestimation of the effects. Due to the long-term follow-up of our study 
a proportion of the participants was unable to complete the entire follow-up 
which may have reduced power in analyses on progression of SVD markers over 
time, since those lost to follow-up had more severe SVD already at baseline 
(Supplementary Table 1). 
Summary
In summary, we report associations between plasma Aβ levels and neuroimaging 
markers of SVD, both cross-sectional on severity of SVD at baseline and 
longitudinal on progression of SVD over time. These findings suggest a relationship 
between Aβ and vascular disease. Plasma Aβ levels might thereby serve as measure 
for identifying individuals with increased risk for progression of SVD.
over time support the first mechanism. Third, a relative overproduction of Aβ 
might lead to enhanced Aβ accumulation in the media of arterioles [179], 
weakening the vessel walls and leading to microbleeds. Fourth, SVD might affect 
plasma amyloid levels through impairment in perivascular clearance [185], leading 
to vascular amyloid deposits and decreased plasma Aβ levels. Since we found 
elevated plasma Aβ levels in participants with SVD we consider the latter 
hypothesis less likely. Finally, the reported associations between plasma Aβ and 
SVD might also be explained by mixed age-related pathologies, i.e. SVD might 
interact with Alzheimer’s type neurodegeneration. This hypothesis has been 
supported by previous studies reporting presence of WMH in AD patients [186, 
187], though our findings that associations between plasma Aβ levels and SVD 
markers were independent of markers for neurodegeneration attenuates this 
hypothesis.
Our findings indicate that plasma Aβ levels are elevated in participants with 
hypertension (Supplementary Table 3), which, in turn, is associated with SVD 
markers (data not shown). This association between hypertension and plasma Aβ 
is also reported in previous studies [34, 36, 172, 173]. In our analyses we adjusted 
for hypertension to confirm that the associations between plasma Aβ levels and 
SVD markers were independent of hypertension. In future it would be interesting 
to study the interactions between blood pressure, plasma Aβ levels and cerebrovas-
cular pathology in more detail. 
Additional analyses on plasma Aβ levels by distribution of microbleeds showed no 
clear distinction in plasma Aβ levels between deep versus lobar microbleeds, 
although analyses might have been underpowered. Together with the associations 
found between plasma Aβ levels and WMH and lacunes, these results suggest that 
plasma Aβ might be a general cerebrovascular disease marker rather than specific 
for CAA.
Major strengths of this study include the large number of elderly participants with 
SVD in whom both plasma Aβ levels and neuroimaging were assessed, and the 
longitudinal design of the study with a long follow-up duration. The long follow-up 
duration enabled us to study progression of SVD makers including WMH, lacunes 
and microbleeds over the course of almost a decade. Furthermore, assessments of 
SVD neuroimaging markers and Aβ levels were performed blinded to clinical data, 
limiting the risk of bias. Finally, our study has high external validity for patients 
with SVD in a general neurology clinic.
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Supplementary Table 1  Baseline characteristics of participants who completed 
follow-up compared to those lost to follow-up
Completed 
follow-up 
(n=258)
Lost to
follow-up
(n=245)
Significance, 
p-value
Demographics
Age, years 62.4 ± 7.7 69.1 ± 8.5 <0.001
Male sex, nr of participants 153 (59.3) 131 (53.5) 0.208
MMSE score 28.6 ± 1.3 27.6 ± 1.8 <0.001
Education > primary school,  
nr of participants
243 (94.2) 211 (86.1) 0.003
Imaging characteristics 
Microbleeds, nr of participants 36 (14.0) 47 (19.2) 0.118
Lacunes, nr of participants 53 (20.5) 85 (34.7) <0.001
WMH volume, ml 2.2 (0.8 – 5.7) 7.3 (2.6 – 16.1) <0.001
Total brain volume, ml 1087.2 ± 70.9 1033.2 ± 80.1 <0.001
White matter volume, ml 465.8 ± 39.5 443.0 ± 49.4 <0.001
Grey matter volume, ml 621.4 ± 49.0 590.2 ± 51.5 <0.001
Plasma Aβ levels
Aβ38, pg/ml 23.0 ± 5.1 23.9 ± 7.3 0.108
Aβ40, pg/ml 184.5 ± 30.8 193.1 ± 54.9 0.029
Aβ42, pg/ml 60.9 ± 6.2 61.6 ± 18.7 0.527
Aβ38/Aβ40 ratio 0.13 ± 0.02 0.12 ± 0.02 0.916
Aβ38/Aβ42 ratio 0.38 ± 0.09 0.39 ± 0.10 0.264
Aβ42/Aβ40 ratio 0.35 ± 0.15 0.34 ± 0.15 0.472
Vascular risk factors
Hypertension, nr of participants 178 (69.0) 191 (78.0) 0.026
Smoking, ever, nr of participants 182 (70.5) 171 (69.8) 0.922
Alcohol, glasses/week 8.2 ± 9.1 7.7 ± 9.6 0.550
Body mass index 27.2 ± 4.1 27.1 ± 4.1 0.733
Glucose-lowering drugs, nr of 
participants
20 (7.8) 46 (18.8) <0.001
Lipid-lowering drugs, nr of 
participants
112 (43.4) 125 (51.0) 0.090
Data represent mean ± SD, nr of participants (%) or median (IQR). Hypertension is defined as usage of 
antihypertensive agents and/or blood pressure equal or higher than 140 systolic or 90 diastolic.
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Supplementary Table 3  Plasma Aβ levels stratified by hypertension status
No hypertension
(n=131)
Hypertension
(n=356)
Plasma Aβ levels
Aβ38, pg/ml 22.0 ± 5.0 24.1 ± 5.7 a, c
Aβ40, pg/ml 179.3 ± 30.2 193.3 ± 40.5 a
Aβ42, pg/ml 60.0 ± 6.0 61.3 ± 6.1 b, c
Plasma Aβ levels (in pg/ml) stratified by hypertension status at baseline. Statistical differences are analyzed by 
one-way ANOVA, followed by a Bonferroni correction. a p<0.001, b p<0.05 unadjusted; c p<0.05 adjusted 
for age and sex.
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Introduction
Neurofilament Light Chain (NfL) is an emerging blood marker for neuroaxonal 
damage. A role of serum NfL has been established in multiple neurological diseases 
affecting the elderly, such as motor neuron disease [188], Alzheimer’s disease [39], 
and frontotemporal dementia [40]. However, the factors influencing serum NfL 
levels in the elderly are incompletely understood. Cerebral small vessel disease 
(SVD) is a highly prevalent condition and a major cause of stroke, vascular cognitive 
impairment and eventually loss of independence [8]. Recent studies suggest that 
cerebrovascular pathology has an effect on serum NfL. Elevated serum levels were 
observed in patients with a recent small subcortical infarct [189] and in patients 
with stroke caused by cervical artery dissection [190]. Also, NfL levels in CSF 
correlated significantly with white matter hyperintensity (WMH) load, one MRI 
marker of SVD burden [191]. However, a detailed account of the relationship 
between SVD burden and NfL in blood is lacking.
The aim of the current study was to assess the association between serum NfL and 
SVD burden as assessed by MRI and clinical status. We first analyzed patients with 
the genetically defined SVD CADASIL (Cerebral Autosomal-Dominant Arteriopathy 
with Subcortical Infarcts and Leukoencephalopathy). Because these patients show 
severe SVD already at young age, confounding by other age-related pathologies 
impacting on serum NfL levels, such as neurodegenerative pathology, can be 
largely excluded [123]. To validate our findings and to assess their generalizability 
towards the more common, sporadic form of SVD, we further analyzed a large, 
independent sample of patients with sporadic SVD.
We hypothesized that serum NfL levels are associated with MRI markers for SVD, 
i.e. white WMH volume, lacune volume, brain volume, microbleed count and mean 
diffusivity from diffusion tensor imaging (DTI). Furthermore, we hypothesized 
that serum NfL levels are associated with clinical status in SVD, in particular 
cognitive performance, focal neurological deficits, and disability.
Methods
Study participants 
CADASIL patients were recruited into the ongoing, prospective ‘VASCAMY’ study. 
The diagnosis was confirmed by either molecular genetic testing or ultrastructural 
analysis of skin biopsies. Exclusion criteria were the presence or history for i) 
diabetes mellitus (because of its pronounced effect on brain structure), ii) other 
Abstract
Background and purpose: Neurofilament Light Chain (NfL) is a blood marker for 
neuroaxonal damage. We assessed the association between serum NfL and cerebral 
small vessel disease (SVD), which is highly prevalent in elderly individuals and a 
major cause of stroke and vascular cognitive impairment.
Methods: Using a cross-sectional design, we studied 53 patients with genetically 
defined SVD (CADASIL), 439 patients with sporadic SVD, and 93 healthy control 
subjects. Serum NfL was measured by an ultrasensitive single-molecule array 
assay. We quantified MRI markers of SVD, i.e. white matter hyperintensity volume, 
lacune volume, brain volume, microbleed count and mean diffusivity obtained 
from diffusion tensor imaging. Clinical characterization included neuropsycho-
logical testing in both SVD samples. CADASIL patients were further characterized 
for focal neurological deficits (NIH stroke scale, NIHSS) and disability (modified 
Rankin scale, mRS).
Results: Serum NfL levels were elevated in both SVD samples (p<1e-05 compared 
with controls) and associated with all SVD MRI markers. The strongest association 
was found for mean diffusivity (CADASIL: R2=0.52, p=1.2e-09; sporadic SVD: 
R2=0.21, p<1e-15). Serum NfL levels were independently related to processing speed 
performance (CADASIL: R2=0.27, p=7.6e-05; sporadic SVD: R2=0.06, p=4.8e-08), 
focal neurological symptoms (CADASIL: NIHSS, p=4.2e-05) and disability (CADASIL: 
mRS, p=3.0e-06).
Conclusions: We found serum NfL levels to be associated with both imaging and 
clinical features of SVD. Serum NfL might complement MRI markers in assessing 
SVD burden. Importantly, SVD needs to be considered when interpreting serum 
NfL levels in the context of other age-related diseases. 
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Neuropsychological testing
Patients underwent comprehensive neuropsychological testing. In the current 
study, we focused on processing speed performance, the main cognitive deficit in 
SVD patients [193, 194]. For CADASIL patients, trail making tests (matrix A and B) 
were available. For sporadic SVD patients, the 1-letter subtask of the Paper-Pencil 
Memory Scanning Test and the Letter-Digit Substitution Task were available. For 
each test, age and education corrected z-scores were first calculated in reference 
to a healthy control population from the literature [195-197]. The mean of both 
z-scores was then used as compound processing speed z-score.
Serum biobanking
Blood samples were collected through a standardized procedure. Blood was drawn 
into serum containers with clotting activator and subsequently allowed to clot for 
at least 30 minutes at room temperature. Separation of serum was achieved by 
centrifugation at 2,000g for 10 minutes. Samples were aliquoted in polypropylene 
screw cap vials and stored deep-frozen until analysis.
Neurofilament light chain (NfL) assay 
All samples were analyzed on the same single molecule array instrument (Simoa 
HD-1, Quanterix, Lexington, MA, USA) in Basel. We used the capture monoclonal 
antibody (mAB) 47:3, and the biotinylated detector mAB 2:1 (UmanDiagnostics, 
Umeå, Sweden) [198], transferred onto the Simoa platform. Bovine lyophilized NfL 
was obtained from UmanDiagnostics. Calibrators ranged from 0 to 2,000 pg/ml. 
Intra- and inter-assay variability of the assay were below 20%, respectively. The 
analytical sensitivity was 0.32 pg/ml. All samples produced signals above the 
analytical sensitivity of the assay.
MRI scanning and analysis
Within a study, all SVD patients were examined on a single MRI scanner (CADASIL: 
3 Tesla Siemens Magnetom Verio; sporadic SVD: 1.5 Tesla Siemens Magnetom 
Sonata, Siemens Healthcare, Erlangen, Germany) with a standardized protocol 
including 3D-T1, FLAIR, T2, and DTI sequences. Sequence parameters have already 
been published [199]. We calculated white matter hyperintensity (WMH) volume, 
lacune volume and brain volume and counted cerebral microbleeds as previously 
described [199, 200]. For normalization, all volumes were divided by the volume of 
the intracranial cavity. 
Mean diffusivity is an established measure for SVD burden calculated from DTI. It 
captures the microstructural integrity of white matter through diffusivity of 
water in the tissue. Diffusion images were first pre-processed to correct for eddy 
known neurological or psychiatric diseases, and iii) clinically apparent stroke 
within the last three months. Fifty-four patients gave consent for the biobanking 
procedure and were therefore included in this analysis. All examinations (clinical 
assessment, neuropsychological testing, blood draw, MRI) were performed on the 
same day or within 2 consecutive days. One subject was excluded because of 
missing MRI data (scanner malfunction). The final sample comprised 53 CADASIL 
patients.
Data for sporadic SVD patients was obtained from the Radboud University Nijmegen 
Diffusion tensor and Magnetic resonance Cohort (RUN DMC). This prospective 
study recruited 503 non-demented elderly (age 50-85) with SVD, defined as the 
presence of lacunes and/or WMH on neuroimaging. Patients were recruited in a 
hospital-based setting. Clinical examination and blood draw were performed on 
the same day, and the majority of patients received the MRI scan within 2 weeks. 
More details can be found in the previously published study protocol [148]. 
Sixty-four subjects were excluded because of the presence of an old, large vessel 
territorial infarct (n=55), insufficient MRI quality (n=4) or missing clinical/neuro-
psychological data (n=5). The final sporadic SVD sample comprised 439 patients. 
In addition, healthy control subjects (n=93) were drawn from our biobank repository, 
where we collect samples from healthy subjects across multiple studies. These subjects 
were relatives of outpatient clinic patients or volunteers recruited through 
advertisements. The absence of cerebrovascular events or other neurological symp-
toms/-diagnoses was established through a clinical interview and a neurological 
examination by a board-certified neurologist.
All measurements were performed blinded from each other. The two SVD samples 
were subjected to independent statistical analyses. The studies were approved by 
the ethics committee of the respective institution. Written and informed consent 
was obtained from all subjects after receiving a complete description of the study.
Clinical characterization
All SVD patients were characterized according to standardized procedures. 
Clinical severity was assessed using established scales for activities of daily living 
(Barthel scale), focal neurological deficits (NIH stroke scale [NIHSS]), and disability 
(modified Rankin scale [mRS]) [192]. The latter two were only available in the 
CADASIL sample. 
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order to enhance the prediction accuracy and interpretability of regression models. 
Serum NfL, all MRI markers, age and sex were included as independent variables 
in lasso regression and variables with non-zero coefficients after cross-validation 
were carried forward to the final multiple regression model.
Results
Characteristics of SVD patients and healthy controls are presented in Table 1. 
Patients in both SVD samples, CADASIL and sporadic SVD, were relatively mildly 
affected as indicated by unimpaired activities of daily living (Barthel scale). 
Healthy controls covered the entire age range of both SVD samples (30 – 85 years). 
In both SVD samples, a substantial number of patients had suffered from a prior 
stroke or transient ischemic attack. Serum NfL levels in these patients were not 
higher than in patients without history for a cerebrovascular event (CADASIL: 
p=0.144, sporadic SVD: p=0.190).
Serum NfL is increased in SVD
In comparison with healthy controls, we found increased serum NfL levels in both 
SVD samples (CADASIL: p=4.1e-06, sporadic SVD: p<1e-15, Wilcoxon rank sum tests 
with Bonferroni correction) (Figure 1A). These differences were also significant 
after correction for age (Supplementary Figure, CADASIL: p=4.2e-12, sporadic 
SVD: p<1e-15). The ability of serum NFL to differentiate between diagnostic groups 
as assessed by receiver operating characteristics is shown in Figure 1B.
In all groups, serum NfL was positively correlated with age (Table 2) but there was 
a significant interaction with diagnosis: Patients with sporadic SVD showed a 
steeper increase of serum NfL levels with age than healthy controls (p=0.011 for 
interaction).
Serum NfL is associated with MRI markers for SVD
We next assessed associations between serum NfL levels and established MRI 
markers for SVD as well as age and sex. Simple linear regression analyses (Table 2) 
showed significant associations between serum NfL and all imaging markers 
as well as age, both in the CADASIL sample and in the sporadic SVD sample. 
Regarding SVD imaging markers, the strongest effect was found for mean diffusivity 
in both samples. Most associations remained significant after controlling for age 
(Table 2).
current induced distortions and motion as previously described [199]. The diffusion 
tensor was estimated using ‘dtifit’, part of the Functional Magnetic Resonance 
Imaging of the Brain (FMRIB) Software Library (FSL) [201, 202]. To avoid contamination 
by CSF partial volume, the analysis of mean diffusivity was restricted to the main 
fiber tracts. For this purpose, diffusion data were skeletonized as implemented in 
the tract-based spatial statistics pipeline (TBSS) of FSL [203]. In brief, all subjects’ 
fractional anisotropy data were aligned into a common space using nonlinear 
registration and the standard FA template provided within FSL. Each subject’s 
fractional anisotropy data was then projected onto the tract skeleton in standard 
space. Finally, mean diffusivity images were projected onto the skeleton using the 
fractional anisotropy derived projection parameters. The final mean diffusivity 
skeletons were masked with the standard skeleton thresholded at a value of 0.3 to 
focus the analysis on main fiber tracts. Furthermore, regions of the skeleton 
directly adjacent to the ventricles were removed by a custom-made mask to further 
minimize the contamination of the skeleton by CSF partial volume. Finally, the 
mean over the entire mean diffusivity skeleton was used for subsequent analyses. 
Statistical analysis
Statistical analyses were performed in ‘R’, version 3.1.2 [204]. For group comparisons, 
we used the non-parametric Wilcoxon rank sum test (with Bonferroni correction 
for multiple comparisons). The ability of serum NfL to discriminate between SVD 
patients and healthy controls was assessed using receiver operating characteristic 
analysis as implemented in the R package ‘ROCR’ (version 1.0-7) [205].
We applied linear regression analysis to assess associations with serum NfL levels 
as well as processing speed compound scores as dependent variables. All R2 values 
reported are ‘adjusted R2’. Variables were power transformed when necessary to 
ensure the appropriateness of linear models as indicated by the distribution of 
residuals. To ensure that regression results were robust and not driven by outliers, 
we conducted a statistical regression outlier test as implemented in the ‘car’ 
package of ‘R’ [206]. As a result, two CADASIL patients and two sporadic SVD 
patients had to be excluded from regression analyses. In order to determine 
associations with clinical scores (NIHSS and mRS as dependent variables), we used 
ordinal logistic regression as implemented in the ‘R’ package ‘ordinal’ [207]. For all 
analyses, correction for multiple testing was performed via the Bonferroni method.
For multiple regression, we first applied lasso (least absolute shrinkage and selection 
operator) regression for variable selection as implemented in the R package 
‘glmnet’ (for linear response) or ‘glmnetcr’ (for ordinal response) with standard 
parameters [208]. Lasso performs both variable selection and regularization in 
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explaining more processing speed variance than serum NfL levels. The associations 
between the other imaging markers and processing speed were weaker than for 
serum NfL.
In the CADASIL sample, the lasso regression model including serum NfL, all 
imaging markers, age and sex as independent variables selected mean diffusivity, 
lacune volume and microbleed count for the final model. In the sporadic SVD 
sample, lasso regression selected mean diffusivity and serum NfL (Table 3).
Serum NfL levels are independently related to symptom severity  
and disability
Using the CADASIL sample, we were also able to assess the association between 
serum NfL levels and clinical scores capturing focal neurological deficits (NIHSS) 
and disability (mRS).
Serum NfL levels are related to processing speed impairment
In order to investigate the association between serum NfL levels and cognitive 
deficits, we focused on processing speed performance, the cognitive domain most 
affected in SVD patients [193, 194]. 
In both samples, CADASIL and sporadic SVD, simple linear regression analysis 
showed a significant association between serum NfL levels and processing speed 
scores (Table 3, Figure 2A). Significant associations were also found between all 
imaging markers and processing speed scores (Table 3). In both samples, mean 
diffusivity showed the strongest effect and was the only imaging parameter 
Table 1  Characteristics of the SVD samples
CADASIL
(Munich)
n=53
Sporadic SVD
(RUN DMC)
n=439
Healthy  
controls 
n=93
Demographic characteristics
Age, median (IQR) [years] 56.0 (11.2) 64.3 (15.2) 59 (12.6)
Female, n (%) 36 (67.9) 199 (45.3) 58 (62.4)
Prior stroke/TIA, n (%) 28 (52.8) 162 (36.9) 0
Last stroke/TIA, median (IQR) [years] 2.9 (8.9) 0.7 (1.7) n/a
Vascular risk factors, n (%)
Hypertension 11 (20.8) 316 (72) 16 (17.2)
Hypercholesterolemia 24 (45.3) 193 (44) 12 (12.9)
Diabetes 0 (0) 59 (13.4) 5 (5.4)
Current or past smoking 34 (64.2) 304 (69.2) n/a
Clinical scores, median (IQR)
Barthel scale score 100 (0) 100 (0) n/a
Processing speed z-score 1.62 (2.21) –0.31 (1.58) n/a
NIHSS score 0 (1) n/a n/a
mRS score 0 (1) n/a n/a
SVD markers, median (IQR)
Serum NfL [pg/ml] 41.7 (46.9) 50.8 (38.9) 26.0 (14.7)
WMH volume [%]a 7.52 (7.39) 0.59 (1.23) n/a
Lacune volume [%]a 0.024 (0.064) 0 (0) n/a
Microbleed count 0 (3) 0 (0) n/a
Brain volume [%]a 78.4 (6.82) 65.5 (7.69) n/a
Mean diffusivity [10-4 mm2/s] 9.86 (1.83) 8.02 (0.55) n/a
IQR, interquartile range; n/a, not available, mRS, modified Rankin scale; NIHSS, NIH stroke scale; NfL, 
neurofilament light chain; SVD, small vessel disease; TIA, transient ischemic attack; WMH, white matter 
hyperintensity; a normalized to intracranial volume
Figure 1   Increased serum NfL in SVD 
A. Compared with healthy controls (HC), serum NfL levels are increased in CADASIL (CAD) and sporadic 
SVD (SVD) patients. Please note the logarithmic scale. ***p<0.001 (Wilcoxon rank sum test with Bonferroni 
correction). B. Receiver operating characteristics analyses for serum NfL: CADASIL vs. healthy controls 
(top panel) and sporadic SVD vs. healthy controls (bottom panel). The analyses were calculated with raw 
serum NfL values (black lines) and values after regressing out the effect of age (grey lines). AUC, area 
under the curve.
A B
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For NIHSS, simple ordinal logistic regression showed the strongest association 
with serum NfL levels (Figure 2B, Table 4). Significant, albeit weaker associations 
were also found between imaging markers (except for microbleeds) and NIHSS 
scores. After ordinal lasso regression including serum NfL levels, all imaging 
markers, age and sex as independent variables, the final model comprised mean 
diffusivity, brain volume and serum NfL (Table 4).
For disability, simple ordinal logistic regression showed the most significant 
association between serum NfL levels and mRS scores (Figure 2C, Table 4), and 
associations between all imaging markers and mRS scores were weaker. The final 
model after lasso regression comprised serum NfL, brain volume, and (at trend 
level) microbleed count and mean diffusivity (Table 4).
Table 2  Linear regression models with serum NfL levels as dependent variable 
Beta† p p|age‡ R2
CADASIL
Mean diffusivity 0.730 1.2e-09* 1.2e-05* 0.52
Age 0.629 7.8e-07* – 0.38
Brain volume§ –0.595 4.1e-06* 0.005* 0.34
WMH volume§ 0.575 1.0e-05* 0.023 0.32
Lacune volume§ 0.558 2.1e-05* 6.41e-04* 0.30
Microbleed count 0.366 0.008 0.021 0.11
Sex 0.117 0.418 0.825 0
Sporadic SVD
Age 0.558 <1e-15* – 0.31
Mean diffusivity 0.461 <1e-15* 7.31e-05* 0.21
WMH volume§ 0.382 <1e-15* 1.08e-05* 0.14
Brain volume§ –0.376 <1e-15* 0.248 0.14
Lacune volume§ 0.264 2.2e-08* 2.18e-06* 0.07
Microbleed count 0.149 0.0019* 0.007 0.02
Sex –0.003 0.947 0.993 0
NfL, neurofilament light chain; WMH, white matter hyperintensity
† standardized beta, ‡ controlled for age, § normalized to intracranial volume
*significant after correction for multiple testing (Bonferroni)
Table 3  Linear regression models with processing speed as dependent variable 
Beta† p R2
CADASIL: Simple linear regression
Mean diffusivity –0.626 9.0e-07* 0.38
Serum NfL –0.526 7.6e-05* 0.27
Lacune volume‡ –0.521 9.0e-05* 0.26
Microbleed count –0.486 3.0e-04* 0.22
WMH volume‡ –0.474 4.5e-04* 0.21
Brain volume‡ 0.374 0.007 0.12
Age –0.240 0.091 0.04
Sex 0.019 0.895 0
CADASIL: Multiple linear regression (lasso): p=6.6e-07, R2=0.45
Mean diffusivity –0.340 0.022 -
Lacune volume –0.283 0.029 -
Microbleed count –0.256 0.041 -
Sporadic SVD: Simple linear regression
Mean diffusivity –0.267 1.5e-08* 0.07
Serum NfL –0.257 4.8e-08* 0.06
WMH volume‡ –0.207 1.3e-05* 0.04
Lacune volume‡ –0.174 2.6e-04* 0.03
Brain volume‡ 0.173 2.7e-04* 0.03
Age –0.149 0.0018* 0.02
Microbleed count –0.140 0.0035* 0.02
Sex 0.105 0.0279 0.01
Sporadic SVD: Multiple linear regression (lasso): p=4.8e-10, R2=0.09
Mean diffusivity –0.188 2.92-04 -
Serum NfL –0.171 9.97e-04 -
NfL, neurofilament light chain; WMH, white matter hyperintensity
a standardized beta, ‡ normalized to intracranial volume
*simple regression significant after correction for multiple testing (Bonferroni)
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Figure 2  Serum NfL levels are associated with clinical deficits
A) Simple linear regression analysis between serum NfL levels and processing speed in the CADASIL (left 
panel) and sporadic SVD (right panel) sample. Dashed lines depict the 95% confidence interval for the 
linear regression. B,C) In the CADASIL sample, logistic regression analysis showed an independent 
association between serum NfL levels and NIH stroke scale (NIHSS) scores (B) as well as modified Rankin 
scale (mRS) scores (C). Associations are visualized using violin plots. Vertical lines depict the median serum 
NfL levels in each score category. For both scores, values of 3 and 4 were grouped together for visualization 
because of the low number of patients in these categories. NfL, neurofilament light chain.
A
B C
Table 4   Logistic regression models with NIHSS and mRS scores as  
dependent variables in the CADASIL sample
OR† OR 95%CI‡ p
NIHSS score: Simple ordinal logistic regression
Serum NfL 4.11 2.16–8.47 4.2e-05*
Mean diffusivity 3.67 1.93–7.67 1.8e-04*
Lacune volume§ 2.99 1.68–5.80 4.3e-04*
Brain volume§ 0.26 0.11–0.53 6.6e-04*
WMH volume§ 2.53 1.38–4.96 0.004*
Age 1.88 0.99–4.01 0.069
Microbleed count 1.41 0.89–2.36 0.121
Sex 1.39 0.79–5.43 0.245
NIHSS score: Multiple ordinal logistic regression (lasso)
Mean diffusivity 3.27 1.23–9.53 0.021
Brain volumec 0.33 0.11–0.86 0.030
Serum NfL 2.51 1.10–6.08 0.032
mRS score: Simple ordinal logistic regression
Serum NfL 5.52 2.83–12.0 3.0e-06*
Mean diffusivity 5.97 2.84–14.4 1.2e-05*
Brain volume§ 0.20 0.08–0.41 7.0e-05*
WMH volume§ 3.47 1.78–7.40 5.5e-04*
Lacune volume§ 2.71 1.57–5.10 7.7e-04*
Microbleed count 6.12 2.17–35.9 0.008
Age 2.52 1.33–5.45 0.009
Sex 1.57 0.92–2.72 0.097
mRS score: Multiple ordinal logistic regression (lasso)
Serum NfL 2.65 1.13–6.63 0.028
Brain volumec 0.38 0.15–0.87 0.029
Microbleed count 2.35 0.99–9.29 0.103
Mean diffusivity 2.14 0.75–6.21 0.151
NfL, Neurofilament light chain; NIHSS, NIH stroke scale; mRS, modified Rankin scale; WMH, white 
matter hyperintensity. † cumulative odds ratio, ‡ 95% confidence interval for the cumulative odds ratio, § 
normalized to intracranial volume
*simple regression significant after correction for multiple testing (Bonferroni)
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damage to axons is also a potential explanation for mean diffusivity changes in 
the white matter. The high inter-correlation might also explain why the association 
between serum NfL and processing was not independent from mean diffusivity 
in the CADASIL sample.
A recent study showed that serum NfL is sensitive to active SVD, i.e. recent 
subcortical infarcts, and that serum NfL levels remain elevated at least 3 months 
after the acute infarct [189]. We did not find a difference in serum NfL levels 
between patients with and without history for stroke or TIA. However, by design, 
all of the events in CADASIL patients occurred more than 3 months ago. In the 
same study, serum NfL levels were especially high in patients with incident SVD 
lesions on follow-up scans. Adding to that study, our results suggest that serum 
NfL levels also reflect the chronic SVD burden, as e.g. captured by mean diffusivity, 
as well as the clinical severity.
MRI will remain the gold standard for assessment of SVD burden. Imaging markers 
have already been refined to serve as surrogate treatment response markers for 
clinical trials in SVD [68, 199, 211]. However, there are relevant limitations of MRI 
in the context of clinical routine and trials: First, some patients cannot be assessed 
because of contraindications (e.g. metal implants) or claustrophobia. Second, data 
quality can be affected by disease severity, therefore leading to bias. For example, 
cognitively impaired patients are more likely to cause motion artifacts [212]. 
Third, MR imaging is relatively expensive and time-consuming. This applies to both 
the examination itself as well as the mandatory post-processing for assessing SVD 
burden [5]. Finally, even after protocol harmonization, MRI is prone to center effects 
in multicenter studies, introduced by inevitable differences in MRI scanner hardware 
and software [145]. In contrast to MRI, blood draws are less costly and less time 
consuming, can be readily repeated at multiple time points in longitudinal studies 
and are less prone to bias. Furthermore, for multicenter-studies, blood biomarkers 
can be centrally analyzed at a single, experienced (reference) laboratory. Serum NfL 
might therefore complement MRI measures in assessing disease burden in SVD patients.
Several other blood biomarkers have been studied in SVD, such as markers for 
inflammation, endothelial dysfunction, subclinical cardiac injury and coagulation. 
Results on these markers have so far been ambiguous: while in some studies 
associations with imaging parameters, such as WMH, have been reported [213-217], 
this was not the case in others [218, 219]. Most importantly, in contrast to our 
present findings for NfL, no other blood marker has been reported to have robust 
associations with both imaging as well as clinical features of SVD. Although NfL 
is not specific for SVD, our results suggest that serum NfL may be used to stage disease 
Discussion
Analyzing two independent SVD samples, we found elevated serum NfL levels compared 
with healthy controls. Serum NfL levels were associated with all MRI markers of 
SVD burden, in particular mean diffusivity. Regarding clinical symptoms, serum 
NfL levels were strongly associated with impaired processing speed performance, 
the cognitive domain most prominently affected in SVD. These findings were 
consistent across young patients with genetically defined SVD (CADASIL) and patients 
with sporadic SVD. In CADASIL patients, serum NfL levels were also strongly and 
independently associated with measures of focal neurological deficits and disability.
Elevated serum NfL is not specific for a particular pathology, as it is released upon 
neuroaxonal damage of any cause. Recent findings indicate a role of serum NfL in 
multiple sclerosis [37], motor neuron disease [188] and – particularly important in 
the elderly – neurodegenerative disorders [38], i.e. Alzheimer’s disease [39] and 
frontotemporal dementia [40]. Our findings demonstrate that SVD burden is a 
relevant contributor to elevated serum NfL levels. The increase of serum NfL in 
SVD compared with healthy controls (approx. 2-fold on average) is equal if not 
higher than the increase seen for patients with Alzheimer’s disease [38, 39]. The 
association between SVD burden and serum NfL together with the high prevalence 
of SVD suggests that SVD needs to be considered when interpreting serum NfL 
levels in elderly patients.
Our results potentially extend the utility of serum NfL as a marker for SVD burden. 
To our knowledge, our analysis of serum NfL is the first study to identify a blood 
based marker associated with both imaging as well as clinical features of SVD. 
For processing speed performance in the sporadic SVD sample, there was an added 
value of serum NfL levels beyond MRI markers. Moreover, in both samples, only 
mean diffusivity explained more variance in processing speed than serum NfL. 
All other imaging markers of SVD – i.e. WMH, lacune or brain volume – showed a 
weaker association with processing speed, suggesting that serum NfL might be of 
equal or even greater utility than these conventional MRI markers. 
The strong relationship between DTI measures and vascular cognitive impairment 
is well established, both in cross-sectional and longitudinal studies [68, 199, 209]. 
DTI quantifies alterations in the microstructural integrity of brain tissue and 
this seems to be a major substrate underlying cognitive impairment in SVD [210].
Interestingly, among imaging markers serum NfL levels showed the strongest 
association with mean diffusivity, suggesting that the two parameters capture a 
similar disease process: NfL is regarded as a marker for neuroaxonal damage, and 
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Supplementary materialseverity. It could potentially also be used to monitor the disease progression, but this 
needs to be tested in longitudinal studies. Ultimately, serum NfL might be used as 
an outcome parameter to assess treatment effects in clinical trials. 
Also, in our study, serum NfL levels were associated with age, a phenomenon already 
observed in some [38, 188], but not all previous studies [220, 221]. Given the age- 
independent associations between serum NfL and MRI markers as well as clinical 
measures, serum NfL levels in our patients with hereditary SVD are most likely 
reflecting disease progression with age rather than a pure age effect. For the sporadic 
SVD sample an even stronger age effect was observed, which might reflect concomitant 
age-related disease processes, such as neurodegenerative pathology.
A limitation of our study is its cross-sectional design, not yet allowing longitudinal 
analyses in regard to the prognostic value of serum NfL levels in SVD patients. 
The lack of neuroimaging in healthy controls can also be considered a limitation, 
as we were not able to exclude subclinical SVD or other covert brain diseases in 
these subjects. Presence of brain pathology leading to neuroaxonal damage and 
therefore elevated serum NfL levels in controls could have led to an underestimation 
of the difference between controls and SVD patients. Another limitation is the 
lack of NIHSS and mRS scores in the sporadic SVD sample. Main strengths of our 
study are the inclusion of patients with genetically defined SVD, thus limiting 
potential confounding factors, as well as the independent validation in a large 
sample of patients with sporadic SVD. All SVD subjects received comprehensive 
and standardized image acquisition and post-processing, including DTI and 
quantitative volumetric analysis, as well as serum sampling according to standard 
operating procedures. Serum NfL was quantified at a single reference laboratory 
using a state-of-the-art [222], highly sensitive Simoa assay.
Conclusions
SVD burden is reflected in serum NfL levels and needs to be considered when 
interpreting elevated NfL levels in the elderly. Serum NfL is associated with 
imaging as well as clinical features in hereditary and sporadic SVD and might 
therefore complement established MRI markers in assessing SVD burden. Since 
neurodegenerative pathology and SVD often co-occur in elderly patients, serum 
NfL might offer the possibility to assess the combined effect of these pathologies 
on brain integrity. Serum NfL might also be a promising candidate marker for 
prognostication and treatment response monitoring, which needs to be addressed 
in longitudinal studies.
Supplementary Figure  Age-adjusted comparisons
A) To account for age differences between the study samples, we calculated age-adjusted serum NfL levels 
(residuals after regressing out the effect of age). Compared with healthy controls (HC), age adjusted 
serum NfL levels were increased in CADASIL (CAD) and sporadic SVD (SVD) patients.
B) Comparison between serum NfL levels after matching healthy control (HC) subgroups for age (using 
similar median and IQR) to either the CADASIL (young HC) or the sporadic SVD (old HC) sample. Please 
note the logarithmic scale in both panels. ***p < 0.001 (Wilcoxon rank sum test with Bonferroni 
correction).
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Introduction
Neurofilament light chain (NfL) is an emerging blood marker for axonal damage 
in various neurological diseases affecting the elderly, including neurodegenerative 
as well as cerebral small vessel disease (SVD) [39, 40, 188, 189, 223, 224]. SVD is a 
frequent condition with increasing prevalence with age and the most important 
vascular contributor to dementia as well as an important cause of stroke [8]. 
The diagnosis of SVD is based on clinical findings as well as the presence of markers 
on magnetic resonance imaging (MRI), including white matter hyperintensities 
(WMH), lacunes and microbleeds [5]. Cross-sectionally, MRI markers have been shown 
to be associated with clinical symptoms attributed to SVD. However, there are 
various potential limitations of MR-imaging, such as contraindications interfering 
with performing MRI, limited availability of MRI, poor image quality due to motion 
artefacts in demented subjects as well as costs and time needed for performing 
imaging. Thus, other more easily accessible markers being less prone to the 
aforementioned limitations, such as blood based markers reflecting the severity 
underlying condition, are warranted. 
In a recent cross-sectional study we observed elevated serum NfL levels in individuals 
with SVD compared to healthy controls and found a relation between serum NfL 
levels and the severity of MRI markers of SVD, especially with the white matters’ 
microstructural tissue damage as operationalized by mean diffusivity (MD), assessed 
by diffusion-tensor-imaging (DTI) [223]. Also, serum NfL levels were strongly associated 
with cognitive impairment of processing speed performance, the cognitive domain 
most affected in SVD patients [193, 194]. Given these significant associations, serum 
NfL may potentially serve as a marker of disease progression in SVD, but prospective 
studies to validate this are currently lacking.
In the present study we therefore wanted to assess the association of serum NfL 
levels with the burden of future MRI markers of SVD as well as with incident 
cognitive decline and dementia in a large cohort of patients with sporadic SVD. 
We hypothesized that baseline serum NfL levels are related to future severity of 
MRI markers of SVD and cognitive performance.
Abstract
Objective: Serum neurofilament light chain (NfL) is a circulating marker for 
axonal injury and has been shown to be associated with severity of cerebral small 
vessel disease (SVD). Here we explored the predictive value of serum NfL for 
incident SVD and cognitive impairment.
Methods: From 503 subjects with sporadic SVD from the RUN DMC-study, baseline 
and follow-up MR-imaging was available for 264 (mean age 62.4 ± 7.7 years, 59.3% 
male) participants with a follow-up period of 8.7 ± 0.2 years. Baseline serum NfL 
was measured by an ultrasensitive single-molecule array assay. MRI markers  of 
SVD including white matter hyperintensity (WMH) volume, lacunes, microbleeds, 
brain atrophy and mean diffusivity (MD) values were assessed both at baseline and 
at follow-up. Baseline and follow-up cognitive testing could be performed in 335 
participants, including the 264 that had also undergone imaging. Cognitive 
testing included performance of global cognition, memory, processing speed and 
executive function. Associations of serum NfL with MRI-markers and cognition 
were assessed using linear regression analyses and ANCOVA. Dementia status at 
follow-up was examined for all 503 participants and cox proportional regression 
analyses were performed.
Results: Serum NfL levels were associated with baseline WMH volume and MD 
values, as well as with presence of lacunes and microbleeds, after correction for 
age. Furthermore, serum NfL levels were associated with future MRI markers of 
SVD (WMH: β=0.173; 95%CI [0.062, 0.327]; p=0.004; MD: β=0.165; 95%CI [0.048, 
0.334]; p=0.009). In addition, NfL levels were associated with occurrence of incident 
lacunes during the follow-up period. Clinically, NfL levels were associated with 
future cognitive impairment, including processing speed at follow-up (β=-0.135; 
95%CI [-0.226, -0.039]; p=0.005), the cognitive domain most affected in SVD. Risk of 
developing dementia increased with higher NfL levels (HR: 5.0; 95%CI 2.6-9.4; 
p<0.001), but significance was lost after adjusting for age (HR: 1.6; 95%CI 0.6-4.1; 
p=0.312).
Conclusions: Serum NfL is associated with incident SVD, as well as with cognitive 
decline. Serum NfL may thus potentially serve as a marker for disease monitoring 
and outcome in SVD and capture both vascular as well as neurodegenerative 
processes in the elderly.
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Small vessel disease and brain volumetry
We rated SVD markers according to the STRIVE criteria [5]. WMH volumes were 
calculated semi-automatically at all three time-points using FLAIR and T1 sequences 
[150]. Segmentations were visually checked for segmentation errors by one trained 
rater, blinded for clinical data. Lacunes and microbleeds were rated manually on 
FLAIR/T1-weighted scans and T2*-weighted MRI scans by two trained raters 
blinded for clinical data. Inter and intra-rater reliability were excellent [152]. 
We calculated grey matter (GM), white matter (WM) and CSF volumes using SPM12 
(http://www.fil.ion.ucl.ac.uk/spm/) unified segmentation routines on T1 images 
corrected for WMH [110]. All images were visually checked for co-registration and 
segmentation artefacts. All volumes were calculated in ml, corrected for interscan 
differences in ICV and normalized to baseline ICV. 
DTI processing
All diffusion weighted images were denoised using a Local Principal Component 
Analyses filter [156], and corrected for cardiac, head motion, and eddy current 
artefacts simultaneously using the ‘PATCH’ algorithm [157], as described previously 
[152]. Diffusion tensor and scalar parameters, including mean diffusivity (MD) 
and fractional anisotropy (FA), were calculated using DTIFIT from FSL’s FDT 
toolbox. We calculated mean MD of the normal appearing white matter (NAWM), 
calculated by subtracting the WMH from the WM masks.
Dementia diagnosis
Dementia case finding was extensively described previously [225]. In short, 
dementia diagnosis was made after examination at the Radboud Alzheimer 
Center or by a consensus diagnosis by a panel consisting of a neurologist, clinical 
neuropsychologist and a geriatrician with expertise in dementia reviewing all 
available cognitive assessments and medical records. All available neuropsycho-
logical and neuroimaging information was reviewed; this included (i) the 
difference in neuropsychological performance between baseline and follow-up, 
(ii) outcome of the Mini International Neuropsychiatric Interview MINI [226], (iii) 
the follow-up MRI scan, or if not available, the baseline MRI scan for classification. 
(iv) Age and level of education were taken into account for the interpretation of 
the data, next to interference with daily living, confirmed by family or caregivers. 
In case participants were not available for follow-up assessment, we reviewed all 
available medical records. In addition, we contacted their general practitioners 
and medical specialists for information on their cognitive status. The diagnosis of 
dementia was based on the DSM-IV criteria [227]. In total, 65 out of 503 participants 
were diagnosed with dementia at the nine-year follow-up.
Methods
Study population
The Radboud University Nijmegen Diffusion tensor and Magnetic resonance imaging 
Cohort (RUN DMC) study is a prospective cohort study of 503 non-demented elderly 
with SVD, that investigates risk factors and clinical consequences of SVD. 
The detailed study protocol including the inclusion and exclusion criteria has 
been published previously [148]. Information on dementia status at follow-up was 
available of all 503 participants. Participants underwent repeated neuroimaging 
and cognitive assessments; baseline assessment has been performed in 2006 
and follow-up assessment in 2015 (mean follow-up duration was 8.7 ± 0.2 years). 
Of 503 participants, 335 participants underwent repeated cognitive assessments and 
could be included in longitudinal analyses on cognitive performance. Of these, 
276 participants underwent repeated MRI assessment [110]. Twelve participants 
were excluded due to missing T2* sequences or scan artefacts, yielding a sample of 
264 participants for longitudinal neuroimaging analyses. The Medical Review 
Ethics Committee region Arnhem-Nijmegen approved the study and all participants 
gave written informed consent. 
Neurofilament light chain (NfL) assay 
All samples were analyzed on the same single molecule array instrument (Simoa 
HD-1, Quanterix, Lexington, MA, USA) in Basel. We used the capture monoclonal 
antibody (mAB) 47:3, and the biotinylated detector mAB 2:1 (UmanDiagnostics, 
Umeå, Sweden)[198], transferred onto the Simoa platform. Bovine lyophilized NfL 
was obtained from UmanDiagnostics. Calibrators ranged from 0 to 2,000 pg/ml. 
Intra- and inter-assay variability of the assay were below 20%, respectively. 
The analytical sensitivity was 0.32 pg/ml. All samples produced signals above the 
analytical sensitivity of the assay.
Neuroimaging protocol
MR images were acquired at three time points on 1.5-Tesla MRI, though only MRI 
assessments from the baseline and follow up imaging  were used in the present 
study (2006: Siemens, Magnetom Sonata; 2015: Siemens, Magnetom Avanto). The 
neuroimaging protocol included the following whole brain scans: a T1-weighted 
3D MPRAGE sequence (isotropic voxel size 1.0 mm3), a FLAIR sequence (2006: voxel 
size 0.5 0.5 5.0 mm, interslice gap 1.0mm; 2015: voxel size 0.5 0.5 2.5 mm; 
interslice gap 0.5 mm) and a DTI sequence (2006: isotropic voxel size 2.5 mm3, 4 
unweighted scans, 30 diffusion weighted scans at b=900 s/mm2; 2015: isotropic 
voxel size 2.5 mm3, 8 unweighted scans, 60 diffusion weighted scans at b=900 s/
mm2). Full acquisition details have been described previously [110, 148].
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(incident) lacunes and microbleeds were calculated by ANCOVA, adjusted for age 
and sex. We performed linear regression analyses, separately for cognitive index, 
memory, processing  speed and executive function, adjusted for age and sex. 
The association between NfL levels and development of dementia was analyzed by 
cox proportional hazard analyses, adjusted for age and sex. 
Results
Baseline characteristics are presented in Table 1. Participants for whom follow-up 
MR-imaging and/or cognitive testing was available were slightly younger and had 
less severe MRI markers of SVD than for those without this information available. 
(Table 1). 
Cognitive function
Cognitive performance was measured using an extensive neuropsychological test 
battery, as has been described previously [228]. In short, the test battery included 
the Mini-Mental State Examination (MMSE), Rey Auditory Verbal Learning Test 
(RAVLT), Rey Complex Figure Task (RCFT), verbal fluency, Paper-Pencil Memory 
Scanning Task (PPMST), Stroop Color Word Test (short form), Symbol Digit 
Substitution Task (SDST), and Verbal Series Attention Test (VSAT). To account for 
possible learning effects, parallel versions of the RAVLT, RCFT and verbal fluency 
task were used for the follow-up assessment. Raw scores of all time-points were 
transformed into z-scores based on the mean and standard deviation of the overall 
study population at baseline. We calculated Speed–Accuracy Trade-Off (SAT) scores 
where appropriate. Cognitive decline over time was calculated for each subject 
individually, by subtracting baseline scores from the follow-up scores.
We calculated compound scores for global cognitive function, memory, processing 
speed and executive function. We calculated the Cognitive Index as a compound 
score for global cognitive function, using the mean of the z-scores of all tests from 
the neuropsychological test battery. Memory was measured using the 2-letter and 
3-letter subtasks of the PPMST and the immediate and delayed recall of the RAVLT 
and the RCF. Processing speed was calculated as the mean of the z-scores of the 
1-letter subtask of the PPMST, the reading and color naming tasks of the Stroop 
Test and the SDST. Executive function was measured using the verbal fluency task, 
the interference score of the Stroop Test, which was calculated by dividing the 
color-word task by the mean of the reading and color naming tasks of the Stroop 
Test, and the VSAT.
Vascular risk factors
We assessed presence of hypertension, smoking, alcohol use, diabetes and hyper-
cholesterolemia at baseline, by standardized questionnaires, as described previously 
[148]. We defined hypertension as the use of antihypertensive agents and/or systolic 
blood pressure greater than or equal to 140 mm Hg and/or diastolic blood pressure 
greater than or equal to 90 mm Hg. We defined diabetes as treatment with antidiabetic 
medication and hypercholesterolemia as the use of lipid-lowering drugs [148].
Statistical analyses
Statistical analyses were performed using SPSS Statistics version 20. Serum NfL 
levels and WMH volumes were log-transformed because of skewedness. Associations 
between baseline serum NfL levels and neuroimaging markers (TBV, GMV, WMV, 
WMH volume, MD, FA) both at baseline and follow-up were analyzed by linear 
regression analyses, adjusted for age and sex. Associations between NfL levels and 
Table 1  Baseline characteristics 
All  
participants
(n=503)
Study 
population 
cognition
(n=335)
Study 
population 
imaging
(n=264)
Demographics
Age, years 65.7 ± 8.8 63.3 ± 8.1 62.3 ± 7.7
Male sex, nr of participants (%) 284 (56.5) 195 (58.0) 157 (59.5)
MMSE score 28.1 ± 1.6 28.5 ± 1.4 28.6 ± 1.3
Education, years 9.8 ± 1.8 10.0 ± 1.6 10.1 ± 1.5
Vascular risk factors
Hypertension, nr of participants (%) 369 (73.4) 233 (69.3) 182 (68.9)
Diabetes, nr of participants (%) 75 (14.9) 37 (11.0) 27 (10.2)
Hypercholesterolemia, nr of 
participants (%)
237 (47.1) 149 (44.3) 113 (42.8)
Smoking, ever, nr of participants (%) 353 (70.2) 238 (70.8) 186 (70.5)
Alcohol, glasses/week 7.9 ± 9.3 8.1 ± 9.1 8.2 ± 9.0
Body mass index, kg/m2 27.1 ± 4.1 27.1 ± 4.0 27.2 ± 4.1
MRI markers 
Total brain volume, ml 1060.9 ± 80.1 1082.8 ± 71.2 1086.4 ± 71.1
Grey matter volume, ml 606.2 ± 52.6 617.8 ± 48.1 620.8 ± 49.1
White matter volume, ml 454.7 ± 46.0 465.1 ± 48.1 465.6 ± 39.3
WMH volume, ml 3.6 (1.2 – 11.4) 2.6 (0.9 – 7.6) 2.2 (0.8 – 5.8)
Lacunes, nr of participants (%) 132 (26.2) 74 (22.0) 54 (20.5)
Microbleeds, nr of participants (%) 83 (16.5) 46 (13.7) 36 (13.6)
Serum NfL, pg/ml 53.4 (38.1 – 77.7) 47.2 (35.0 – 68.8) 44.4 (33.0 – 62.0)
Data represent mean ± SD, nr of participants (%) or median (IQR).
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Median level of serum NfL was 44.4 (IQR: 33.0 - 62.0) pg/ml in the 264 participants 
with longitudinal neuroimaging assessments and 47.2 (IQR: 35.0 – 68.8) pg/ml in 
the 335 participants with baseline and follow-up cognitive testing. Changes in MRI 
markers of SVD and cognitive performance over time are shown in Supplementary 
Table 1: while there was no change of MD in NAWM over time, all other markers 
showed progression over the follow-up period (p<0.001). This was also the case for 
cognitive performance.
Serum NfL levels are associated with SVD markers at baseline and follow-up
For both – baseline and follow-up – NfL levels were associated with WMH volume, 
lacunes, as well as MD (Table 2 and 3, Figure 1), but not with microbleeds. Furthermore, 
NfL levels were associated with incident lacunes (Table 3). These associations remained 
present after adjustment for age. 
Associations of serum NfL levels with cognitive performance and dementia 
In the overall cohort, serum NfL levels were higher in the subgroup of participants 
who developed dementia during the follow-up period (n=65; NfL 74.8 pg/ml) versus 
those who did not develop dementia (n=438; NfL 50.1 pg/ml; p<0.001). However, 
this difference disappeared when adjusting for age. Cox proportional hazard 
analyses revealed increased risk of developing dementia with higher NfL levels 
(HR: 5.0; 95%CI 2.6-9.4; p<0.001), but again significance was lost after adjusting for 
age (HR: 1.6; 95%CI 0.6-4.1; p=0.312).
Next, we analyzed the associations of serum NfL levels with cognitive performance, 
both at baseline and follow-up (Table 4). For both baseline and follow-up, NfL levels 
were associated with cognitive index and processing speed, which remained after 
correction for age. Figure 2 displays the association of NfL with future processing 
speed. In addition, NfL was also associated with memory impairment at follow-up, 
again independent of age (Table 4).
Table 2  Associations between NfL levels and brain volumes and MRI markers of SVD
Baseline MRI markers Future MRI markers
 [95%CI] P-value  [95%CI] P-value
MRI markers 
Total brain volume -0.086 [-0.207; 0.014] 0.087 -0.071 [-0.183; 0.025] 0.136
Gray matter volume -0.061 [-0.184; 0.047] 0.241 -0.028 [-0.144; 0.082] 0.587
White matter volume -0.079 [-0.221; 0.043] 0.187 -0.093 [-0.229; 0.021] 0.103
WMH volume 0.212 [0.106; 0.370] <0.001 0.173 [0.062; 0.327] 0.004
Mean Diffusivity 0.142 [0.045; 0.284] 0.007 0.165 [0.048; 0.334] 0.009
Fractional Anisotropy -0.084 [-0.236; 0.048] 0.195 -0.089 [-0.247; 0.049] 0.188
Associations are presented as standardized betas with 95% confidence intervals, analyzed by linear 
regression analyses adjusted for age and sex. NfL levels and WMH volumes were log-transformed.
Table 3  Serum NfL levels in SVD patients with or without lacunes and microbleeds
Absent Present P-value
Lacunes
Baseline 42.7 [31.9-58.5] 55.7 [43.1-85.5] <0.001
Follow-up 41.2 [31.6-55.4] 55.3 [42.4-78.5] <0.001
Incidence 41.3 [31.8-55.9] 57.2 [42.9-82.4] <0.001
Microbleeds
Baseline 44.0 [32.6-59.8] 56.9 [41.2-82.2] 0.002
Follow-up 43.1 [32.3-59.3] 50.1 [40.1-73.5] 0.549
Incidence 43.5 [32.6-60.2] 50.7 [41.2-71.5] 0.921
Data represent NfL levels in pg/ml (median with interquartile range) for participants with and without 
(incident) lacunes or microbleeds. Differences are calculated by ANCOVA with Bonferroni correction, 
adjusted for age and sex.
136 137
CHAPTER 7 SERUM NEUROFILAMENT LIGHT CHAIN AND FUTURE CEREBRAL SMALL VESSEL DISEASE
7
Figure 1  Associations of serum NfL with future white matter hyperintensities 
and mean diffusivity
Serum neurofilament light chain (NfL) levels were associated with future MRI markers. Simple linear 
regression analysis between serum NfL levels and WMH volume and mean diffusivity (MD) at follow-up, 
adjusted for age and sex. Dashed lines depict the 95% confidence interval for the linear regression. NfL 
levels and WMH volumes were log-transformed.
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Table 4   Associations between baseline NfL levels and cognitive performance 
during baseline and follow-up
Baseline cognition Future cognition
 [95%CI] P-value  [95%CI] P-value
Cognitive performance
Cognitive index -0.131 [-0.173; -0.017] 0.017 -0.120 [-0.192; -0.028] 0.009
Memory -0.109 [-0.158; 0.001] 0.053 -0.116 [-0.199; -0.022] 0.015
Processing speed -0.180 [-0.251; -0.064] 0.001 -0.135 [-0.226; -0.039] 0.005
Executive function -0.045 [-0.120; 0.050] 0.419 -0.066 [-0.152; 0.028] 0.175
Associations between NfL levels and cognitive performance for all participants who completed repeated 
cognitive assessments (n=335), presented as standardized betas with 95% confidence intervals, analyzed 
by linear regression analyses. NfL levels were log-transformed. P-values, adjusted for age and sex.
Figure 2  Associations of serum NfL with future processing speed
Serum neurofilament light chain (NfL) levels were associated with future cognitive performance. Simple 
linear regression analysis between serum NfL levels and processing speed at follow-up, adjusted for age and 
sex. Dashed lines depict the 95% confidence interval for the linear regression. NfL levels were log-trans-
formed.
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being an early marker of more progressive subsequent white matter damage 
related to SVD.
Besides association with MRI markers of SVD, we found NfL to be associated with 
processing speed, the cognitive domain mostly affected in SVD [193, 194]. The 
association of serum NfL with processing speed was observed independent of age 
at baseline and at follow-up and was observed also after adjustment for MD. DTI 
measures such as MD have been recognized as an important underlying substrate 
of vascular cognitive impairment in SVD [68, 199, 210]. Our findings indicate that 
serum NfL also seems to be a sensitive marker of vascular neuroaxonal damage, 
reflecting the disease process underlying cognitive impairment in SVD. However, 
the associations of NfL levels with both global cognitive index and memory 
performance at follow-up and the association with age suggest that NfL may not 
only reflect vascular, but also neurodegenerative pathologies associated with 
aging.
Some methodological considerations need to be addressed: we did not have serum 
NfL values at follow-up, thus not allowing to study the temporal course of NfL 
levels over the follow-up period. Besides, there were differences in MRI scanner 
and FLAIR and DTI sequences between baseline and follow-up, which might have 
led to segmentation differences between baseline and follow-up images. However, 
we consider this unlikely because we previously validated our findings on the 
associations between MD and WMH progression by repeating analyses for all 
time-periods within the RUN DMC-cohort separately: the results for the first 
follow-up and the overall time-interval were comparable to the results for the 
second follow-up period in which scanner and sequence protocols remained 
identical [229]. Finally, due to the long-term follow-up of our study a proportion of 
the participants was unable to complete the entire follow-up. However, this 
attrition bias most likely will lead to an underestimation of the observed findings, 
since more affected subjects not included in the imaging analyses are likely to 
have more severe lesion burden. The strengths of our study are the large cohort of 
SVD patients and the longitudinal design over a period of approximately nine 
years and the comprehensive and standardized clinical and imaging work-up that 
was performed at both time points. Furthermore, measurements of serum NfL 
were performed at a single, experienced centre using a very sensitive state-of-the 
art Simoa assay [222]. 
Further research should investigate whether NfL levels predict progression of MRI 
markers of SVD better than its baseline MRI markers. In addition, it needs to be 
investigated whether NfL levels are able to disentangle SVD progression from for 
Discussion
In the present longitudinal study, we found serum NfL levels to be related to future 
and incident MRI markers of SVD after a follow-up period of approximately nine 
years. These included MD, WMH and lacunes. Furthermore, NfL was associated 
with future cognitive impairment comprising processing speed, the cognitive 
domain mostly affected in SVD [223], but also other cognitive deficits, including 
memory function.
Our findings extend the results from our recent cross-sectional study of the value 
of NfL as a marker of SVD burden and cognitive performance [223], where we 
identified serum NfL as the first blood-based marker in SVD, reflecting both 
SVD-related lesion burden on MR-imaging as well as its related cognitive 
impairment. Adding to this, our present study showed an association of serum NfL 
levels and markers of SVD after an average a follow-up period of nine years. This 
was true for WMH volume, the most established MRI-marker of SVD in clinical 
routine, as well as for microstructural tissue damage as assessed by MD on DTI. In 
SVD, MD indicates microstructural tissue damage in normal appearing white 
matter (NAWM) that later may convert into WMH [229]. The here observed strong 
association of serum NfL with MD and WMH – both cross-sectional as well as 
longitudinally – suggest a pathological process of tissue damage in SVD with 
axonal damage as a common denominator. As for MD, we observed an association 
of serum NfL with WMH volume at follow-up. Although we also observed 
progression of WMH volume over time, this was not associated with baseline NfL, 
most likely due to the strong correlation of both WMH progression and NfL with 
age [223]. In contrast to WMH volume, we did not observe an association with 
overall white matter volume, indicating that NfL may reflect earlier, more active 
white matter damage, rather than later stages of secondary atrophy. 
Of note, NfL was not only related to the presence of lacunes at follow-up, but also 
to the occurrence of incident lacunes during the follow-up period. Besides WMH, 
lacunes are a hallmark of SVD and the occurrence of lacunes is known to be of 
clinical relevance in SVD [230, 231]. Lacunes have been shown to occur in a tempo-
ro-spatial relation to WMH, appearing later than WMH and often being localised 
at the edge of WMH [123]. Our finding of serum NfL as a sensitive marker of 
neuroaxonal damage being associated with white matter damage and predicting 
the later occurrence of incident lacunes is in line with this course of tissue damage 
in SVD. In fact, a recent study showed serum NfL to be sensitive to active SVD [8]. 
Furthermore, NfL has recently been shown to predict lacunar cavitation in small 
subcortical infarcts [232]. Our findings thus support this notion of serum NfL 
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Supplementary materialexample age related reductions in brain volumes. When proven, the next step 
should include the investigation of NfL as a biomarker of SVD progression, that 
can for example be used in a clinical trial.  
In conclusion, serum NfL is associated with future white matter tissue damage as 
well as cognitive performance in SVD. This included association with newly 
occurring lacunar lesions, indicating a potential value of serum NfL as a marker of 
active and progressive SVD. Serum NfL may thus potentially serve as a marker for 
disease monitoring and outcome in SVD. Furthermore, given the association with 
a broader spectrum of future cognitive impairment, NfL may reflect both vascular 
as well as neurodegenerative processes in the elderly.
Supplementary Table 1  MRI markers and cognitive performance over time
Baseline  
(n=264) 
Follow-up
(n=264)
P-value
MRI markers 
Total brain volume, ml 1086.4 ± 71.1 1043.6 ± 80.8 <0.001
Grey matter volume, ml 620.8 ± 49.1 599.2 ± 51.7 <0.001
White matter volume, ml 465.6 ± 39.3 444.4 ± 46.0 <0.001
WMH volume, ml 2.2 (0.8 – 5.8) 4.6 (2.0 – 11.4) <0.001
Lacunes, nr of participants (%) 54 (20.5) 83 (31.4) <0.001
Microbleeds, nr of participants (%) 36 (13.6) 66 (25.0) <0.001
NAWM mean diffusivity, 10-3 mm2/s 0.85 ± 0.04 0.85± 0.07 0.999
Baseline
(n=335)
Follow-up
(n=355)
P-value
Cognitive performance
Cognitive index 0.19 ± 0.68 -0.15 ± 0.85 <0.001
Memory 0.17 ± 0.67 -0.07 ± 0.89 <0.001
Processing speed 0.21 ± 0.82 -0.27 ± 0.92 <0.001
Executive function 0.16 ± 0.73 -0.14 ± 0.87 <0.001
Data represent mean ± SD, nr of participants (%) or median (IQR). For cognitive performance z-scores 
based on the mean and standard deviation of the overall study population at baseline were used. 
Significant differences were calculated by repeated measures ANOVA for normally distributed variables 
and nonparametric tests. NAWM: normal appearing white matter.
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Introduction
Life expectancy is higher than ever before and is predicted to increase continuously 
in the future in industrialized countries [233]. As a result, age-related diseases will 
increasingly pose challenges to societies and healthcare systems. Globally, over 
40 million people currently have dementia and this number is predicted to almost 
double every 20 years [234]. Cerebral small vessel disease (SVD), which was once 
thought to be innocuous, is now recognized to be the most important vascular 
contributor to dementia [235]. Furthermore, this condition causes ~20% of all 
ischemic strokes and is associated with gait impairment and mood disturbances 
[5, 43, 236, 237]. Consequently, a proper understanding of how SVD exerts its 
action on the ageing brain and leads to clinical symptoms is urgently needed.
SVD is present to some extent in virtually every individual aged 60 years or older [6]. 
It affects the smallest cerebral blood vessels, including the perforating arterioles, 
capillaries and venules [8]. Although in vivo assessment of the smallest blood 
vessels is not yet possible with conventional imaging techniques, a spectrum of 
radiological manifestations can be detected that are thought to result from SVD. 
Common radiological markers of SVD include white matter hyperintensities (WMH), 
lacunes, enlarged perivascular spaces, microbleeds, recent small subcortical infarcts 
and brain atrophy, and the detection of these features is now complemented by 
the examination of losses in microstructural integrity of the white matter and the 
presence of cortical microinfarcts (FIG. 1) [5].
SVD historically has been perceived as a slowly progressing disease that affects 
frontal subcortical networks, leading to corresponding frontal symptoms [238]. 
These symptoms include loss of mental processing speed and executive function, 
and affect cognitive function, motor performance and mood regulation. Compared 
with the healthy ageing population, individuals with SVD are at an increased risk 
of cognitive decline and, ultimately, dementia [43, 239]. In addition, slowing of 
gait is a frequent observation in people with SVD and can result in parkinsonism 
[42, 236, 240, 241]. Finally, apathy (defined as a lack of motivation expressed by 
reduced initiative, diminished interest and lowered emotional responsiveness to 
stimuli [242, 243]), and depressive symptoms are common in individuals with 
SVD [237, 244, 245]. 
At least two reasons support re-evaluation of this classic concept of SVD. First, despite 
loss of executive control and speed in behavioral performance, the spectrum of 
cognitive symptoms attributable to SVD is more diverse than previously thought 
and can also include deficits in language, memory, attention and visuospatial 
Abstract
Cerebral small vessel disease (SVD) is commonly observed on neuroimaging among 
elderly individuals and is recognized as a major vascular contributor to dementia, 
cognitive decline, gait impairment, mood disturbance and stroke. However, clinical 
symptoms are often highly inconsistent in nature and severity among patients with 
similar degrees of SVD on brain imaging. Here, we provide a new framework based 
on new advances in structural and functional neuroimaging that aims to explain 
the remarkable clinical variation in SVD. First, we discuss the heterogeneous 
pathology present in SVD lesions despite an identical appearance on imaging, and 
the perilesional and remote effects of these lesions. We review effects of SVD on 
structural and functional connectivity in the brain, and discuss how network 
disruption by SVD can lead to clinical deficits. We address reserve and compensatory 
mechanisms in SVD and discuss the part played by other age-related pathologies. 
Finally, we conclude that SVD should be considered a global rather than a focal 
disease, as the classically recognized focal lesions affect remote brain structures, 
and structural and functional network connections. The large variability in clinical 
symptoms among patients with SVD can probably be understood by taking into 
account the heterogeneity of SVD lesions, the effects of SVD beyond the focal lesions, 
and the interaction with reserve mechanisms, compensatory mechanisms and the 
contribution of neurodegenerative pathologies other than SVD.
Key points
•  Cerebral small vessel disease (SVD) is associated with a remarkable degree of variation 
in clinical symptoms — both in nature and in severity — which cannot be explained 
fully by conventional markers of SVD.
•  Conventional MRI does not capture the heterogeneity present in SVD lesions with a 
similar appearance, and only reveals the tip of the iceberg of the total SVD-related 
brain damage. 
•  SVD affects brain tissue beyond the commonly recognized focal lesions by inducing a 
cascade of events that spread from the initial lesion to remote brain areas, which probably 
contributes to clinical outcome.
•  SVD disturbs structural and functional network connectivity and thereby disrupts 
efficient communication in brain networks, which is necessary for functional performance.
•  Brain resilience protects against clinical deterioration caused by SVD via reserve and 
compensatory mechanisms, which explains the clinical variation observed in patients 
with apparently equal SVD lesion burden.
•  The clinical notion that SVD mostly constitutes a subcortical disease of focal lesions 
requires reconsideration.
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abilities [45, 46, 246-249]. These symptoms typically have not been attributed to 
SVD as they are considered to result from cortical lesions rather than subcortical 
lesions. This view is also consistent with findings in case studies, which have 
reported the occurrence of acute memory loss in patients with an isolated lacunar 
infarct in the thalamus [250, 251] or internal capsule [252, 253]. Second, clinicians 
often observe a remarkable heterogeneity in clinical symptoms among patients 
with a similar radiological degree of SVD-associated features on brain imaging. 
In a hospital-based cohort of individuals with SVD, the 5.5-year cumulative risk of 
dementia was 11%, which indicates that SVD might go unnoticed or result in only 
mild functional deficits in the majority of people [254].
Advances in structural and functional neuroimaging have now begun to shed 
light on these remarkable clinical observations in SVD. In this Review we will 
summarize these advances and provide a new framework for clinical observations 
in patients with SVD on the basis of an analysis of the latest literature on this 
topic. First, we will discuss the heterogeneous pathology present in SVD lesions 
that seem radiologically identical, and the effects of SVD on perilesional and 
remote brain regions. Second, we will review the effects of SVD on structural and 
functional networks in the brain and provide reasons supporting the notion that 
SVD is a disconnection syndrome. We will address the clinical variation in SVD 
from the perspective of brain resilience, comprising brain reserve and compensatory 
mechanisms, and briefly address mixed age-related pathologies in SVD. We will 
conclude with a discussion on methodological considerations and future perspectives. 
The focus of this Review is on the most frequently occurring, sporadic form of 
SVD — that is, age-related and vascular risk-factor-related SVD [8] with predominantly 
ischemic manifestations (Box 1). Illustrative examples of mechanisms of action 
that have been demonstrated in other types of SVD, such as cerebral amyloid 
angiopathy (CAA) or inherited SVD are sometimes used as a model.
Focal and remote effects of SVD
Heterogeneity of SVD lesions with an identical appearance on imaging
MRI-based markers of SVD have a homogeneous appearance on conventional 
imaging. However, post-mortem histopathology studies have shown that these markers 
are in fact heterogeneous with regard to disease severity and etiology [255-258].
Pathological examination of WMH has shown different degrees of demyelination, 
gliosis and loss of fibers and oligodendrocytes in different lesions, with more- 
extensive abnormalities in more-severe and confluent lesions [255]. Periventricular 
and deep WMH are characterized by vessel wall thickening, enlarged perivascular 
spaces, decreased vascular density, increased vessel tortuosity and the presence of 
Figure 1  Features of cerebral small vessel disease on MRI
Cerebral small vessel disease (SVD) is associated with a wide range of tissue alterations detectable with 
MRI, which are reported here according to the STRIVE (Standards for Reporting Vascular Changes on 
Neuroimaging) criteria [5]. CSF, cerebrospinal fluid; FLAIR, fluid-attenuated inversion recovery.
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failure of interstitial fluid drainage, and might also increase vascular resistance, 
which may cause perfusion deficits in deep white matter areas [261, 262].
On histopathological examination, lacunes are irregularly shaped fluid-filled 
cavities that are surrounded by some degree of myelin and axonal loss and gliosis 
[255, 263]. Different pathological findings have been described with respect to the 
age of the lacune. In contrast to more recently formed lacunes, older lacunes are 
characterized by a decreased concentration of macrophages and necrotic waste, 
and an increased density of gliosis [255, 263]. In addition, a distinct type of lacunar 
infarcts has been proposed; these so-called incomplete infarcts are either not 
cavitated or are only minimally cavitated but show evidence of myelin loss and 
neuronal loss and a variable extent of gliosis [256].
MRI-defined microbleeds have also been associated with various degrees of gliosis 
and tissue loss and different pathological correlates have been identified. A pathology 
study that examined patients with CAA distinguished between acute and old 
microbleeds by the presence of intact red blood cells in acute lesions and of 
 hemosiderin-laden macrophages in older microbleeds [258]. Histopathological 
evidence suggests that the majority of microbleeds reflect true microhemorrhages 
caused by vessel wall disruption [255, 257, 258]. However, some microbleed mimics 
have been identified reflecting a vasculopathy rather than a parenchymal hemorrhage, 
including vessel wall dissection, microaneurysms or vessel wall thickening due to 
accumulation of fibrin and red blood cells in the vessel wall [255, 257, 258]. Finally, 
markers of an underlying ischemic process have been observed in some microbleeds, 
suggesting hemorrhagic transformation of a previous infarct [255, 258].
These pathological findings indicate heterogeneity of radiological similar 
appearing SVD lesions, which is also increasingly being recognized in vivo on MRI 
[117, 264-266]. Conventional MRI techniques, such as fluid-attenuated inversion 
recovery (FLAIR), coarsely dichotomize tissue into abnormal and normal tissue 
and do not, for example, reliably reflect the degree of demyelination [267], whereas 
quantitative imaging techniques, including magnetization transfer imaging and 
diffusion tensor imaging (DTI), can provide a detailed evaluation of the underlying 
tissue alterations at the voxel level [28]. DTI is a technique that applies a 
tensor-based model to acquired diffusion-weighted imaging (DWI) scans, a MRI 
sequence sensitive to the diffusion of water molecules, and thereby provides 
information on the microstructural organization of white matter [29]. In a study 
that investigated DTI changes within WMH that had not changed on FLAIR 
imaging over a 3-year period, diffusion metrics showed a significant change over 
time in these WMH [117]. Similarly, within acute or subacute incidental DWI+ 
plasma proteins. Furthermore, activated endothelial cells within capillaries, especially 
in deep WMH, and immunologically activated microglial cells, in particular in 
periventricular WMH, have been observed [255]. On the basis of these different 
pathological observations, ischemia and blood–brain barrier breakdown have 
been suggested as mechanisms that contribute to the origin of WMH [255]. 
However, new hypotheses on the pathophysiology of WMH include the dysfunction 
of oligodendrocyte precursor cells, which are involved in the formation of myelin, 
and failure of the glymphatic system, responsible for clearance of neurotoxic waste 
products [259, 260]. In addition, evidence increasingly suggests a role for pathological 
changes of the venules in the origin of WMH, especially venous collagenosis [261]. 
Thickening of the walls of venules due to collagen deposition could contribute to 
Box 1  Different types of cerebral small vessel disease
Although the pathological processes that underlie MRI markers of cerebral small vessel 
disease (SVD) are incompletely understood, changes that result in disorganization of the 
vessel structure and function of the intraparenchymal and leptomeningeal blood vessel 
walls are key [8]. A previous report described six types of SVD [8]. The most prevalent type 
of SVD comprises a set of pathological changes under the influence of age and vascular 
risk factors, especially hypertension, that mainly affect the perforating arterioles [8, 341, 
342]. This type is characterized by arteriolar wall thickening (mainly due to deposition 
of collagen, plasma proteins and inflammatory cells in the vessel wall), loss of smooth 
muscle cells involved in the regulation of arterial pressure and blood flow [343], and 
leakage of plasma proteins into the perivascular tissue [8, 341, 342]. Arteriolosclerosis 
represents an early stage of the disease, whereas lipohyalinosis and fibroid necrosis are 
observed at later stages — although these early and late stages can occur simultaneously 
in one vessel [8, 341, 342]. The second most common type of SVD is cerebral amyloid 
angiopathy (CAA), which is characterized by the deposition of amyloid-β in the walls of 
small arteries, arterioles and, infrequently, capillaries and venules, predominantly in 
the cerebral cortex and leptomeninges [8, 341]. In addition, vasculopathic changes 
observed in CAA include vessel wall thickening, loss of smooth muscle cells, fibrinoid 
necrosis and exudation of blood breakdown products into perivascular tissue [13, 341]. In 
both of these types of SVD, the described vessel wall alterations are associated with 
enlarged perivascular spaces [341]. Furthermore, occlusion or rupture of the blood vessel 
can occur, which leads to infarction or hemorrhage, although CAA is typically associated 
with lobar hemorrhages [13, 341]. Sometimes, microatheroma and microaneurysms are 
formed, which can also cause an infarct or hemorrhage [8, 341]. The remaining four 
types of SVD result from rare causes, and consist of hereditary forms of SVD (such as 
CADASIL), inflammatory and immunologically mediated SVD, venous collagenosis and 
finally a category of other causes of SVD (such as post-radiation angiopathy) [8].
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lesions, suggestive of being infarcts, diffusion metrics were significantly changed 
on follow-up imaging 7 months later, compared to the pre-lesional scan [264]. 
Interestingly, this ongoing change in diffusion parameters occurred irrespective 
of whether or not an infarct remained visible on FLAIR or T1-weighted MRI [264].
Besides showing heterogeneity with regard to disease severity, MRI is increasingly 
able to contribute to our understanding of the various mechanisms implicated in 
the origin of SVD, including perfusion deficits, blood-brain barrier breakdown and 
venous pathology [268-270]. Finally, imaging evidence has converged on a shared 
origin of different types of SVD lesions. Acute DWI-positive lesions have now been 
shown to evolve either into a WMH, lacune, microbleed or normal-appearing 
tissue [264, 271, 272].
In summary, the histopathological characteristics of lesions with similar appearances 
on MRI can vary. Consequently, the effects that these lesions have on the cerebral 
tissue can also vary (Figure 2A,B).
Perilesional effects of SVD
In addition to overlooking the heterogeneous pathology present in similar 
appearing SVD lesions, conventional MRI manifestations of SVD are well known to 
represent only the tip of the iceberg with regards to SVD-related brain damage. In 
fact, DTI studies have shown that SVD lesions, such as WMH, are surrounded by 
areas with altered diffusion metrics that otherwise look normal on conventional 
MRI, the so-called SVD penumbra (Figure 2B) [273, 274]. Diffusion abnormalities in 
penumbral areas are associated with the overall WMH load and depend on the 
distance from the WMH, with more severe abnormalities in regions proximal to 
WMH than in distant regions [273, 274].
A cross-sectional study demonstrated that a gradient of diffusion abnormalities 
also surrounds lacunes and extends up to centimeters from the lacune into the 
white matter tract containing that lacune (Figure 2B) [275]. In a longitudinal study 
on the effect of acute and subacute DWI+ lesions on the DTI characteristics of the 
perilesional tissue, water diffusion in perilesional tissue was slightly less anisotropic, 
at the post-lesional scan compared to the pre-lesional scan — albeit not to a significant 
extent, perhaps due to the small number of six patients demonstrating a lesion 
[264]. An autopsy study in six patients with a lacunar infarct confirmed previous 
imaging findings suggesting the presence of a penumbra surrounding the lacunar 
infarct. The investigators revealed axonal damage in the penumbral area of the 
lacunar infarct at a distance 1.5 times the diameter of the lacune [276]. Changes 
included loss of nodes of Ranvier and increased length between each node. 
Figure 2  What you see is not what you get
A) MRI markers of cerebral small vessel disease (SVD), including white matter hyperintensities (WMH), 
lacunes, enlarged perivascular spaces, microbleeds and cortical microinfarcts. B) Pathology studies 
show heterogeneity with regard to underlying disease severity and nature in SVD lesions with a similar 
appearance on MRI (shown for WMH). A penumbra (lighter areas) can surround SVD lesions. When 
penumbras of cortical microinfarcts overlap, these microinfarcts can coalesce with a resultant larger 
cortical infarct. Besides having perilesional effects, SVD is also associated with remote effects, such as 
cortical thinning (purple) caused by lacunes and possibly WMH via the disconnection of white matter 
tracts (green). C) SVD lesions can impair structural (left) and functional (right) connectivity by affecting 
the nodes of a network or the connections between them. Strategic infarcts affect rich clubs (red circles) 
or rich club connections (red lines). D) A larger total brain volume, increased network efficiency and 
compensatory (increased) functional connectivity can make the brain resilient to a certain degree of 
damage. ACC, anterior cingulate cortex; dlPFC, dorsolateral prefrontal cortex; PPC, posterior parietal cortex. 
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isolated microinfarcts overlapped, a coalescence of infarcts was observed, resulting 
in a larger cortical infarct (Figure 2B) [282]. An ex vivo study in human brain tissue 
showed that, similar to what was observed in the penumbra surrounding lacunar 
infarcts, cortical microinfarcts caused disruption in the organization of adjacent 
axons, which was characterized predominantly by a loss of axon initial segments 
and increased length between nodes of Ranvier [281]. The investigators suggested 
that these changes could ultimately reduce the capability of the axons to conduct 
action potentials [281]. The debilitating effect of cortical microinfarcts on axonal 
communication might be yet another mechanism by which the accumulation of 
cortical microinfarcts can induce clinical deficits (Figure 2B) [281].
Remote effects of SVD
Previous studies have demonstrated suppression of brain function in areas far 
from subcortical infarcts and WMH, as indicated by reduced perfusion and 
glucose metabolism on PET, suggesting the presence of sequelae of SVD remote 
from subcortical MRI markers [247, 251, 286]. In addition to these functional 
changes, a growing body of evidence suggests that SVD is accompanied by 
structural changes remote from the initial SVD MRI markers. Several cross- 
sectional studies have shown negative associations between WMH and cortical 
thickness [287-289]. More specifically, one study demonstrated a particular pattern 
of frontal–parietal–occipital grey matter atrophy related to WMH progression, 
which was thought to be responsible for the observed decline in total brain volume 
[49]. However, among patients less-severely affected with SVD, a longitudinal 
association between progression of WMH and reduction of cortical thickness 
could not be confirmed [287].
A study of patients with cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy (CADASIL), a genetic form of SVD, 
demonstrated that incident lacunar infarcts cause thinning in cortical tissue 
connected to the infarct area, providing the first direct proof for SVD-induced 
secondary degeneration in remote cortex [147]. Cortical thinning was most 
pronounced in areas that had a high probability of connectivity via the lacune-af-
fected white matter tract (Figure 2B). Indeed, in a subsequent study this group 
demonstrated that infarcts are accompanied by DTI changes in white matter 
tracts connecting to the infarct area, with larger changes of white matter 
microstructure associated with more cortical thinning [290]. Interestingly, 
cortical thinning was independent of the final infarct fate — that is, whether the 
infarct was cavitating (complete or partial tissue loss) or non-cavitating (no visible 
tissue loss) — suggesting that less-severe infarcts can also induce long-term remote 
effects [290].
Although the axon and myelin sheath were preserved, the investigators argued 
that the injured axons could be susceptible to future axonal degeneration [276].
In addition to WMH and lacunes, a penumbra can also surround cerebral micro- 
bleeds and perivascular spaces, although this phenomenon requires further 
investigation. One case report observed a temporary perilesional edema surrounding 
an acute microbleed, which was thought to cause the transient clinical symptoms 
observed in this individual [277]. The dilation of perivascular spaces could affect 
the integrity of surrounding grey or white matter tissue, although this remains to 
be proven.
Interestingly, in contrast to conventional markers of SVD such as WMH or lacunar 
volume, which have consistently shown only weak relations with clinical symptoms, 
diffusion metrics generally yield robust relations with cognitive, motor and mood 
symptoms associated with SVD, which remain after adjustment for the typical 
SVD imaging markers in statistical analyses [116, 278, 279]. A DTI study demonstrated 
an association between abnormal diffusion metrics in the penumbra surrounding 
lacunes and deficits on tests of executive functioning and information processing 
speed, independent of the size and side (that is, left or right hemisphere) of the 
lacune and independent of total WMH load [275]. This finding indicates that 
cognitive performance is determined not only by SVD lesions that are visible on 
conventional MRI, but also by the extent to which the penumbra is affected. In the 
past few years, two global brain DTI derived metrics — the peak width of skeletonized 
mean diffusivity (which is based on skeletonization of white matter tracts and 
histogram analysis [199]) and segmentation of DTI images [280] — have been shown 
to be strongly related with processing speed [199, 280] and executive functioning 
[280] in patients with SVD, well beyond the associations with classic SVD makers. 
These findings illustrate that SVD truly exerts its action outside the visible lesion, 
which contributes to clinical outcome.
A penumbra seems to surround not only conventional SVD markers, but also cortical 
microinfarcts (Figure 2B) [281-283]. Cortical microinfarcts are frequently observed at 
brain autopsy in elderly people, are associated with cognitive decline and dementia 
[284] and, within the past few years, have also been recognized on MRI [285]. 
Two studies in rodents demonstrated that the occlusion of a single penetrating arteriole 
to induce a cortical microinfarct led to structural, functional and hemodynamic 
changes that were measureable millimeters away from the infarct core [282, 283]. In 
fact, decreased neuronal activity was estimated to extend over a cortical region at 
least 12 times larger than the volume of the microinfarct core itself, whereas MRI 
could only visualize the core [283]. Remarkably, when perilesional areas of multiple, 
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With respect to the specific connections being disrupted in patients with severe 
SVD, a study revealed a subnetwork comprising the most impaired connections, 
which included predominantly interhemispheric and prefrontal connections [53]. 
Whereas the distribution of SVD near the ventricles and within the centrum 
semiovale could explain the reduced connectivity of interhemispheric tracts, the 
disruption of frontal connections was interpreted as remote effects of SVD. 
Additional insights into the extent and location of structural network disruption 
in SVD have been provided by rich-club analyses (Box 2): rich-club organization of 
a network refers to the presence of nodes (brain regions) that are rich in 
connections that are more densely connected to each other than to other nodes 
[56]. The connections between the rich-club regions are centrally located in the 
network and are thereby the most important connections for integration of 
information [55]. Rich-club nodes identified in SVD comprise the precuneus, 
putamen, thalamus, superior occipital gyrus and regions in the superior frontal 
gyrus [57]. Reduced connectivity was predominantly observed for connections 
between the rich-club nodes rather than a generalized, random reduction of the 
white matter connectivity (Figure 2C) [57]. This observation might be explained in 
part by the location of SVD damage, which often overlaps with the location of rich 
clubs.
Several studies in patients with SVD have demonstrated that the degree of brain 
network disruption, reflected by decreased global efficiency, was related to 
increased cognitive impairment [53, 54, 295] and depressive symptoms [296]. 
Furthermore, decreased global efficiency was linked to an increased risk of 
all-cause dementia over a 5-year period [297]. In addition, associations between 
the presence of conventional MRI markers of SVD and decreased cognitive 
functions were, at least in part, mediated through network disruption [53, 54, 
289]. In particular, rich-club connectivity strength mediated the association of 
WMH with processing speed and executive functioning, in that higher rich-club 
connectivity strength was associated with better cognitive performance [57]. 
These findings were corroborated by others, who found that only microstructural 
changes in central network connections, as opposed to non-central connections, 
mediated the association between WMH volume and executive functioning [58]. 
Due to their central role in brain networks and high connectivity with other 
nodes, damage to rich clubs or central connections might have a more widespread 
effect on network functioning compared with damage to peripheral nodes or 
peripheral connections in a network. Consequently, strategic infarctions, even 
when small in size, could result in a highly heterogeneous clinical phenotype, 
deviant from the typical ‘subcortical’ clinical picture when they are located near 
rich clubs or central connections (Figure 2C) [298].
Brain atrophy is an important predictor of cognitive decline and has been shown 
to mediate the relationship between presence of WMH and cognitive decline in 
individuals [109, 291]. Similar to lacunar infarcts, WMH can affect the cortex via 
disruption of white matter tracts (Figure 2B) and consequently can lead to cognitive 
symptoms, although this hypothesis remains to be proven in longitudinal studies. 
We previously showed that decreased cortical thickness played an intermediate 
role in the associations between WMH volume and deficits in various cognitive 
domains (namely global cognition, verbal memory, psychomotor speed, and 
attention and executive functioning) [289]. In line with our observations, others 
have identified an intermediate role for cortical thickness of the left medial frontal 
lobe in the relationship between lacunar infarct volume within the anterior 
thalamic radiation and reductions in processing speed, whereas anterior thalamic 
radiation lacunar volume itself was not related to processing speed [292]. The role 
of cortical thickness in SVD is probably not limited to its effects on cognitive 
performance: another study showed that periventricular WMH affected gait 
impairment via disruption of white matter tracts and cortical thinning [293].
Structural and functional connectivity
Functional performance results from the complex interplay between brain regions 
connected with each other through the white matter tracts, together forming 
brain networks. Advances in human connectomics have led to better understanding 
of how SVD might give rise to clinical symptoms through its effects on structural 
or functional connected brain networks (Box 2).
Structural connectivity in SVD
The white matter tracts are crucial for information transfer between brain regions. 
These tracts can be reconstructed using DTI tractography techniques and represent 
the connections in structural brain networks. Subsequently, the organizational 
properties of a network, such as its global efficiency of information transfer, 
a measure of how well-connected the brain regions are, can be quantified using 
principles from graph theory (Box 2). Several studies demonstrated structural 
network changes in patients with SVD through the application of this approach 
[53, 54, 57, 294]. These network changes were characterized by a reduction in the 
number of connections, reduced strength of connectivity and decreased local and 
global efficiency. The degree of brain network disruption was associated with the 
extent of MRI markers of SVD, including WMH volume, number of lacunes and 
number of microbleeds, and with brain volume and microstructural integrity.
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Box 2  Brain networks and graph theory
Brain networks can be explored using graph theory, which conceptualizes the brain as a network (i.e. a 
graph) with connections that mediate the interaction between brain regions. A network consists of 
nodes (brain regions) linked by edges (the connections between nodes), in which nodes are defined 
by a parcellation scheme (arbitrary scheme shown in figure). Brain networks can be constructed 
using structural and functional neuroimaging data. In structural imaging, connectivity between 
nodes A and B is retrieved from diffusion tensor tractography and thereby represents their anatomical 
connections. In functional imaging, connectivity between nodes A and B is based on the correlation 
between their functional MRI blood-oxygen-level dependent time series. Functionally connected 
regions might or might not have a structural underpinning. Regions with correlated activity are likely 
to form a network and several such brain networks have been identified, including the default mode 
network, dorsal attention network and frontoparietal control network [300, 344]. Once brain networks 
are constructed, the topological organization and properties of these networks can be explored [50, 51], 
of which some are discussed here. Path length is defined as the shortest distance or minimum number 
of connections between two nodes (orange connections). Network efficiency is inversely related to path 
length, whereby global efficiency of the network is reflected by the average efficiency for all node pairs. 
Node degree refers to the number of connections that link a node to the rest of the network (orange 
connections). The human brain consists of a few central connected regions, known as hubs. Several 
hubs are also highly interconnected with each other and with the rest of the network, and represent 
rich clubs. Connections between the rich club nodes are referred to as rich club connections and play 
an important part in the integration of information by creating short paths [55, 56]. 
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many individuals remain functionally independent despite a considerable burden 
of SVD. An alternative approach might be to look not only at the sum of SVD 
burden and brain damage, but also to explicitly take into account brain resilience, 
which is the capacity for patients to tolerate a certain degree of brain damage 
before clinical symptoms become manifest. Brain resilience can be separated into 
reserve mechanisms including brain reserve (referring to structural or functional 
metrics of the brain, such as intracranial volume) and cognitive reserve (referring 
to lifetime experiences, such as education) that offer protection against brain 
pathology, and compensatory mechanisms via which the brain actively compensates 
for clinical deterioration in the presence of pathology (Figure 2D) [316]. 
The concept of brain reserve states that individuals with a larger brain reserve 
tolerate a greater burden of pathology before clinical symptoms arise than do 
individuals with lower brain reserve [317]. One study reported a lower risk of 
dementia in patients with a larger brain volume [318] and another study reported 
that patients with WMH who had no cortical atrophy had a lower risk of dementia 
than did those with cortical atrophy [319]. Structural network efficiency can also 
be viewed as a form of brain reserve, whereby more efficient networks might protect 
against clinical deterioration in the presence of brain pathology. In other words, 
patients with highly efficient networks (for example, networks with many 
connections between nodes) could cope well with pathology, as these individuals 
are able to compensate for the disruption of white matter tracts by using 
alternative connections. This hypothesis is supported by the finding that patients 
with SVD who did not develop dementia had higher global network efficiency 
than did patients who converted to dementia, independent of SVD markers, 
including WMH volume, presence of lacunes and microbleeds, and brain atrophy 
[297].
The concept of cognitive reserve is that high intellectual enrichment or high 
cognitive reserve (usually operationalized as IQ and level of education) offers 
increased protection against age-related brain pathology [316, 317, 320-322]. 
Specifically, in the context of cognitive impairment associated with SVD, several 
studies reported that high cognitive reserve attenuated the negative effects of 
SVD on cognition [317, 320, 323-328]. Higher cognitive reserve was associated with 
a slower rate of decline in processing speed, executive functions and memory, 
independently of WMH severity, which supports the hypothesis that cognitive 
reserve protects against the clinical manifestations of SVD and could partly 
explain the variation in cognitive performance in patients with a similar burden 
of SVD markers [329].
Functional connectivity in SVD
Functional neuroimaging enables the functional neuroanatomy of specific brain 
functions to be probed. Our brain consists of spatially distributed but functionally 
linked regions that continuously share information with each other. Functional 
connectivity is defined as the temporal dependency of neuronal activation patterns 
in anatomically separated brain regions [299]. Functional connectivity thus refers 
to correlated activity between functionally related brain regions, rather than to 
connections via existing white matter tracts, as is the case in structural connectivity 
based on diffusion tensor tractography (Box 2).
Functional neuroimaging studies have reported reduced functional connectivity 
across distributed networks in SVD (Figure 2C). Three networks that are commonly 
affected in SVD are the default mode network (DMN), the dorsal attention network 
(DAN) and the frontoparietal control network (FPCN), which play an important 
part in goal-directed attention and executive functions [300, 301]. Patients with 
SVD showed reduced functional connectivity between nodes within the FPCN and 
the DAN [302-307], which was related to SVD severity [302, 303, 307-310]. These 
findings suggest that damage to long association fibers, caused by SVD, can manifest 
as reductions in functional connectivity between major nodes of the attentional 
networks. Furthermore, brain regions within the DMN normally show highly 
correlated brain activity during rest and reduced activity during attentionally 
demanding tasks, which is considered to be important for the maintenance of 
task-related goals. However, patients with SVD showed hyperactivation or impaired 
DMN deactivation during attentionally demanding tasks [311-314]. For example, 
WMH severity was associated with hyperactivation of the anterior cingulated 
cortex, a key structure of the DMN [311]. 
These alterations to functional networks provide novel insights into the mechanisms 
of cognitive decline in SVD. Several studies have reported that reduced functional 
connectivity within the FPCN, DAN and DMN was related to an increased degree 
of cognitive impairment [302, 308-310, 315]. Evidence suggests that cognitive 
impairments due to SVD result from disruption of frontal–subcortical circuits and 
long association fibers that in turn impair communication between crucial neural 
networks responsible for cognitive control or attention, such as the DMN, FPCN, 
and DAN (Figure 2C) [301].
Brain resilience
In the previous sections we described the clinical consequences of SVD and 
discussed the mechanisms by which SVD might lead to these clinical deficits. 
Nevertheless, these clinical deficits cannot entirely be explained by SVD alone as 
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Methodological considerations 
Several methodological considerations must be addressed regarding the studies 
discussed in this article. We will discuss factors related to neuroimaging and to 
study design, as well as possible solutions to tackle these methodological issues in 
future studies.
The reproducibility of SVD imaging markers is a major concern, especially across 
different centers [145]. One review identified several aspects — from acquisition of 
imaging data to processing — that influence the reproducibility [145]. 
Quantification of SVD markers depends on magnetic field strength, choice of MRI 
sequence, image resolution, and the segmentation method used, the latter of 
which can range from qualitative visual rating scales to quantitative automatic 
segmentation routines [145, 146]. With the publication of the Standards for 
ReportIng Vascular Changes on Neuroimaging (STRIVE), which provides 
definitions of visible SVD features and recommendations for image acquisition, 
analyses and scientific reporting to reduce the large variation between studies, a 
higher consistency between studies has been reached [5]. Nonetheless, variation 
between studies is still considerable, hampering progress in our understanding of 
how SVD might contribute to clinical symptoms.
In connectivity analyses, the presence of SVD lesions, such as WMH, affects the 
reconstruction of white matter fiber tracts with the use of DTI data and 
consequently affects the investigation of remote effects via white matter tracts 
connected to the lesion or the assessment of structural connectivity. In functional 
connectivity, brain activity is measured by blood-oxygen-level dependent imaging 
that relies on regional differences in cerebral blood flow, which is often affected 
in patients with SVD. Additionally, cerebral blood flow can be affected by antihy-
pertensive treatment [339].
With regards to the design of the discussed studies, most are cross-sectional and 
consequently cannot elaborate on causality or on the directionality of the 
associations. Furthermore, studies might be susceptible to selection bias, as 
patients with the most severe SVD lesion load are often institutionalized and 
might not have been able to participate. Finally, study populations differ between 
different studies — ranging from pure SVD to SVD with concomitant AD pathology 
and from population-based studies to studies including patients with symptomatic 
lacunar stroke — and this variability should be taken into account when 
interpreting results on the clinical consequences of SVD.
Compensatory functional connectivity refers to the ability of the brain to adapt to 
pathology by the use and development of compensatory networks when the 
primary networks are no longer capable of executing a certain task [321, 330]. A 
functional neuroimaging study reported associations between decreased grey 
matter volume within the primary network and increased use of an alternative 
network to maintain task performance [331], supporting the theory of compensatory 
connectivity. In addition, a ‘less wiring, more firing’ hypothesis has been proposed, 
which states that neurons compensate for age-related impairments in white 
matter via greater synaptic responsiveness [332]. Taken together, altered functional 
connectivity patterns in patients with SVD have been observed in several studies, 
with compensatory activation in networks being important to maintain cognitive 
performance [302, 308-310]. 
Mixed age-related pathologies 
The variability in clinical symptoms between patients with apparently similar 
degrees of SVD might also be explained by the presence of other neurodegenera-
tive pathologies, such as Alzheimer disease (AD). A neuroimaging study in patients 
with AD has reported reductions in network integrity that were associated with 
increased volume of WMH and lacunes, specifically in networks important for 
cognitive functioning, such as in executive and default-mode networks as well as 
in connections between hippocampus, thalamus, putamen and cortical regions 
[333].
The question remains to what extent these pathologies truly interact. Some 
neuroimaging studies have found a synergistic effect between WMH and markers 
suggestive of AD pathology (for example hippocampal volume) on cognitive 
performance [334, 335]. Studies using AD transgenic mouse models have suggested 
that neurovascular dysfunction potentiates the production of amyloid-β [336]. 
However, longitudinal evidence on the directionality of associations between 
vascular pathology and AD pathology in humans is limited [336, 337]. Neuroimaging 
studies in cognitively normal elderly individuals and patients with cognitive 
impairment have suggested that cerebrovascular pathology and AD pathology 
negatively affect cognition independently of each other [327, 338]. The same 
conclusion was also reached by two recent reviews [336, 337].
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despite the presence of focal subcortical lesions. Hence, what we see, is not what 
we get. This notion has also become apparent in other neurological diseases, 
for instance in multiple sclerosis which clinical course is increasingly better 
understood from the perspective of a global, rather than a focal brain disease 
[340].
In conclusion, advances in structural and functional imaging and network analyses 
have increased our understanding of the clinical symptoms in SVD beyond the 
classic spectrum, and of the heterogeneity of these symptoms between individuals. 
Future prospective studies with in-depth phenotyping of patients and multimodal 
structural and functional MRI with high temporal and spatial resolution will 
shed light on the sequence of events in SVD from the very first MRI manifestation 
of focal SVD to its global remote effects.
 Future directions
Comprehensive studies with in-depth phenotyping of patients are warranted to 
further unravel the mechanisms by which SVD might lead to clinical deficits. 
Studies should include patients of a younger age, as currently often patients above 
age 60 are studied, which would enable elaboration on the factors involved in the 
origin of SVD. Future studies should also take into account all neuroimaging 
markers of SVD and include advanced multimodal structural and functional 
magnetic resonance sequences with high spatial resolution. Moreover, studies 
with longitudinal designs, including those with short inter-scan intervals of weeks 
or months, are of utmost importance to elucidate the directionality of associations 
and the sequence of events from focal SVD towards global remote effects and 
clinical symptoms. Furthermore, rather than solely focusing on vascular dementia 
or AD as isolated diseases, the field would benefit from a focus on the interaction 
of SVD pathology with other neurodegenerative pathologies. Finally, the pathological 
correlates of MRI-defined SVD lesions should be further investigated.
Conclusion
SVD is associated with a remarkable variation of clinical symptoms that differ 
both in nature and in severity. In this Review, we elaborate on how SVD affects the 
brain and we provide a framework to explain the remarkable disparities between 
patients. SVD markers visible on conventional MRI only reveal the tip of the iceberg 
with regards to the changes associated with the disease. Despite an identical 
appearance on MRI, SVD lesions are pathologically heterogeneous and a cascade 
of events seems to spread from the initial SVD lesion to remote areas, with an as 
yet unknown time course. Furthermore, SVD disturbs structural and functional 
network integrity, especially in central connections, thereby disrupting efficient 
communication in brain networks. Consequently, even a small focal lesion can 
lead to widespread effects. In addition, reserve and compensatory mechanisms 
allow patients to maintain cognitive and motor performance at the pre-morbid 
level until these mechanisms are exhausted and functional performance drops. 
Finally, other neurodegenerative pathologies can be present and probably contribute 
to the clinical presentation. 
Although SVD lesions mostly occur in subcortical areas, they exert their effect 
throughout the brain. Consequently, the clinical notion of SVD being a focal 
subcortical disease must be reconsidered. Following the identification of SVD 
markers on MRI, clinicians should be aware that the entire brain is affected, 
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Review criteria
Articles were selected from PubMed. To select articles on SVD we used the following 
search terms appearing in title and abstract: “cerebral small vessel disease”, “cerebral 
microangiopath*”, “white matter hyperintensities”, “leukoaraiosis”, “lacunar stroke”, 
“lacunar infarct”, “perivascular spaces” or “microbleeds”. We combined these searches 
with search terms covering the topics in this Review, including “cognition”, 
“motor”, “cerebral cortex”, “network” or “connect*”. We only included articles in 
English and focused on articles published within the past decade to discuss the 
most recent scientific findings. Furthermore, reference lists of cited articles and 
articles in our personal databases were screened for eligibility.
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Introduction
Markers of cerebral small vessel disease (SVD) include white matter hyperintensities 
(WMH), lacunes and microbleeds and are frequently observed on neuroimaging 
in older individuals [5]. SVD has been recognized as the most important vascular 
contributor to the development of cognitive decline and dementia [3].
Progression of SVD has been considered a continuous progressive process, but 
increasing evidence suggests that SVD progression is a dynamic process, sometimes 
interrupted by regression of SVD [59, 61, 110, 345, 346]. Specifically, a decrease 
over time in WMH volume, number of lacunes and number of microbleeds has 
been reported [345]. A neuroimaging study in patients with minor stroke observed 
WMH volume decline in 37 percent of participants [346] and we previously observed 
SVD regression in 20 percent of participants [110], suggesting that SVD regression 
might be a true phenomenon, with unknown clinical implications. 
 
SVD regression might affect clinical outcome in two ways [345]. First, SVD regression 
might accompany global brain atrophy and thereby lead to impaired clinical 
outcome. Second, SVD regression might reflect reversibility of white matter damage 
(i.e. before permanent axonal injury or demyelination has occurred) and hence 
account for recovery of clinical symptoms [28, 346]. 
We therefore examined the cognitive consequences of SVD regression in a cohort 
of 276 older adults with SVD, using neuroimaging and cognitive assessments at 
three time points over nine years. We additionally tested whether SVD regression 
accompanied global brain atrophy.
Methods
Study population
The RUN DMC study prospectively investigates risk factors and clinical consequences 
of SVD in 503 non-demented older adults with SVD [148]. In the present study, 
we included 276 participants with repeated MRI assessment of sufficient quality 
[110]. The data that support the findings of this study are available from the 
corresponding author upon request.
Abstract
Background: Recent studies have shown that neuroimaging markers of cerebral 
small vessel disease (SVD) can also regress over time. If, and how, regression affects 
cognitive outcome remains to be established. We therefore investigated the cognitive 
consequences of regression of SVD markers in a cohort of elderly with SVD.
Methods: 276 participants of the RUN DMC study underwent neuroimaging and 
cognitive assessments at three time points over 8.7 years. We semi-automatically 
assessed WMH volumes and manually rated lacunes and microbleeds. We analyzed 
differences in cognitive decline and accompanying brain atrophy between 
participants with regression, progression and stable SVD by ANOVA.
Results: Of 276 participants (mean age 62.5±7.7 years; 59.1% male), 56 participants 
(20.3%) showed regression of SVD markers: 31 (11.2%) showed WMH regression, 10 
(3.6%) vanishing lacunes and 27 (9.8%) vanishing microbleeds. Participants with 
regression showed a decline in overall cognition, memory, psychomotor speed and 
executive function similar to stable SVD. In addition, participants with WMH 
regression showed less cognitive decline compared to those with WMH progression 
(mean difference [95% confidence interval]: .29 [.02, .56]; p=.035 for cognitive index 
and .42 [.08, .76]; p=.010 for memory), and participants with vanishing lacunes 
showed less decline in psychomotor speed compared to participants with incident 
lacunes (.48 [.01, .96]; p=.043), although significance was lost after adjustments. 
Loss of total brain, gray matter and white matter volume did not differ between 
participants with SVD regression and stable SVD, while participants with SVD 
progression showed more volume loss of total brain (mean difference -11.9 [-21.1, 
-2.8]; p=.006) and gray matter (-6.7 [-13.1, -.20]; p=.041) compared to stable SVD, 
though significance disappeared after adjustments.
Conclusions: Regression of SVD markers was associated with similar cognitive 
decline compared to stable SVD and did not accompany brain atrophy, suggesting 
that SVD regression follows a relatively benign clinical course.
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Participants with regression showed similar cognitive decline compared to those 
with stable SVD, during the nine-year follow-up (Figure 1). Participants with SVD 
progression showed more cognitive decline compared to those with stable SVD 
(WMH: mean difference [95% confidence interval] -.23 [-.56, -.02]; p=.017 for cognitive 
index; -.34 [-.59, -.09]; p=.004 for memory; and -.29 [-.51, -.06]; p=.006 for executive 
function; lacunes: -.21 [-.41, -.01]; p=.036 for executive function; microbleeds: -.22 
[-.42, -.02]; p=.024 for cognitive index; -.29 [-.54, -.04]; p=.019 for memory and -.24 
[-.47, -.02]; p=.029 for executive function), although significance was lost after 
adjustments for age and sex. In addition, participants with WMH regression showed 
less cognitive decline compared to those with WMH progression (.29 [.02, .56]; 
p=.035 for cognitive index and .42 [.08, .76]; p=.010 for memory), and participants 
Cognitive function
All participants underwent neuropsychological assessment at three time points 
using validated cognitive tasks [228]. We calculated a compound score for global 
cognitive function (cognitive index) and for three cognitive domains: memory, 
psychomotor speed and executive function. Raw scores of all time points were 
transformed into z-scores based on the baseline mean and standard deviation (SD). 
Neuroimaging
MR images were acquired at three time points on 1.5-Tesla MRI and included 
T1-weighted 3D MPRAGE, FLAIR and T2*-weighted gradient echo sequences [110, 
148]. We calculated total brain, gray matter (GM) and white matter (WM) volumes 
using SPM12 (http://www.fil.ion.ucl.ac.uk/spm/) [110]. WMH volumes were calculated 
semi-automatically and lacunes and microbleeds were rated manually, according 
to the STRIVE criteria [5, 110]. All images were visually checked for co-registration 
and segmentation artefacts and volumes were corrected for inter-scan differences 
and normalized to baseline intracranial volume (ICV).
Statistical analyses
We compared baseline characteristics between participants with SVD regression, 
progression and stable SVD using univariate analyses. We defined SVD regression 
as >0.25ml WMH volume decline or having a vanishing lacune or microbleed, and 
SVD progression as >1SD WMH progression or at least one incident lacune or 
microbleed, according to our previous study [110]. We defined ‘stable SVD’ as a 
change in WMH volume between -0.25ml and +1SD and having no incident or 
vanishing lacunes or microbleeds. We assessed differences in cognitive decline 
and in brain atrophy between participants with SVD regression, progression and 
stable SVD by one-way ANOVA with Bonferroni-correction, additionally adjusted 
for age and sex.
Results
56 participants (20.3%) showed regression of SVD markers: 31 participants (11.2%) 
showed WMH regression, 10 (3.6%) vanishing lacunes and 27 (9.8%) vanishing micro- 
bleeds [110]. Characteristics of participants with SVD regression are presented in 
Table 1. Stratified by time-period, 42 participants (15.2%) showed regression during 
the first time-interval, 30 participants (10.9%) during the second time-interval, 
and 23 participants (8.3%) during the overall follow-up. 
Table 1   Baseline characteristics of participants with SVD regression
Study 
population
(n=276)
SVD change
Stable SVD
(n=143)
Regression
(n=56)
Progression
(n=77)
Demographics
Age, years 62.5 ± 7.7 60.6 ± 7.2 62.8 ± 7.5 65.7 ± 7.8 ***
Male sex, n 163 (59.1) 82 (57.3) 34 (60.7) 47 (61.0)
MMSE score 28.6 ± 1.3 28.7 ± 1.4 28.6 ± 1.3 28.6 ± 1.2
Education, years 10.1 ± 1.5 10.2 ± 1.2 10.1 ± 1.9 9.9 ± 1.7
Vascular risk factors
Hypertension, n 190 (68.8) 88 (61.5) 42 (75.0) 60 (77.9) *
Diabetes, n 30 (10.9) 13 (9.1) 6 (10.7) 11 (14.3)
Hypercholesterolemia, n 118 (42.8) 58 (40.6) 25 (44.6) 35 (45.5)
Smoking, ever, n 196 (71.0) 107 (74.8) 40 (71.4) 49 (63.6)
Alcohol, glasses/week 8.3 ± 9.0 8.5 ± 8.8 7.9 ± 9.9 8.1 ± 8.8
Body mass index, kg/m2 27.1 ± 4.1 26.9 ± 4.2 26.3 ± 3.6 28.1 ± 4.0 †
Imaging characteristics
Total brain volume, ml 1086.3 ± 70.6 1104.6 ± 61.7 1076.0 ± 73.3 * 1059.6 ± 74.9 *** 
Gray matter volume, ml 620.7 ± 48.9 631.5 ± 44.3 616.1 ± 53.4 603.8 ± 49.1 ***
White matter volume, ml 465.6 ± 38.9 473.1 ± 34.6 459.9 ± 43.3 455.8 ± 40.8 **
WMH volume, ml 2.3 (0.8–6.1) 1.3 (0.6–2.8) 5.1 (2.4–14.0) *** 3.7 (1.3–13.3) ***
Lacunes, n 55 (19.9) 12 (8.4) 20 (35.7) *** 23 (29.9) ***
Microbleeds, n 36 (13.0) 7 (4.9) 26 (46.4) *** 3 (3.9) †††
Data represent mean ± SD, number (n) of participants (%) or median (IQR). Comparisons were performed 
by ANOVA, Chi-square or Mann-Whitney-U test. ***p<0.001, **p<0.01, *p<0.05 versus participants with 
stable SVD; †††p<0.001, †p<0.05 versus participants with regression. n: number of participants; MMSE: 
Mini-Mental State Examination.
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Figure 1  Cognitive consequences of SVD regression Figure 1  Continued
Cognitive decline over the overall nine-year follow-up (2006-2015) per cognitive domain, separately for 
A) participants with stable WMH (light gray; n=208), WMH regression (dark gray; n=31) and WMH 
progression (black; n=37) at any time-period; B) participants without incident or vanishing lacunes (light 
gray; n=219), vanishing lacunes (dark gray; n=10) and incident lacunes (black; n=47) at any time-period; 
and C) for participants without incident or vanishing microbleeds (light gray; n=212), vanishing 
microbleeds (dark gray; n=27) and incident microbleeds (black; n=37) at any time-period. Bars represent 
mean decline in z-score with standard errors as whiskers. Statistical differences are analyzed by one-way 
ANOVA, followed by a Bonferroni-correction. ^^^p<0.001, ^^p<0.01, ^p<0.05 for participants with 
progression versus participants with stable SVD, unadjusted; †p<0.05 for participants with regression 
versus participants with stable SVD, unadjusted. Significance was lost after adjustments for age and sex.
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second hypothesis. Of note, is that differences between the three SVD groups 
(progression, regression, stable) lost significance after adjustments, possibly due 
to reduced statistical power in relatively small groups. Our results should thus be 
interpreted with caution and require verification in larger studies.
Our findings might have clinical implications, as they suggest that future 
therapeutic strategies targeting vascular contributions to dementia may be 
particularly interested in regression of SVD. Previously observed associations 
between blood pressure reduction and WMH regression in patients with minor 
stroke [346] suggest that anti-hypertensive treatments might lead to regression of 
SVD, though future (intervention) studies are required to assess the role of 
vascular risk factor control on SVD regression and recovery of clinical symptoms. 
Strengths of this study include the long follow-up of participants with SVD and 
the use of neuroimaging assessments at three time points. Study limitations 
include the possibility that regression of SVD markers might have a radiological 
explanation, for example by slight changes in neuroimaging protocols between 
baseline and first follow-up which might have led to an overestimation of WMH 
regression.[110] However, by taking into account the third MRI assessment and 
reslicing follow-up FLAIR to baseline images, we were able to capture most of this 
possible bias. Besides, due to the long-term follow-up a considerable proportion of 
participants was not able to complete all follow-up assessments, reducing power 
in statistical analyses. 
In conclusion, our findings of comparable cognitive decline between participants 
with regression and stable SVD might suggest that SVD regression has a relative 
benign cognitive outcome. Future studies are required to validate these findings 
and to assess the role of vascular risk factor control on SVD regression and possible 
recovery of clinical symptoms.
with vanishing lacunes showed less decline in psychomotor speed compared to 
participants with incident lacunes (.48 [.01, .96]; p=.043), although significance was 
lost after adjustments.
Loss of total brain, gray matter and white matter volume did not differ between 
participants with SVD regression and stable SVD, while participants with SVD 
progression showed more volume loss of total brain (mean difference -11.9 [-21.1, 
-2.8]; p=.006) and gray matter (-6.7 [-13.1, -.20]; p=.041) compared to those with stable 
SVD (Table 2), although significance disappeared after adjustments.
Discussion
We observed regression of SVD markers in a considerable proportion of participants 
who showed similar cognitive decline compared to participants with stable SVD. 
In addition, SVD regression did not accompany brain atrophy.
WMH regression has recently been related to fewer composite recurrent cerebro-
vascular events [346], but its associations with cognitive performance have not 
been investigated. We had two hypotheses on how SVD regression might affect 
cognitive outcome [345]. First, SVD regression might accompany brain atrophy and 
thereby lead to impaired clinical outcome. This hypothesis is less likely, since both 
brain atrophy and cognitive decline of participants with SVD regression were 
comparable to participants with stable SVD. Second, SVD regression might reflect 
resolution of transient white matter damage and thereby account for recovery of 
clinical symptoms [28, 345]. Our observations of comparable cognitive decline 
between participants with regression and stable SVD might be supportive of the 
Table 2   Regression of SVD markers and accompanying brain atrophy
Stable
(n=160)
Regression
(n=23)
Progression
(n=89)
Brain atrophy
Total brain, ml -39.5 ± 23.8 -43.2 ± 29.3 -51.4 ± 35.9 ^^
Gray matter, ml -20.0 ± 17.6 -20.0 ± 21.9 -26.7 ± 24.0 ^
White matter, ml -19.4 ± 13.6 -23.3 ± 16.3 -24.7 ± 22.3
Brain atrophy over time is displayed in ml as mean ± SD, separately for participants with stable SVD and 
for participants with regression or progression of their SVD. Statistical differences are analyzed by 
one-way ANOVA, followed by a Bonferroni correction. ^^p<0.01, ^p<0.05 versus participants with stable 
SVD, unadjusted. Significance was lost after adjustments for age and sex.
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Introduction
White matter hyperintensities (WMH) are frequently observed on neuroimaging 
in older adults [6] and constitute an important radiological marker of cerebral 
small vessel disease (SVD) [5]. WMH have been associated with cognitive deficits in 
virtually every domain, including working memory and episodic memory  [3, 43]. 
Working memory relies on prefrontal and parietal cortical regions that are largely 
affected in SVD [347, 348]. The role of WMH in episodic memory deficits, however, 
is less well understood, as episodic memory performance is mainly supported by 
structures in the medial temporal lobes and especially the hippocampus [47, 48], 
which are typically unaffected by WMH [49].
Several studies have reported associations between WMH and hippocampal 
volumes [186, 335, 349-352] and have found a cumulative effect of WMH and 
hippocampal atrophy on the degree of cognitive performance [3, 334, 335], while 
others have reported that these pathologies are independent processes that both 
affect cognition adversely [327, 338]. Thus far, studies have not thoroughly 
investigated the interactions of WMH, hippocampal atrophy and memory decline 
longitudinally. This is especially important as age is an important risk factor for 
all of these three phenomena and WMH progresses exponentially over time [110].
There is increasing awareness that SVD exerts its clinical effects by affecting 
remote brain structures [49, 147], suggesting that disruptions in white matter 
connections due to WMH might lead to secondary hippocampal atrophy and a 
concomitant memory decline in patients with SVD.  A recent cross-sectional neuro- 
imaging study in patients with Alzheimer’s Disease (AD) showed that WMH 
contributed indirectly to memory deficits by contributing to temporal lobe 
atrophy [353]. Prospective studies, however, would be required to elaborate on the 
directionality of the associations.
In this paper we specifically examined the temporal interactions between WMH 
and hippocampal atrophy for these two memory systems longitudinally, using 
three neuroimaging and cognitive assessments over nine years in an SVD cohort. 
Specifically, we tested two hypotheses as to how WMH and hippocampal atrophy 
might affect memory decline (Figure 1). First, we tested whether WMH and 
hippocampal atrophy interacted in predicting memory deficits. Second, we tested 
whether the effect of WMH on memory decline was mediated by hippocampal 
atrophy.
Abstract
Background: White matter hyperintensities (WMH) constitute the visible 
spectrum of cerebral small vessel disease (SVD) markers and are associated with 
cognitive decline, although they do not fully account for memory decline observed 
in individuals with SVD. We hypothesize that WMH might exert their effect on 
memory decline indirectly by affecting remote brain structures such as the 
hippocampus. We investigated the temporal interactions between WMH, 
hippocampal atrophy and memory decline in older adults with SVD.
Methods: 503 participants of the RUNDMC study underwent neuroimaging and 
cognitive assessments up to 3 times over 8.7 years. We assessed WMH volumes 
semi-automatically and calculated hippocampal volumes (HV) using FreeSurfer. 
We used linear mixed effects models and causal mediation analyses to assess both 
interaction and mediation effects of hippocampal atrophy in the associations 
between WMH and memory decline, separately for working memory and episodic 
memory.
Results: Linear mixed effect models revealed that the interaction between WMH 
and hippocampal volumes explained memory decline (working memory: β=0.067; 
95%CI[0.024–0.111]; p<0.01; episodic memory: β=0.061; 95%CI[0.025–0.098]; p<0.01), 
with better model fit when the WMH*HV interaction term was added to the model, 
for both working memory (likelihood ratio test, χ2(1)=9.3, p<0.01) and for episodic 
memory (likelihood ratio test, χ2(1)=10.7, p<0.01). Mediation models showed that 
both baseline WMH volume (β=-0.170; p=0.001) and hippocampal atrophy (β=0.126; 
p=0.009) were independently related to episodic memory decline, but the effect of 
baseline WMH on episodic memory decline was not mediated by hippocampal 
atrophy (p-value indirect effect: 0.572).
Conclusions: Memory decline in elderly with SVD was best explained by the 
interaction of WMH and hippocampal volumes. The relationship between WMH 
and memory was not causally mediated by hippocampal atrophy, suggesting that 
memory decline during aging is a heterogeneous condition in which different 
pathologies contribute to the memory decline observed in elderly with SVD.
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compound scores for working memory and episodic memory. Working memory is 
a compound score of the SAT scores of the 2-letter and 3-letter subtasks of the 
PPMST [196]. Episodic memory is a compound score of the mean of the z-scores of 
the three learning trials and the delayed recall of the RAVLT and the mean of the 
z-scores of the immediate recall trial and the delayed recall trial of the RCFT. 
Cognitive decline over time was calculated for each participant individually, by 
subtracting baseline scores from the follow-up scores.
Vascular risk factors
We assessed the presence of hypertension, smoking, alcohol use, body mass index, 
diabetes and hypercholesterolemia using standardized questionnaires, as described 
previously [148]. Hypertension was defined as the use of antihypertensive agents 
and/or systolic blood pressure greater than or equal to 140 mmHg and/or diastolic 
blood pressure greater than or equal to 90 mmHg. Diabetes was defined as treatment 
with diabetic medication and hypercholesterolemia as the use of lipid-lowering 
drugs [148]. 
Neuroimaging protocols
MR images were acquired at three time-points on 1.5-Tesla MRI (2006: Siemens, 
Magnetom Sonata; 2011 and 2015: Siemens, Magnetom Avanto) and included the 
following whole brain scans: T1-weighted 3D MPRAGE sequence (isotropic voxel 
size 1.0 mm3), a FLAIR sequence (2006: voxel size 0.5×0.5×5.0 mm, interslice gap 
1.0mm; 2011 and 2015: voxel size 0.5×0.5×2.5 mm; interslice gap 0.5 mm) and a 
DTI sequence (2006: isotropic voxel size 2.5 mm3, 4 unweighted scans, 30 diffusion 
weighted scans at b=900 s/mm2; 2011 and 2015: isotropic voxel size 2.5 mm3, 8 
unweighted scans, 60 diffusion weighted scans at b=900 s/mm2). Full acquisition 
details have been described previously [110, 148, 229] and can be found in the 
Supplementary Methods.
Brain volumetry
We assessed grey matter (GMV), white matter (WMV) and CSF volumes using 
SPM12 (http://www.fil.ion.ucl.ac.uk/spm/) unified segmentation routines on the 
T1 MPRAGE images corrected for WMH, as has been described in detail elsewhere 
[110].
White matter hyperintensities
WMH volumes were calculated by a semi-automatic WMH segmentation method, 
which has been described previously [150]. Segmentations were visually checked 
for segmentation errors by one trained rater, blinded for clinical data. WMH 
volumes were corrected for inter-scan-differences in ICV and then normalized to 
Methods
Study population
This study is part of the RUN DMC study, a prospective cohort study among 503 
non-demented older adults with SVD, aged between 50 and 85 years, that investigates 
risk factors and clinical consequences of SVD. Symptoms of SVD include both 
acute symptoms, such as transient ischemic attack (TIA) or lacunar syndromes, 
and subacute manifestations such as cognitive and motor (gait) disturbances [354]. 
As the onset of SVD is often insidious, clinically heterogeneous, and typically with 
mild symptoms, the selection of participants with SVD was based on neuroimaging 
characteristics, including WMH and lacunes [174]. The detailed study protocol has 
been published previously [148]. In short, 503 independently living older adults 
with SVD, without dementia, were included for baseline assessment in 2006. 
Inclusion criteria were age between 50 and 85 years and presence of SVD on 
neuroimaging (i.e. WMH and/or lacunes). Subsequently, the above mentioned acute 
and subacute clinical symptoms of SVD were assessed. Of these 503 participants, 
361 underwent repeated MRI assessment at first follow-up in 2011, and 296 
participants at second follow-up in 2015 [110]. Of those, 7 participants were excluded 
because of insufficient scan quality at baseline, 15 participants at first follow-up, 
and 7 at second follow-up, yielding a sample of 496 participants for neuroimaging 
analyses at baseline, 346 at first follow-up, and 289 at second follow-up. Thus, in 
total 1131 observations could be used for linear mixed effect analyses. In total, 
263 participants underwent repeated cognitive and neuroimaging assessments of 
sufficient quality at all three time-points and could be used for longitudinal 
analyses (Supplemental Figure 1). The Medical Review Ethics Committee region 
Arnhem -Nijmegen approved the study and all participants gave written informed 
consent.
Cognitive function
Cognitive performance was measured using an extensive neuropsychological test 
battery during all three waves of data collection[228]. In the present study, we used 
the immediate and delayed recall of the Rey Auditory Verbal Learning Test (RAVLT) 
[355] and Rey Complex Figure Task (RCFT) [356] as well as Speed–Accuracy Trade-Off 
(SAT) scores of the 2-letter and 3-letter subtasks of the Paper-Pencil Memory 
Scanning Task (PPMST) [196].To account for possible learning effects, parallel 
versions of the RAVLT and RCFT were used for the second follow-up assessment. 
Performance across tests was made comparable by transforming the raw test scores 
into z-scores, where higher z-scores indicate better performance. Raw scores of all 
three time-points were transformed into z-scores based on the mean and standard 
deviation (SD) of the baseline study population. We subsequently calculated 
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[154]. All analyses were performed separately for working and episodic memory. 
LME models allow for the simultaneous modeling of fixed (population-average) 
and random (subject-specific) effects, allowing us to examine memory decline in 
the entire population while accounting for individual differences in rates of 
memory decline. We fitted four models: (1) a null model including baseline age, 
sex and the level of education at baseline. Time between baseline and follow-up 
assessments was added as a fixed effect and a subject-specific random intercept 
and slope, such that the fixed effect coefficient estimates group-level memory 
decline per year, while the random terms are the individual trajectories of 
memory decline over time. In addition, we included a quadratic term for time, as 
WMH were found to progress nonlinearly over time [110]. In the second model (2) 
we additionally added WMH volumes of all available time-points and the 
interaction between WMH and time-squared, indicating the effect of nonlinear 
WMH progression on memory decline. In the third model (3) we added hippocampal 
volumes of all available time-points and the interaction between HV and linear 
time to the null model, to estimate the effect of hippocampal atrophy over time 
on memory decline. (4) In the fully-specified model we additionally added an 
interaction term between WMH and HV. We compared model fit between the four 
models using a likelihood ratio test, and we evaluated the change in Akaike 
information criterion (AIC) and Bayesian information criterion (BIC). For both 
indexes, smaller values indicate better fit. 
baseline ICV. We calculated individual annualized WMH progression rates using 
linear mixed effects (LME) models based on all available time-points. The individual 
WMH progression rates were extracted and used for further analyses.
Hippocampal volumes
Hippocampal volume segmentations were automatically processed with the 
longitudinal stream [357] in FreeSurfer 5.3 (http://surfer.nmr.mgh.harvard.edu/). 
In short, the T1-weighted images from all three time-points were first processed 
separately using the standard processing stream. Subsequently, an unbiased 
within-subject template was created from all time-points for each subject using the 
longitudinal processing stream, and several processing steps were then initialized 
with common information from the within-subject template, to increase the 
reliability of the segmentation of brain regions over time [357]. For those participants 
who were only able to complete one or two neuroimaging assessments, we ran the 
same longitudinal pipeline using the available T1-weighted images, to ensure 
that all images underwent the same processing steps [358]. All segmentations were 
visually checked for segmentation accuracy at each time-point and manually 
adjusted when necessary. We used LME models to estimate individual annualized 
hippocampal atrophy rates based on all available time-points, with negative values 
reflecting more hippocampal atrophy. The individual hippocampal atrophy rates 
were extracted and used for further analyses.
Statistical analysis
All statistical analyses were carried out in R 3.4.2 (https://www.r-project.org/). Change 
in WMH, HV and cognitive performance over time was tested using repeated 
measures ANOVA. We visualized the change in both working memory and episodic 
memory over time according to quartiles of baseline WMH and hippocampal 
volumes. We analyzed WMH and hippocampal volumes in quartiles of their 
distribution and tested continuous linear trend per stratum. We additionally 
displayed the change in working and episodic memory according to the interaction 
between WMH and hippocampal volumes. We therefore identified low WMH 
volume (WMH+), high WMH volume (WMH-), high hippocampal volume (HV+) and 
low hippocampal volume (HV-) based on median split of baseline volumes, thereby 
creating 4 groups: WMH+/HV+, WMH-/HV+, WMH+/HV- and WMH-/HV-. Differences 
between these groups were calculated using one-way ANOVA with post-hoc 
 Bonferroni-correction.
To test whether WMH and hippocampal volumes interacted in predicting memory 
deficits (Figure 1 – Hypothesis I), we fitted linear mixed effects (LME) models with 
memory performance as the dependent variable using ‘lme4’ version 1.1-14 in R 
Figure 1  Illustration of the tested hypotheses
We tested two hypotheses on how white matter hyperintensities and hippocampal atrophy might affect 
memory decline: I. WMH and hippocampal atrophy interact in predicting memory decline; II. The effect of 
WMH on memory decline is mediated via hippocampal atrophy.
I. Interaction II. Mediation
WMH Memory decline
Hippocampal 
atrophy
WMH
Memory
HV
WMH*HV
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Results
Baseline characteristics of the study population are presented in Table 1. Mean age 
at baseline was 65.7 (SD 8.8) years and 57% of the participants were male. WMH 
and hippocampal volumes and cognitive performance over time is shown in 
Supplementary Table 1. Higher WMH volumes were related to both lower working 
memory and lower episodic memory performance (working memory: β=-0.295; 
95%CI [-0.348 - -0.241]; p<0.001; episodic memory: β=-0.271; 95%CI [-0.324 - -0.217]; 
p<0.001) and higher hippocampal volumes were related to both higher working 
memory and higher episodic memory performance (working memory: β=0.307; 
95%CI [0.253 - 0.359]; p<0.001; episodic memory: β=0.392; 95%CI [0.341 - 0.440]; 
p<0.001), modified by age (Figure 2). Change in both working memory and episodic 
memory over time according to quartiles of baseline WMH and hippocampal 
We performed additional analyses on the temporal interactions between WMH, 
HV and memory decline. For this, we first used LME models to estimate individual 
annualized WMH progression and hippocampal atrophy rates based on all available 
time-points. The individual WMH progression and hippocampal atrophy rates 
were extracted and used for further analyses. Using ‘lavaan’ version 0.5-23.1097 in 
R [359], we estimated the effects of baseline WMH volume, WMH progression, 
baseline hippocampal volume and hippocampal atrophy on memory decline, 
separately for working and episodic memory decline. We also tested the effect of 
the interaction term between baseline WMH and hippocampal volumes on 
memory decline. Analyses were adjusted for baseline age, sex and level of education 
at baseline. We compared model fit between the models with and without the 
interaction term using a likelihood ratio test.
To test whether interactions between WMH and HV in predicting memory deficits 
were specifically attributed to hippocampal atrophy, we performed the same 
analyses with global gray matter atrophy instead of hippocampal atrophy. Hence, 
we compared four models: in the first model (1) we added WMH and the interaction 
between WMH and quadratic time only. In the second model (2) we additionally 
added HV, the interaction between HV and time, and the interaction term between 
WMH and HV. In the third model (3) we added GMV, the interaction between 
GMV and time, and an interaction term between WMH and GMV to the first model, 
to estimate the effect of global gray matter atrophy on memory decline. 
We additionally fitted a fourth model (4), in which we added both HV and GMV 
together with their interaction terms, to estimate the relative strengths of hippo - 
campal and global gray matter atrophy in explaining memory decline. 
To test whether hippocampal atrophy mediated the association between WMH and 
memory decline (Figure 1, Hypothesis II), we performed mediation analyses using 
‘lavaan’ version 0.5-23.1097 in R [359] .` For this, we first used LME models to 
estimate individual annualized hippocampal atrophy rates based on all available 
time-points. The individual hippocampal atrophy rates were extracted and used 
for further analyses. Using lavaan, we estimated the direct effect of baseline WMH 
volume on memory decline and the indirect effect of baseline WMH volume on 
memory decline via hippocampal atrophy, separately for working and episodic 
memory decline. 
Table 1   Baseline characteristics
Study population
(n=503)
Demographics
Age, years 65.7 ± 8.8
Male sex, nr of participants 284 (56.5)
MMSE score 28.1 ± 1.6
Education, years 9.8 ± 1.8
Vascular risk factors
Hypertension, nr of participants 369 (73.4)
Hypercholesterolemia, nr of participants 237 (47.1)
Diabetes, nr of participants 75 (14.9)
Smoking, ever, nr of participants 353 (70.2)
Alcohol, glasses/week 7.9 ± 9.3
Body mass index, kg/m2 27.1 ± 4.1
Imaging characteristics
Total brain volume, ml 1060.9 ± 80.1
Grey matter volume, ml 606.2 ± 52.6
White matter volume, ml 454.7 ± 46.0
Microbleeds, nr of participants 83 (16.5)
Lacunes, nr of participants 132 (26.2)
WMH volume, ml 3.6 (1.2 – 11.4)
Hippocampus volume, ml 7.6 ± 1.0
Data represent number of participants (%), mean ± SD or median (IQR). 
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volumes as well as their interaction was graphically displayed in Figure 3. We observed 
more decline in the WMH-/HV- group compared to both WMH-/HV+ and WMH+/
HV- groups.
Memory decline explained by interactions between WMH and  
hippocampal atrophy
The results of the mixed effect models are shown in Table 2. Both models with WMH 
only and HV only provided significantly better fits in comparison to the null model, 
for both working memory (WMH only versus null model: likelihood ratio test, 
χ2(2)=7.3, p<0.05; HV only versus null model: χ2(2)=9.8, p<0.01) and for episodic memory 
(WMH only versus null model: χ2(2)=28.3, p<0.001; HV only versus null model: 
χ2(2)=74.4, p<0.001). The models with HV alone fitted better than the models with 
WMH alone, not only for episodic memory (likelihood ratio test, χ2(0)=46.1, p<0.001), 
but also for working memory (likelihood ratio test, χ2(0)=2.4, p<0.001). Importantly, 
including the WMH*HV interaction term significantly improved the model, for 
both working memory (likelihood ratio test model with both WMH & HV versus full 
model with WMH*HV interaction term , χ2(1)=9.3, p<0.01) and for episodic memory 
(likelihood ratio test model with both WMH & HV versus full model with WMH*HV 
interaction term, χ2(1)=10.7, p<0.01). The WMH*HV interaction term was significantly 
associated with memory function (working memory: β=0.067; 95%CI [0.024 – 0.111]; 
p<0.01; episodic memory: β=0.061; 95%CI [0.025 – 0.098]; p<0.01). More hippocampal 
atrophy was associated with lower episodic memory performance (β=0.017; 95%CI 
[0.009 – 0.025]; p<0.001).
The results of the interaction analyses on decline in working memory and episodic 
memory are shown in Figure 4. Lower baseline hippocampal volumes (β=0.132; 
p<0.001) and higher baseline WMH volumes (β=-0.164; p<0.001) were associated 
with more episodic memory decline. More hippocampal atrophy was associated 
with more episodic memory decline (β=0.120; p<0.001). Including the WMH*HV 
interaction term significantly improved the model, for both working memory 
(likelihood ratio test, χ2(1)=6.0, p<0.05) and episodic memory (likelihood ratio test, 
χ2(1)=10.1, p<0.01).
Additional analyses on global gray matter atrophy revealed a significant interaction 
effect of WMH*GMV for working memory (β=0.090; 95%CI [0.004 – 0.177]; p<0.05), 
though the addition of both hippocampal and gray matter atrophy to the model 
rendered the WMH*GMV interaction term non-significant (β=0.027; 95%CI [-0.077 
– 0.131]; p>0.05) where the WMH*HV interaction term remained significant 
(β=0.059; 95%CI [0.007 – 0.111]; p<0.05). There was no significant interaction effect 
of WMH*GMV for episodic memory (β=0.073; 95%CI [-0.001 – 0.147]; p>0.05).
Figure 2  Age-related working and episodic memory performance by white matter 
hyperintensities and hippocampal volumes
A. Spaghetti plots showing the trajectories of working memory performance (left) and episodic memory 
performance (right) over time. B. Age-related working memory performance by white matter hyperinten-
sities (left) and hippocampal volumes (right). C. Age-related episodic memory performance by white 
matter hyperintensities (left) and hippocampal volumes (right). Dots are color-coded by age, with 
baseline age of participants ranging from 50 years in light blue to 85 years in dark blue.
B. Working memory
C. Episodic memory
A. Spaghetti plots
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Interestingly we observed an interaction between WMH and hippocampal atrophy 
for working memory, although the relative involvement of the hippocampus itself 
was lower for working memory performance than for episodic memory performance. 
While it has been argued that working memory processing should not rely on the 
hippocampus [48, 348], and we hypothesized that working memory performance 
would be related to WMH specifically, some degree of long-term encoding has 
been demonstrated during working memory tasks related to the specific task 
demands [361]. That is, working memory tasks are rarely “process pure”, but may 
also include components that promote incidental long-term encoding (e.g., 
maintaining the target items in the PPMT over a longer period of time). 
Several mechanisms might be proposed for the association between WMH and 
memory decline. WMH might exert their clinical effects in a direct way by 
disconnecting white matter tracts, or indirectly through incident stroke [122] or 
by affecting remote brain structures [49, 147]. Alternatively, vascular risk factors 
might lead to cognitive decline in patients with SVD through other mechanisms, 
such as inflammatory responses, hormonal dysregulation or damage to neu-
rotransmitter systems [362-364]. Finally, memory decline in patients with SVD 
might also be explained by the interaction of SVD pathology with other neurode-
generative pathologies, such as seen in AD [3, 14, 187, 360]. Our observations that 
WMH and hippocampal atrophy interact in explaining memory decline in 
patients with SVD support this hypothesis. This is in line with a study in patients 
with AD showed that reduced network integrity was associated with SVD severity, 
specifically in networks important for cognition [333]. Animal studies have 
suggested that neurovascular dysfunction could potentiate the production of 
amyloid beta [336], suggesting that cerebrovascular pathology might be a risk 
factor for AD, although longitudinal evidence on the directionality of associations 
between vascular and Alzheimer’s pathology in humans remains limited.
The presence of an interaction effect in the absence of a causal mediation effect 
suggests that WMH and hippocampal atrophy are independent processes that syn-
ergistically affect memory decline. These findings suggest that age-related 
memory decline is a heterogeneous condition in which different pathologies 
contribute to the memory decline observed in elderly with SVD. 
Major strengths of this study include the large number of participants with SVD 
included in the study and the longitudinal design of our study with three 
neuroimaging assessments over nine years, which enabled us to study temporal 
interactions between WMH progression, hippocampal atrophy and memory 
decline beyond cross-sectional associations. Several methodological issues and 
Mediation of the associations between WMH and memory decline by 
hippocampal atrophy
The results of the causal mediation analyses are shown in Figure 5, separately for 
working memory and episodic memory decline. Decline in working memory 
performance over time was not associated with baseline WMH volume (β=-0.022; 
p=0.707) or hippocampal atrophy (β=0.056; p=0.306) after adjusting for age, sex 
and education. The direct effects of both baseline WMH volume (β=-0.170; p=0.001) 
and hippocampal atrophy (β=0.126; p=0.009) on episodic memory decline were 
significantly different from zero. The effect of baseline WMH on episodic memory 
decline was not mediated by hippocampal atrophy (p-value indirect effect: 0.572).
Discussion
We observed that memory decline in individuals with SVD was best explained by 
an interaction of WMH and hippocampal atrophy, rather than these two variables 
independently. In addition, we showed that the association between WMH and 
episodic memory decline was not causally mediated by hippocampal atrophy. 
Finally, we demonstrated that these effects were specific to hippocampal atrophy, 
rather than general grey matter atrophy. Together, our findings suggest that 
memory decline in patients with SVD is a heterogeneous condition to which 
different pathologies contribute.
Our findings that memory decline could be best explained by the interaction of 
WMH and hippocampal atrophy are consistent with imaging studies showing an 
additive effect of WMH and hippocampal atrophy on the level of cognitive decline 
[3, 334, 335], although there are also studies that have reported that AD and 
vascular pathologies are independent processes [327]. These variable findings 
might be due to differences in the relative proportion of cerebrovascular and AD 
pathologies, with both pathologies being present in many older adults with 
dementia [360]. Our study adds to these findings by describing the temporal 
interactions between both pathologies and memory decline longitudinally, over a 
long follow-up of almost nine years. We found that memory decline could be best 
explained by the interaction of WMH and hippocampal atrophy and that the 
associations between WMH and hippocampal atrophy were not causally mediated 
by hippocampal atrophy, suggesting that WMH and hippocampal atrophy syner-
gistically affect memory decline. Moreover, we found that this effect of 
hippocampal atrophy was not just the result of global brain atrophy, as the effect 
of hippocampal atrophy was stronger than the effect of global gray matter atrophy. 
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Supplementary material
Supplementary methods
Neuroimaging protocols 
MR images were acquired at three time-points on 1.5-Tesla MRI (2006: Siemens, 
Magnetom Sonata; 2011 and 2015: Siemens, Magnetom Avanto) and included the 
following whole brain scans: T1-weighted 3-dimensional MPRAGE (isotropic voxel 
size 1.0 mm3), FLAIR (2006: voxel size 0.5 0.5 5.0 mm, interslice gap 1.0 mm; 2011 
and 2015: voxel size 0.5 0.5 2.5 mm; interslice gap 0.5 mm), a transversal 
T2*-weighted gradient echo sequence (voxel size 1.3x1.0x5.0 mm, interslice gap 
1.0mm) and DTI (2006: isotropic voxel size 2.5 mm3, 4 unweighted scans, 30 
diffusion weighted scans at b=900 s/mm2; 2011 and 2015: isotropic voxel size 2.5 
mm3, 8 unweighted scans, 60 diffusion weighted scans at b=900 s/mm2) [110, 148, 
229]. The same head coil was used at all three time-points. To minimize effects of 
changes in FLAIR sequence we resliced follow-up FLAIR images to match slice 
thickness of baseline images using linear interpolation.  
Brain volumetry 
Grey matter (GM), white matter (WM) and CSF probability maps were computed 
using SPM12 (http://www.fil.ion.ucl.ac.uk/spm/) unified segmentation routines on 
the T1 MPRAGE images [110]. Additionally, we used the WMH masks to correct the 
segmentation images, since several brain regions with WMH damage were 
initially misclassified. All WMH voxels were given mean WM intensity and these 
corrected T1 images were segmented using SPM12. All images were visually 
checked for co-registration and segmentation artefacts. GM, WM and CSF volumes 
(GMV, WMV and CSFV) were computed by summing all voxels belonging to that 
tissue class multiplied by voxel volume in mL. Intracranial volume (ICV) was 
determined by summing GMV, WMV and CSFV and total brain volume (TBV) by 
summing GMV and WMV. To account for inter-scan-effects we corrected for 
differences in ICV between baseline and follow-up. We normalized all volumes to 
baseline ICV to account for head size.[149] 
White matter hyperintensities 
WMH volumes were calculated by a semi-automatic WMH segmentation method 
[110, 150]. Segmentations were visually checked for segmentation errors by one 
trained rater, blinded for clinical data. WMH volumes were corrected for in-
ter-scan-differences in ICV and then normalized to baseline ICV. Besides, we 
calculated WMH volumes for odd and even slices separately to determine the 
effects of change in slice thickness of the FLAIR sequence.
limitations deserve consideration. First, slight changes in neuroimaging protocols 
between baseline and first follow-up might be a potential source of bias. To minimize 
effects of changes in FLAIR sequence we resliced follow-up FLAIR images to match 
the slice thickness of baseline images using linear interpolation. Besides, we calculated 
WMH volumes for odd and even slices separately to determine the effects of change 
in slice thickness of the FLAIR sequence. This revealed similar results. Furthermore, 
hippocampal volumes were calculated using subject templates as part of the 
longitudinal segmentation pipeline, reducing the risk of bias in longitudinal 
volume calculations. Another limitation might be that learning effects have led to 
an underestimation of memory decline in our study population. We limited these 
possible learning effects by the use of alternative versions of the memory tasks 
during the second follow-up assessment. Due to the long-term follow-up of our 
study a proportion of the participants was unable to complete the entire follow-up. 
This attrition bias might have led to an underestimation of the effects, since those 
lost to follow-up had more severe WMH, smaller hippocampal volumes and were 
cognitively more impaired already at baseline. However, by using mixed effects 
models we could also take into account the participants with one or more missing 
values, thereby limiting the effect of the attrition bias. Finally, as we did not have 
pathological confirmations on cerebrovascular or AD pathologies, we used WMH 
and hippocampal volumes as markers of these two diseases. 
In conclusion, memory decline in elderly with SVD was best explained by the 
interaction of WMH with hippocampal atrophy. The relationship between WMH 
and memory was not causally mediated by hippocampal atrophy, suggesting that 
memory decline during aging is a heterogeneous condition in which different 
pathologies contribute to the memory decline observed in elderly patients with 
SVD.
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Supplementary Figure 1  Flowchart Supplementary Table 1   WMH and hippocampal volume and memory 
performance over time
Baseline
(2006)
Follow-up 1
(2011)
Follow-up 2
(2015)
Repeated 
measures 
ANOVA
Imaging characteristics
WMH volume, ml 2.3 (0.8 – 6.1) 2.8 (1.2 – 7.7) 4.7 (2.0 – 11.5) p<0.001
Hippocampal volume, ml 7.9 ± 0.9 7.6 ± 1.0 7.4 ± 1.1 p<0.001
Cognitive performance
Working memory, z-score 0.21 ± 0.88 -0.19 ± 0.90 -0.41 ± 1.00 p<0.001
Episodic memory, z-score 0.18 ± 0.77 -0.26 ± 0.79 0.15 ± 0.99 p<0.001
WMH and hippocampal volumes and memory performance over time for all participants with repeated 
neuroimaging and cognitive assessments at three time-points (n=263), displayed as median (IQR) or 
mean ± SD. Z-scores are calculated based on the mean and SD from the baseline study population. 
Significant decline was tested using repeated measures ANOVA.
Baseline (2006)
participants with MRI
n=503
49 participants deceased
Follow-up 1 (2011)
participants with MRI
n=361
Follow-up 2 (2015)
participants with MRI
n=296
Participants with MRI in
2006 & 2011 & 2015
n=263
43 participants deceased
20 participants excluded in longitudinal study
- MRI assessment in 2015 but not 2011 n=15
- Insufficient scan quality (2006) n=7
- Insufficient scan quality (2011) n=15
- Insufficient scan quality (2015) n=7
Participants eligible for
follow-up 1 (2011)
n=454 93 participants without MRI in 2011
- Lost to follow-up n=2
- Unable to vsit research centre n=54
- MRI contra-indications n=37
Note: These 93 participants were again contacted
for second follow-up assessment in 2015.
115 participants without MRI in 2015
- Unable to vsit research centre n=65
- MRI contra-indications n=50
Participants eligible for
follow-up 2 (2015)
n=411
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Introduction
Cerebral small vessel disease (SVD) is considered the most important vascular 
contributor to the development of cognitive impairment and dementia [3, 4, 41]. 
Markers of SVD include white matter hyperintensities (WMH), lacunes and micro - 
bleeds [5] and are present on neuroimaging in virtually every individual over 
60 [6], although in a highly variable degree. All these conventional SVD markers 
have been associated with cognitive impairment, but exactly how these associations 
result in cognitive decline or dementia is hitherto incompletely understood [5, 365].
There is increasing awareness that SVD exerts its clinical effects by disrupting 
white matter connections [53, 366, 367]. That is, structural network connectivity 
might mediate the associations between conventional SVD markers and cognitive 
deficits by disrupting large-scale brain networks [53, 54]. Structural brain connectivity 
can be assessed using Diffusion Tensor Imaging (DTI)-based whole-brain tractography 
techniques [368]. Additional insights into the extent and location of structural 
network disruption in SVD have been provided by rich club analyses, referring to 
the presence of nodes that are both highly connected to the network and highly 
interconnected with each other, hence called rich clubs [55, 56]. Due to their central 
role in brain networks and high connectivity with other nodes, rich clubs play 
a pivotal role in the integration of information [55], and damage to rich club 
connections might therefore have a more widespread effect on network functioning 
compared with damage to peripheral connections in a network.
Several cross-sectional studies in patients with SVD have shown that reduced 
structural network integrity, reflected by decreased global efficiency, was related 
to increased cognitive impairment [53, 54, 295] and to an increased risk of future 
dementia [297]. In addition, associations between conventional MRI markers of 
SVD and decreased cognitive functions were, at least in part, mediated through 
network disruption [53, 54, 289]. In particular, reduced connectivity was predominantly 
observed for connections between the rich club nodes rather than a generalized, 
random reduction of  white matter connectivity [57]. Moreover, rich club connectivity 
strength mediated the association of WMH with processing speed and executive 
functioning, such that higher rich club connectivity strength was associated with 
better cognitive performance [57]. However, how SVD-related disturbances in rich 
club organization progress over time and how this relates to subsequent cognitive 
decline is unknown, but could provide new insights into the temporal course and 
location of disruptions of white matter connections.
Abstract
Background: Cerebral small vessel disease (SVD) is considered the most important 
vascular contributor to the development of cognitive impairment and dementia. 
There is increasing awareness that SVD exerts its clinical effects by disrupting 
white matter connections, predominantly disrupting connections between rich 
club nodes, a set of highly connected and interconnected regions. However, exactly 
how SVD-related disturbances in rich club organization progress over time and 
how this relates to subsequent cognitive decline is unknown. Here we examined 
the progression of disturbances in rich club organization in older adults with SVD 
and how it is associated with conventional SVD markers and cognitive decline. 
We additionally investigated associations of baseline network measures with dementia.
Methods: In 270 participants of the RUN DMC study, we performed diffusion tensor 
imaging (DTI) and cognitive assessments longitudinally. Rich club organization was 
examined in structural networks derived from DTI followed by deterministic 
tractography.
Results: Global efficiency (p<0.05), network density (p<0.01) and strength of rich 
club connections (p<0.001) declined from baseline to follow-up. Decline in global 
network efficiency was associated with worse cognitive index and psychomotor 
speed (β=0.116 and β=0.146; p<0.05). Decline in strength of peripheral connections 
was associated with a decline in overall cognition (β=0.164; p<0.01), psychomotor 
speed (β=0.151; p<0.05) and executive function (β=0.117; p<0.05). Baseline network 
measures were reduced in participants with dementia at follow-up, and the 
association between WMH and dementia was causally mediated by global efficiency 
(indirect p-value=0.037) and peripheral connection strength (indirect p-value=0.040).
Conclusions: SVD-related disturbances in rich club organization progress over 
time, which in turn are associated with decline in psychomotor speed and executive 
function. The effect of WMH on dementia was causally mediated by global network 
efficiency and the strength of peripheral connections, suggesting an important 
role for network disruption in causing cognitive decline and dementia in older 
adults with SVD.
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function. For the cognitive index, we calculated the mean of the z-scores of all 
tests from the neuropsychological test battery. To measure memory, we used the 
immediate and delayed recall of the Rey Auditory Verbal Learning Test (RAVLT) 
[355] and the Rey Complex Figure Task (RCFT) [356], as well as Speed–Accuracy 
Trade-Off (SAT) scores of the 2- and 3-letter subtasks of the Paper-Pencil Memory 
Scanning Task (PPMST) [196]. Psychomotor speed was calculated as the mean of 
the z-scores of the 1-letter subtask of the PPMST, the reading and color naming 
tasks of an adapted version of the Stroop Test [369] and the Symbol Digit 
Substitution Task (SDST) [370]. For executive function, we calculated the 
interference score of the Stroop Test by dividing SAT-scores of the color-word task 
by the mean SAT-scores of the reading and color naming tasks of the Stroop Test 
[371], the verbal fluency task [372] and SAT-scores of the Verbal Series Attention 
Test (VSAT) [373]. To account for possible material-specific practice effects, parallel 
versions of the RAVLT, RCFT and verbal fluency test were used for the follow-up 
assessment.
Dementia diagnosis
Dementia case finding was extensively described previously [225]. In short, 
dementia was diagnosed after outpatient evaluation of the individual patient 
findings at the Radboud Alzheimer Center memory clinic, or by a consensus 
diagnosis by a panel consisting of a neurologist, clinical neuropsychologist and a 
geriatrician with expertise in dementia, who reviewed all available cognitive 
assessments and medical records. The diagnosis of dementia was based on the 
DSM-IV-TR criteria [227]. In total, 23 out of 329 participants were diagnosed with 
dementia at follow-up.
Vascular risk factors
We recorded the presence of hypertension, smoking, alcohol use, diabetes and 
hypercholesterolemia at baseline by standardized questionnaires, as described 
previously [148]. We defined hypertension as the use of antihypertensive agents 
and/or systolic blood pressure greater than or equal to 140 mm Hg and/or diastolic 
blood pressure greater than or equal to 90 mm Hg [148].
MRI acquisition
MR images were acquired at two time points (2011 and 2015) on the same 1.5-Tesla 
Siemens Magnetom Avanto scanner and included the following whole brain scans: 
T1-weighted 3D MPRAGE imaging (isotropic voxel size 1.0 mm3), a FLAIR sequence 
(voxel size 0.5 0.5 2.5 mm; interslice gap 0.5 mm) and a DTI sequence (isotropic 
voxel size 2.5 mm3, 8 unweighted scans, 60 diffusion weighted scans at b=900 s/mm2). 
Full acquisition details have been described previously [110, 148].
We therefore longitudinally examined changes in structural network organization 
in 270 participants with SVD. The specific aims of this study were (1) to assess 
how SVD-related disturbances in structural network, and specifically rich club 
organization, progress over time; (2) to study whether the decline in structural 
network organization is related to the progression of conventional SVD markers; 
(3) to relate this decline in network organization to cognitive decline; and (4) to 
examine whether baseline alterations in network organization are associated with 
incident dementia and whether these alterations mediate the association between 
conventional SVD markers with dementia.
Methods
Study population
This study was part of the Radboud University Nijmegen Diffusion tensor and 
Magnetic resonance imaging Cohort (RUN DMC) study, a prospective cohort study 
of 503 older adults with SVD that investigates risk factors and clinical consequences 
of SVD. The detailed study protocol has been published previously [148]. In the 
present study, we only used data available from the first (2011) and second (2015) 
follow-up assessments and excluded data from the baseline (2006) assessment due 
to slight changes in scanner protocol between 2006 and 2011. In the rest of this 
article, we will refer to the 2011 assessment as ‘baseline’ and to the 2015 assessment 
as ‘follow-up’. Of the 503 participants (during the 2006 examination), 329 participants 
were available for baseline (2011) analyses. In addition, 281 participants underwent 
repeated neuroimaging assessments [110], 11 of whom were excluded because of 
neuroimaging artefacts, yielding 270 participants for the longitudinal analyses. 
The Medical Review Ethics Committee region Arnhem-Nijmegen approved the 
study and all participants gave written informed consent.
Cognitive assessment
Cognitive performance was measured using an extensive neuropsychological test 
battery during all waves of data collection, as has been described previously [228]. 
Raw scores of all time-points were transformed into z-scores based on the mean 
and standard deviation (SD) of the baseline study population. We calculated Speed–
Accuracy Trade-Off (SAT) scores where appropriate. Cognitive decline over time 
was calculated for each participant individually, by subtracting baseline scores 
from the follow-up scores.
We calculated a compound score for global cognitive function (cognitive index) as 
well as for three cognitive domains: memory, psychomotor speed and executive 
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Network measures
Graph theoretical measures were calculated from the structural network using 
the Brain Connectivity Toolbox [52]. These measures included: (1) node degree, 
representing the number of connections of a node; (2) network density, defined as 
the ratio between the number of connections present and the number of total 
possible connections in a network; (3) total network strength, computed as the 
sum of all connection strengths in a network; (4) global efficiency, expressed as 
the average inverse of the shortest path length between two nodes.
Rich club measures
Rich club regions included the bilateral superior frontal gyrus, precuneus, 
superior parietal gyrus and the insula. This selection of rich cub nodes was based 
on the literature and the selection of these nodes as rich club nodes has been 
validated by previous studies [375, 376]. The connections of the network were then 
classified for further analysis [55, 56]: connections between the rich club nodes 
were classified as rich club connections; connections to the rich club nodes as 
feeder connections and connections between the non-rich club nodes as peripheral 
connections. The strength of these three types of connections was calculated as 
the average of the edge weights for that group.
Statistical analysis
To assess how SVD-related disturbances in structural network organization 
progress over time, we calculated differences in network density, network strength, 
global connectivity and strength of rich club, feeder and peripheral connections 
over time using repeated measures ANOVA. We additionally analyzed whether 
the changes in rich club organization differed between participants with mild 
versus severe WMH. Therefore, we stratified WMH severity based on median split 
of baseline WMH volumes. Differences between participants with mild versus 
severe WMH were calculated using one-way ANOVA, adjusted for age and sex.
To study the associations between conventional SVD markers (i.e. WMH and 
presence of lacunes and microbleeds) and structural network measures, we 
performed linear regression analyses, adjusted for age and sex. In addition, we 
assessed whether the decline in structural network organization was affected by 
the progression of conventional SVD markers. We therefore performed linear 
regression analyses using WMH progression, incident lacunes and microbleeds 
and difference (Δ) scores of network measures, with adjustments for age and sex.
Conventional markers for SVD and brain volumetry
We calculated grey matter (GM), white matter (WM) and CSF volumes using SPM12 
(https://www.fil.ion.ucl.ac.uk/spm/) unified segmentation routines on the T1 MPRAGE 
images, which were first corrected for the presence of WMH as described in [110]. 
All segmentations were visually checked for artefacts and segmentation errors 
and excluded from analyses when necessary.
WMH were segmented semi-automatically using FLAIR and T1 sequences [150]. 
All segmentations were visually checked for segmentation errors by one trained 
rater, blinded for clinical data. WMH volumes were calculated in ml, corrected 
for interscan differences in intracranial volume (ICV) and normalized to baseline 
ICV [110]. 
DTI preprocessing
All diffusion weighted images were denoised using a Local Principal Component 
Analyses filter [156], and corrected for cardiac, head motion, and eddy current 
artefacts simultaneously using the ‘PATCH’ algorithm [157], as described previously 
[57, 152]. Diffusion tensor and scalar parameters were calculated using DTIFIT 
from FSL’s FDT toolbox. Whole-brain deterministic tractography has been described 
previously [53]. Streamlines were terminated at an angle, exceeding 40° between 
principal eigenvectors, or FA<0.2.
Network nodes and edges
Brain regions were parcellated in each participant using the Automatic Anatomical 
Label (AAL) template [374] into 90 regions, excluding the cerebellar regions. For 
each participant, T1-weighted images were first registered to the b0-image using 
FLIRT. The T1-weighted images were then non-linearly registered to Montreal 
Neurological Institute (MNI) 152 template using ANTs. Linear and non-linear trans-
formations were finally combined to register the AAL template to each participant’s 
diffusion space.
Two regions were considered connected if the endpoints of a tractography 
streamline were located within the pair of brain regions. Connection strengths 
were estimated based on a modified method of Hagmann and colleagues [53, 368] 
and calculated as the sum of the inverse of the streamlines length, including a 
scaling factor to correct for the number of seeds per squared millimeter. Weighted 
edges were thresholded at 1, to reduce noise-related false-positive connections. 
This resulted in individual weighted connectivity matrices.
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11of feeder and peripheral connections was affected by WMH volume and by the number of lacunes and microbleeds (p<0.001 for all SVD markers). The progression 
of conventional SVD markers was not  associated with changes in rich club, feeder 
or peripheral connections.
Effects of rich club organization on cognitive performance
The results from linear regression analyses on the associations between 
longitudinal changes in rich club organization and cognitive decline are shown 
in Table 3. The degree of reduction in global efficiency and network strength were 
associated with greater decline in cognitive index (global efficiency: β=0.116; 
p<0.05; network strength: β=0.147; p<0.01) and psychomotor speed (global 
Additionally, we aimed to relate the decline in network organization to cognitive 
decline. Therefore, we performed linear regression analyses, separately for decline 
in cognitive index, memory, psychomotor speed and executive function, adjusted 
for age, sex and education. 
Finally, to examine whether baseline alterations in network organization are 
associated with dementia status at follow-up, we analyzed differences in network 
measures for participants with and without dementia using one-way ANOVA, 
adjusted for age, sex and education. To assess whether these network alterations 
mediated the association between conventional SVD markers with dementia, we 
additionally performed mediation analyses using ‘lavaan’ version 0.5-23.1097 in R 
[359]. Using lavaan, we estimated the direct effect of baseline WMH volume on the 
development of dementia and the indirect effect of baseline WMH volume on the 
development of dementia via structural network measures, separately for global 
efficiency and strength of rich club, feeder and peripheral connections. Statistical 
analyses were performed using R 3.5.2 (https://www.r-project.org/) and SPSS 
Statistics version 20.
Results
Baseline characteristics of the study population are presented in Table 1. Mean age 
was 67.9 (SD 7.8) years and mean follow-up duration was 3.4 (SD 0.2) years.
Progression of rich club organization over time, by SVD severity
We first assessed if and how disturbances in rich club organization progress over 
time. The progression of rich club organization over time is shown in Figure 1. 
The strength of rich club connections declined over time (mean difference [95% 
confidence interval]: -0.44 [-0.63 – -0.26]; p<0.001), in contrast to the strength of 
feeder (mean difference: -0.03 [-0.073 – 0.023]; p=0.303) and peripheral connections 
(mean difference: -0.02 [-0.040 – 0.003]; p=0.094). In terms of global network 
measures, both network density and global efficiency declined over time. Network 
disturbances were most pronounced in participants with severe WMH (Figure 1). 
In addition, the strength of peripheral connections declined in participants with 
severe baseline WMH, but not in participants with mild baseline WMH (Figure 1).
Effects of SVD markers on changes in rich club organization
To assess whether disruptions in rich club organization are affected by the severity 
and progression of conventional SVD markers, we performed linear regression 
analyses (Table 2). The strength of rich club connections was affected by WMH 
volume (β=-0.189; p<0.001) and the number of lacunes (β=-0.067, p<0.01). The strength 
Table 1   Characteristics of the study population
Baseline 2011 
(n=270)
Demographics
Age, years 67.9 ± 7.8
Male sex, number of participants (%) 162 (59.6)
MMSE score 28.4 ± 1.8
Education, years 10.1 ± 1.5
Vascular risk factors
Hypertension, number of participants (%) 162 (59.6)
Diabetes, number of participants (%) 37 (13.6)
Hypercholesterolemia, number of participants (%) 124 (45.6)
Smoking, ever, number of participants (%) 194 (71.3)
Alcohol, glasses/week 3.8 ± 4.0
Body mass index, kg/m2 27.8 ± 4.2
Imaging characteristics
Total brain volume, ml 1066.2 ± 77.7
Grey matter volume, ml 610.6 ± 50.1
White matter volume, ml 455.7 ± 44.0
WMH volume, ml 2.8 (1.3 – 7.8)
Lacunes, number of participants (%) 69 (25.4)
Microbleeds, number of participants (%) 47 (17.3)
NAWM MD, 10-3 mm2/s 0.84 ± 0.04
NAWM FA 0.38 ± 0.02
Data represent mean ± SD or number of participants (%). WMH volume was expressed as median (IQR). 
MMSE: Mini-Mental State Examination; WMH: white matter hyperintensities; NAWM: normal appearing 
white matter; MD: mean diffusivity; FA: fractional anisotropy.
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efficiency: β=0.146; p<0.05; network strength: β=0.160; p<0.01). With respect to 
disruptions in rich club organization, the decline in peripheral connection 
strength was associated with decline in cognitive index (β=0.164; p<0.01), 
psychomotor speed (β=0.151; p<0.05) and executive function (β=0.117; p<0.05). 
Decline in rich club or feeder connection strength was not  associated with decline 
in cognitive performance.
Associations between baseline network characteristics and dementia
Of the 329 participants, 23 participants had been diagnosed with dementia at 
follow-up. We examined whether the degree of network organization at baseline 
examination was associated with dementia at follow-up and whether these 
alterations mediated the association between conventional SVD markers with 
dementia. Participants with dementia had, at baseline, lower total network 
Figure 1  Progression of rich club organization over time
Progression of rich club organization from baseline to follow-up. Data indicate mean connection 
strength ± SEM for the study population (black), and additionally for patients with mild WMH (blue) and 
with severe WMH (red). WMH volumes are stratified based on median split of WMH volumes in 2011. All 
network measures are statistically different for patients with severe versus mild WMH (p<0.001 for all 
network measures). Statistical differences between baseline and follow-up have been calculated using 
repeated measures ANOVA. Differences between participants with mild versus severe WMH have been 
calculated using one-way ANOVA, adjusted for age and sex. *p<0.05; **p<0.01; ***p<0.001.
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Table 2   Associations between SVD markers and rich club organization
Rich club  
strength
Feeder
strength
Peripheral  
strength
Age, years -.500*** -.322*** -.474***
[-.587, -.414] [-.403, -.241] [-.547, -.400]
Sex .238** -.038 .038
[.095, .382] [-.172, .096] [-.083, .160]
Time, years -.040 .046 .025
[-.118, .038] [-.027, .120] [-.042, .091]
WMH -.189*** -.336*** -.270***
[-.278, -.101] [-.419, -.254] [-.344, -.195]
WMH progression -.016 -.041 -.036
[-.094, .063] [-.115, .032] [-.102, .031]
Lacunes -.067** -.089*** -.108***
[-.116, -.018] [-.136, -.043] [-.150, -.066]
Incident lacunes .021 .002 .014
[-.024, .067] [-.041, .044] [-.025, .053]
Microbleeds -.005 -.033*** -.034***
[-.024, .013] [-.050, -.015] [-.049, -.018]
Incident microbleeds .003 -.0002 -.003
[-.015, .021] [-.017, .017] [-.018, .013]
Associations of the conventional SVD markers WMH, lacunes and microbleeds with structural network 
measures. Data are displayed as standardized betas [95% confidence intervals], analyzed using linear 
regression analyses. *p<0.05; **p<0.01; ***p<0.001.
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density (mean difference [95% confidence interval]: -0.012 [-0.019 – -0.005]; p=0.001), 
lower network strength (mean difference: -21.0 [-38.0 – -4.0]; p=0.015) and lower 
global efficiency (mean difference: -1.2 [-2.1 – -0.30]; p=0.009) as compared with the 
group without dementia. Moreover, participants with dementia also showed, at 
baseline, lower strength of peripheral connections (Figure 2; mean difference: 
-0.21 [-0.37 – -0.05]; p=0.009). No differences were observed for rich club (mean 
difference: -0.13 [-1.2 – 1.5]; p=0.848) and feeder connection strength (mean 
difference: -0.37 [-0.76 – 0.01]; p=0.059) between participants with and without 
dementia. Mediation analyses revealed no direct effect of WMH on dementia, in 
contrast with the indirect effects of WMH on dementia via global efficiency 
(p=0.037) and peripheral connection strength (p=0.040)(Figure 3), suggesting that 
the effect of WMH on dementia is causally mediated by global network efficiency 
and the strength of peripheral connections.
Table 3   Rich club organization and cognitive decline
Δ Cognitive 
Index
Δ Memory Δ Psychomotor 
speed
Δ Executive 
function
Δ Global network characteristics
Global efficiency .116*
[.003, .229]
.004
[-.115, .124]
.146*
[.027, .266]
.090
[-.029, .208]
Network strength .147**
[.036, .258]
.042
[-.076, .160]
.160**
[.042, .278]
.108
[-.009, .225]
Δ Connection strength
Rich club .024
[-.087, .136]
-.022
[-.140, .096]
.074
[-.044, .194]
.000
[-.117, .118]
Feeder .059
[-.053, .172]
-.005
[-.123, .113]
.115
[-.004, .234]
.054
[-.064, .172]
Peripheral .164**
[.054, .274]
.061
[-.056, .178]
.151*
[.034, .268]
.117*
[.001, .233]
Longitudinal associations between network measures and cognitive decline. Data are displayed as 
standardized betas [95% confidence intervals]. Statistical differences were analyzed using linear 
regression analyses, adjusted for age, sex and education. *p<0.05; **p<0.01; ***p<0.001.
Figure 2  Network characteristics at baseline stratified by dementia status at follow-up
Network characteristics at baseline, separately for participants with (dark grey, n=23) and without 
dementia (light grey, n=306). Top: The global network measures (network density, network strength and 
global efficiency) were reduced in participants with dementia. Bottom: Strength of rich club, feeder and 
peripheral connections in participants with and without dementia. Statistical differences were analyzed 
using one-way ANOVA, adjusted for age, sex and education. *p<0.05; **p<0.01; ***p<0.001.
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argued that especially the rich club nodes have a high rate of metabolic activity 
and that the long fibers connecting the rich club nodes require higher levels of 
energy consumption [50, 379]. As damage in SVD is presumably caused by ischemia, 
the progression of small vessel damage might preferentially affect the highly 
metabolic rich club connections.
Disturbances in rich club organization were predominantly observed in participants 
with severe baseline WMH, both in rich club connections and in feeder as well as 
peripheral connections. These findings suggest an important role for global 
network function in older adults with SVD, rather than rich club disruption 
specifically, further supporting the notion that SVD should be considered a global 
rather than a focal disease [380].
Interestingly, we did not observe any associations between decline in rich club 
connection strength and decline in cognitive performance. While rich club 
connection strength was significantly associated with cognitive performance in 
cross-sectional analyses, cognitive decline over time was only associated with 
decline in peripheral connection strength, rather than with a decline in rich club 
or feeder connection strength. Although we are not aware of any studies 
investigating the preferential role of specific connections for cognitive function 
in elderly with SVD longitudinally, these results are in contrast to what we would 
expect based on findings from several cross-sectional studies reporting an 
important role for rich club connections in cognitive processes, specifically for 
psychomotor speed and executive function [57, 381]. There may be several 
explanations for not finding this association. First, it might be that the cognitive 
domains measured in our study reflect localized rather than global cognitive 
functions, for which proper network function and integration is required. 
However, since we observed associations between rich club connection strength 
and psychomotor speed and executive function – known to rely on the integration 
of distributed brain areas – rather than with memory performance in cross- 
sectional analyses, we consider this hypothesis less likely. Second, the selection of 
rich club nodes was based on node degree in healthy controls; although this 
selection has been validated in several studies [375, 376] and these nodes were 
among the highest ranked nodes in our study population (data not shown), the 
rich club organization in our study population was already disrupted at baseline 
due to their SVD [57]. Possibly, the contribution of decline in rich club connection 
strength to cognitive decline, in addition to the baseline disruption of rich club 
connections, is limited relative to peripheral connections. Third, it might be that 
initial disruptions of the rich club connections are followed by secondary 
disruptions of the feeder or peripheral connections and that impairments in 
Discussion
In this longitudinal study, we investigated the progression of structural network 
connectivity and rich club organization over time in participants with SVD. 
SVD-related disturbances in rich club organization progressed significantly over 
3.4 years, predominantly in participants with severe WMH. Declines in global 
network efficiency and peripheral, but not rich club or feeder, connection strength 
were associated with cognitive decline and dementia. The effect of WMH on 
dementia was causally mediated by global network efficiency and the strength of 
peripheral connections, suggesting an important role for global network, rather 
than rich club disruption in causing cognitive decline and dementia in elderly 
with SVD.
Our study provides evidence that SVD-related disturbances in rich club organization 
progress over time, which in turn is related to cognitive decline. Previous cross- 
sectional studies have shown reductions in network global efficiency in participants 
with SVD that mediated the relationship between conventional MRI markers of 
SVD and cognitive impairment or dementia [53, 54, 289, 295, 297]. In particular, 
reduced connectivity was predominantly observed for rich club connections, mediating 
the association of WMH with processing speed and executive functioning [57]. 
However, differentiating causality from association is impossible in cross-sectional 
studies. Two previous longitudinal studies have reported associations between 
declines in global efficiency and cognitive performance in patients with cerebral 
amyloid angiopathy (CAA) [377] and in patients with severe symptomatic SVD 
[378]. However, to our knowledge, no longitudinal studies have addressed the 
progression of disturbances in rich club organization over time in patients with 
SVD and its relation to subsequent cognitive decline. Our longitudinal findings 
support the hypothesis that conventional MRI markers of SVD (such as WMH, 
lacunes and microbleeds) cause cognitive decline and dementia via disruption of 
complex brain networks.
Several mechanisms can be hypothesized that may explain the progression of 
network disturbances over time. First, the location of incident SVD might be 
consistent with the location of disrupted connections (i.e. WMH progression or 
incident lacunes or microbleeds might target specific connections and thereby 
disrupt white matter connections). However, we showed that, on top of baseline 
SVD, the progression of conventional SVD markers was not significantly associated 
with the strength of rich club, feeder or peripheral connections (Table 2). We therefore 
consider this hypothesis as less likely. An alternative explanation might be the high 
metabolic demand of especially the rich club nodes and connections. It has been 
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would also have caused bias, since participants with severe SVD would have fewer 
connections and less interconnected nodes, and we would have investigated 
different rich clubs across participants. Future studies are should investigate how 
the definition of the rich club influences rich club properties, especially in 
longitudinal studies and in patients with severe SVD. Third, it might as well be 
that our observed changes in rich club organization and cognitive performance 
over time are not solely attributable to SVD, but also to the effects of normal aging 
or to other pathologies such as neurodegeneration or Alzheimer’s disease, or 
interaction with these pathologies. However, the associations between conventional 
SVD markers with measures of rich club organization and the causal mediations 
of the associations between WMH and dementia via structural network properties 
indicate that the disruption of structural networks is important in explaining 
cognitive decline in elderly with SVD.
In conclusion, SVD causes disturbances in rich club organization, which in turn 
were associated with declines in psychomotor speed and executive function. The 
effect of WMH on dementia was causally mediated by global network efficiency 
and the strength of peripheral connections, suggesting an important role for 
global, rather than rich club network disruption in causing cognitive decline and 
dementia in elderly with SVD.
peripheral connections only lead to clinical overt symptoms after a certain 
threshold of structural network disruption is reached [379]. Finally, it might be 
that cortical structures have an important role in causing cognitive decline and 
dementia. Gray matter atrophy in frontal brain areas, for example, might explain 
executive dysfunction in participants with SVD [382]. This hypothesis was 
supported by previous studies reporting that lower cortical thickness in fronto-
temporal regions was related to cognitive deficits independent of WMH [289, 383].
Our finding that baseline measures of global efficiency and peripheral connections 
are impaired in participants who developed dementia is clinically relevant, 
because it suggests that network parameters might be useful as markers to predict 
cognitive decline and the risk of progression to dementia. Additionally, the finding 
that the effect of WMH on dementia is causally mediated by global network 
efficiency and the strength of peripheral connections provides additional insights 
into the underlying mechanisms of cognitive symptoms attributable to SVD. 
Altogether, these findings suggest that the structural network acts as a mediator 
between conventional SVD markers and cognitive outcome and may allow 
identification of individuals at high risk of developing dementia. 
Major strengths of the study were the large cohort of individuals covering a wide 
range of the SVD spectrum, the detailed phenotyping of the patients, including 
the diagnosis of dementia according to a standardized approach in all patients 
and the availability of longitudinal neuroimaging data obtained from the same 
scanner without upgrade or change over the full data collection period. However, 
several methodological issues should also be considered. First, the identification of 
structural networks was based on DTI acquired at 1.5 Tesla with relatively few 
diffusion directions and deterministic streamlining using tensor reconstruction 
models, limiting the identification of long-distance fibers and the reconstruction 
of white matter tracts in a complex white matter architecture due to noise and 
partial volume effects [384]. Although high-resolution imaging and more advanced 
tractography methods are required to provide more detailed information about 
the white matter architecture, the consistency of our findings on impaired global 
efficiency in SVD and its relation with cognitive performance with other studies 
[53, 54, 295] indicate that our network analyses in participants with SVD are 
reliable. A second consideration is the selection of rich club nodes. Our main 
findings are based on a rich club defined from the eight nodes with highest degrees 
in healthy controls. Although these nodes were among the highest ranked nodes 
in our study population (data not shown) and have been validated in several studies 
[375, 376], this might have influenced the results from our longitudinal analyses. 
However, it should be noted that defining rich club nodes based on individuals 
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The aim of this thesis was to gain insights into the time course, the etiology and 
the cognitive consequences of cerebral small vessel disease. In this chapter I will 
summarize the main findings.
Temporal dynamics of cerebral small vessel disease
In Part II of this thesis, I described the change of SVD markers over time, or, 
the “temporal dynamics” of SVD. The course of SVD has usually been described as 
a linear progressive process, mainly due to the availability of studies with only 
two neuroimaging assessments. 
In Chapter 2, I elaborated on the dynamic course of SVD progression by reviewing 
the existing literature on progression of SVD over time. Where regression of SVD 
markers was previously often attributed to measurement error or classified as ‘no 
progression’, SVD regression appears to be a true phenomenon with clinical 
implications. 
In Chapter 3, I showed the temporal dynamics of SVD, using three neuroimaging 
assessments over a period of nine years in the RUN DMC study. Progression of all 
SVD markers (i.e. WMH, lacunes and microbleeds) occurred in a non-linear 
fashion, accelerating over time consistent with a quadratic course. In addition, 
SVD progression was predominantly seen in participants with moderate or severe 
WMH at baseline, whereas participants with mild baseline WMH rarely showed 
progression over a period of nine years. Interestingly, progression of SVD markers 
was alternated by regression in 20.3% of participants: 11.2% showed WMH 
regression, 3.6% vanishing lacunes and 9.8% vanishing microbleeds, suggesting 
that SVD progression is sometimes interrupted by regression of SVD. 
These findings suggest a paradigm shift: traditionally seen as a continuous progressive 
process, it should rather be considered a dynamic and highly heterogeneous process, 
sometimes with regression of SVD, which might also imply heterogeneity in etiology 
and cognitive consequences of SVD.
The etiology of cerebral small vessel disease
In Part III of this thesis, I elaborated on the etiology of SVD. To gain additional 
insights into the underlying mechanisms of SVD, I used diffusion tensor imaging 
to infer on the microstructural integrity of the white matter as well as biomarkers 
in blood to assess their associations with severity and progression of SVD.
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In Chapter 7, I additionally analyzed whether serum NfL levels were associated 
with future white matter damage. Serum NfL levels were associated with future 
MRI markers of SVD (WMH: β=0.173; 95%CI [0.062-0.327]; p=0.004 and MD: β=0.165; 
95%CI [0.048-0.334]; p=0.009) and with future psychomotor speed (β=-0.135; 95%CI 
[-0.226, -0.039]; p=0.005). Together, our findings that serum NfL levels are 
associated with future microstructural tissue damage and future cognitive 
performance, suggest that serum NfL may potentially serve as a biomarker for 
disease monitoring and outcome in SVD.
Cognitive consequences of cerebral small vessel disease
In Part IV, I elaborated on the cognitive consequences of SVD. Where SVD was 
previously thought to be mainly associated with psychomotor speed, the spectrum 
of cognitive symptoms attributable to SVD seems to be much broader than 
previously thought and cannot solely be explained by the severity and location of 
SVD markers on neuroimaging. In this part, I therefore examined additional 
explanations for the remarkable variation of SVD-related cognitive symptoms, 
first by reviewing the existing literature and second by studying additional MRI 
markers (remote effects, network disruptions and interactions with neurodegen-
eration).
In Chapter 8, I elaborated on cognitive symptoms attributable to SVD and provided 
a framework to explain the variation of cognitive deficits in patients with SVD, by 
reviewing the existing literature on neuroimaging markers and cognitive 
consequences of SVD. First, SVD markers visible on conventional MRI only reveal 
the tip of the iceberg and, despite an identical appearance on MRI, SVD lesions are 
pathologically heterogeneous and a cascade of events seems to spread from the 
initial SVD lesion to remote brain regions, thereby leading to cognitive deficits. 
Second, SVD disturbs structural and functional network integrity, especially in 
central connections, thereby disrupting efficient communication in brain 
networks. Consequently, even a small focal lesion can lead to widespread effects. 
In addition, reserve and compensatory mechanisms allow patients to maintain 
cognitive performance until these mechanisms are exhausted and functional 
performance drops. Finally, other neurodegenerative pathologies can be present 
and probably contribute to the clinical presentation. Although SVD lesions mostly 
occur in subcortical areas, they exert their effect throughout the brain. 
Consequently, the clinical notion of SVD being a focal subcortical disease must be 
reconsidered. Following the identification of SVD markers on MRI, clinicians 
should be aware that the entire brain is affected, despite the presence of focal 
subcortical lesions. 
In Chapter 4, I showed that impaired microstructural integrity in the NAWM 
preceded conversion into WMH and that WM microstructural integrity declined 
over time. Adding an additional time point with a total follow-up of nine years 
enabled us to distinguish between NAWM converting into WMH within the first 
and the second time-period. This revealed that baseline MD values were higher in 
NAWM areas converting into WMH within five years than in NAWM areas that 
converted into WMH between five and nine years. Moreover, participants with 
severe baseline WMH showed more loss of structural integrity compared with 
participants with mild WMH in all areas of the WM, including the remaining 
NAWM and WMH. The continuously ongoing decline of microstructural integrity 
within the WM underlines that WMH progression visible on conventional FLAIR 
imaging is only the “tip of the iceberg” with underlying loss of microstructural 
integrity occurring years before WMH can be detected on conventional MRI. 
In Chapter 5, I assessed the associations between amyloid β levels in blood plasma 
with severity and progression of SVD. Our study showed that higher plasma Aβ 
levels were associated with neuroimaging markers of SVD at the cross-sectional 
level and with progression of SVD over a follow-up of almost nine years. The 
longitudinal design of our study enabled us to elaborate on the directionality of 
the associations between plasma Aβ levels and cerebrovascular pathology. In our 
study, progression of WMH and incident microbleeds and lacunes were associated 
with higher baseline plasma Aβ levels of one or more of the peptides: plasma Aβ40 
levels were elevated in participants with WMH progression (mean 194.6 vs. 182.9 
pg/ml; p<0.05), both Aβ38 and Aβ40 were elevated in participants with incident 
lacunes (Aβ38 24.5 vs. 22.5 pg/ml; p<0.05; Aβ40 194.9 vs. 181.2 pg/ml; p<0.01), and 
Aβ42 in participants with incident microbleeds (62.8 vs. 60.4 pg/ml; p<0.05). 
Altogether, our findings that higher plasma Aβ levels were not only associated 
with severity of SVD markers but also with progression of SVD markers, suggest 
that amyloid β pathology might contribute to the development and progression of 
SVD. 
In Chapter 6, I analyzed a second blood marker, serum Neurofilament Light Chain 
(NfL), in relation to neuroimaging markers of SVD. Serum NfL levels were elevated 
in participants with SVD (p<1e-05 compared with healthy controls). In addition, 
serum NfL levels were associated with all SVD markers, in particular Mean 
Diffusivity (R2=0.21, p<1e-15). Serum NfL levels were independently related to 
psychomotor speed (R2=0.06, p=4.8e-08), the cognitive domain most often affected 
in patients with SVD, suggesting that serum NfL might complement established 
MRI markers in assessing SVD burden. 
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feeder connection strength, was associated with a greater decline in cognitive 
index (β=0.164; p<0.01), psychomotor speed (β=0.151; p<0.05) and executive 
function (β=0.117; p<0.05). Moreover, participants with dementia showed lower 
global efficiency and peripheral connection strength compared with participants 
without dementia, and the association between WMH and dementia was causally 
mediated via global efficiency and peripheral connection strength, suggesting an 
important role for network disruption in causing cognitive decline and dementia 
in elderly with SVD.
In Chapter 9, I described the cognitive consequences of regression of SVD markers 
over time. Regression of SVD markers was observed in 20.3% of participants. SVD 
regression did not accompany global brain atrophy and was associated with 
similar cognitive decline compared to participants with stable SVD. In addition, 
participants with WMH regression showed less cognitive decline compared to 
those with WMH progression (mean difference [95%CI]: 0.29 [0.02, 0.56]; p=0.035 
for cognitive index and 0.42 [0.08, 0.76]; p=0.010 for memory), and participants 
with vanishing lacunes showed less decline in psychomotor speed compared to 
participants with incident lacunes (0.48 [0.01, 0.96]; p=0.043), although significance 
was lost after adjustments. Together, our findings of comparable cognitive decline 
between participants with regression and stable SVD might suggest that SVD 
regression has a relative benign cognitive outcome.
In Chapter 10, I elaborated on memory deficits in participants with SVD. Memory 
deficits are not often observed in patients with SVD and cannot be completely 
explained by the location of SVD, but are rather thought to result from hippocampal 
atrophy. I therefore examined the interaction of SVD with hippocampal atrophy. 
Memory decline in individuals with SVD was best explained by the interaction of 
WMH with hippocampal volumes, rather than these two variables independently 
(AIC model with both WMH & HV 1996.6 versus AIC full model with WMH*HV 
interaction term 1987.9, likelihood ratio test, χ2(1)=10.7, p<0.01). The WMH*HV 
interaction term was significantly associated with memory function (β=0.061; 
95%CI [0.025 – 0.098]; p<0.01). Mediation models showed that both WMH volume 
(β=-0.170; p=0.001) and hippocampal atrophy (β=0.126; p=0.009) were independently 
related to memory decline, but the effect of WMH on memory decline was not 
causally mediated by hippocampal atrophy (p-value indirect effect: 0.572), 
suggesting that WMH and hippocampal atrophy are independent processes that 
synergistically affect memory decline. Moreover, we found that this effect of 
hippocampal atrophy was not just the result of global brain atrophy, as the effect 
of hippocampal atrophy was stronger than the effect of global gray matter atrophy. 
These findings suggest that memory decline in patients with SVD is a heterogeneous 
condition to which different pathologies contribute.
In Chapter 11, I assessed the importance of decline in structural network connectivity, 
and specifically in rich club connection strength, for cognitive performance. 
SVD-related disturbances of rich club organization progressed over time (mean 
difference -0.44; 95%CI [-0.63 – -0.26]; p<0.001), predominantly in participants with 
severe baseline WMH. Declines of rich club, feeder and peripheral connection 
strength were affected by the severity of SVD, but not by the progression of SVD. 
A greater decline in peripheral connection strength, rather than rich club or 
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The aim of this thesis was to gain insights into the time course, the etiology and 
the cognitive consequences of cerebral small vessel disease (SVD). The studies 
presented in this thesis are based on the Radboud University Nijmegen Diffusion 
tensor and Magnetic resonance imaging Cohort (RUN DMC) study, a prospective 
cohort study on the risk factors and clinical consequences of SVD using three 
neuroimaging and cognitive assessments over nine years in elderly with SVD.
In this chapter I will discuss some methodological considerations with respect to 
the study design and to the validity, inference and generalizability of the results. 
Thereafter, I will discuss the main findings of this thesis, both in context of 
existing literature and with respect to possible clinical implications of these 
findings. Finally, I will discuss some future perspectives within the field.
Methodological considerations
Study design
The RUN DMC study is a prospective hospital-based cohort study on the causes and 
consequences of SVD among 503 non-demented older adults, aged between 50 and 
85 years, with signs of SVD on neuroimaging [148]. As the onset of SVD is often 
insidious, clinically heterogeneous, and typically with mild symptoms, the selection 
of participants with SVD was based on neuroimaging characteristics, including 
WMH and lacunes [174]. Accordingly, all individuals aged between 50 and 85 years 
who were referred to the Department of Neurology between 2002 and 2006 and 
underwent routine diagnostic brain imaging for various reasons, including 
stroke, transient ischemic attack and mood or cognitive complaints, were selected 
for participation. All participants were free of dementia at baseline and were 
invited for repeated neuroimaging and cognitive assessments for three times over 
nine years: baseline assessment has been performed in 2006, first follow-up in 
2011 and second follow-up in 2015. 
Validity of results
The internal validity is a property of a study reflecting the extent to which the 
associations measured in a study are truly caused by the exposure [385]. In this 
section, I will discuss the precision of measurements and three types of bias that 
are related to the validity of the results of this thesis: selection bias (including 
attrition bias), information bias (including measurement error from cognitive 
assessments and neuroimaging analyses), and confounding.
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underwent repeated neuroimaging assessments at three time-points over the 
nine-years follow-up. A considerable proportion of our study population could not 
complete follow-up assessments, because they were deceased, were unable to visit 
our research centre or developed contra-indications for MRI acquisition. This 
might have influenced our results on SVD progression and cognitive decline as 
participation during follow-up most likely will have depended on the outcome of 
our study (i.e. progression of SVD). This probably may have led to an underestima-
tion of the strength of the associations. 
Information bias
Information bias may occur by not properly defined determinants or outcomes or 
improper methods to collect data on them, which may lead to misclassification of 
these variables [385]. In the RUN DMC study, the risk of information bias was 
reduced by the single-centre design of the study, which allowed us to systematically 
and uniformly perform clinical assessments. Furthermore, the assessments of 
SVD neuroimaging markers, blood levels and cognitive performance were 
performed independently and blinded to each other, further limiting the risk of 
information bias. Information bias might, however, have arisen from both 
cognitive assessments and neuroimaging acquisition and analyses, which will be 
discussed in the following sections. With respect to misclassification due to 
imaging measures, I will focus on the assessment of SVD markers, longitudinal 
neuroimaging analyses, microstructural integrity and structural networks 
including rich club organization.
The assessment of cognitive decline was vulnerable to misclassification, as 
cognitive performance was measured at three time-points over nine years and 
cognitive assessments have been performed by different researchers at both 
follow-up assessments. Although we feel that these effects are limited due to 
extensive trainings from the researcher who performed the previous assessments, 
this might have lead to either an underestimation or an overestimation of the 
effects. Additionally, learning effects might have led to an underestimation of the 
true memory decline in our study population, especially since those who were 
able to complete both follow-up assessments performed significantly better on 
cognitive tasks at baseline compared to those who did not complete all follow-up 
assessments [228]. We limited these possible learning effects by the use of 
alternative versions of the memory tasks during the second follow-up assessment.
WMH volumes were calculated by a semi-automatic WMH segmentation method, 
enabling us to study WMH quantitatively which was much more sensitive than 
qualitative rating scales. The segmentations from all three time-points were 
Precision of measurements
Precision reflects the amount of random error in a study and thereby affects the 
reproducibility of a study [385]. Random error often results in imprecise effect 
estimates, reflected by broad confidence intervals. Precision can be improved by 
increasing the size of a study and by measuring the outcome and determinants by 
means of validated procedures. In the RUN DMC study, we reduced random error 
by the inclusion of a large number of participants with SVD. In addition, we rated 
SVD according to standardized procedures [5], segmented WMH semi-automatical-
ly, calculated brain volumes using the latest segmentation routines of SPM12 and 
visually checked for artefacts and segmentation errors, to more precisely measure 
the change in SVD markers, thereby minimizing the risk of misclassification and 
optimizing the accuracy of measurements. We therefore believe that the studies 
reported in this thesis have a high reproducibility. Yet, despite these efforts to 
optimize the measurements, precision could have been further improved. Some 
analyses included subgroups that contained only a small number of participants 
(for example in Chapter 9 where we analyzed cognitive decline separately in 
subgroups of progression, regression and stable SVD), resulting in large random 
variation in the estimations, reflected by wide confidence intervals. Besides, 
precision of SVD measurements including more detailed characterization of SVD 
and visualization of underlying mechanisms of conversion of NAWM into SVD 
could be improved by more advanced neuroimaging protocols.
Selection bias
Selection bias can occur when participation is related to the outcome of the study, 
i.e. the relation between determinants and outcome is different for participants 
and those who do not participate in the study [385]. In the RUN DMC study, 
selection bias may have occurred during the initial inclusion in the study at 
baseline and during follow-up. During the initial baseline selection, the RUN DMC 
had a high response of 71.3%. However, those who did not participate in the study 
were older (response rate in individuals between 50 and 60 years was 82% compared 
to 56.5% in individuals aged between 70 and 85 years) and had more severe WMH 
(measured by the Age Related White Matter Changes scale [386]) than participants. 
This might have led to an underestimation of the effects, since age and SVD 
severity are important predictors for cognitive impairment and those who did not 
participate in the study thus likely would have had more SVD-related cognitive 
deficits. 
Additionally, attrition bias might have occurred due to the long follow-up of our 
study, which is a special form of selection bias occurring due to selective drop-outs 
in longitudinal studies. In the RUN DMC study, 54.9% of baseline participants 
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because co-registrations of all images to MNI space have been performed with 
great caution using an intermediate subject-template and the most robust and 
accurate registration routines [162]. Moreover, the availability of the three time- 
points enabled us to validate findings in the other follow-up periods. For example, 
in our analyses on alterations in microstructural integrity preceding WMH 
progression (Chapter 4), the results for the first follow-up and the overall 
time-interval were comparable with the results for the second follow-up period in 
which scanner and sequence protocols remained identical. Thus, although we 
could not completely exclude misclassification due to scanner changes, our efforts 
to estimate and minimize the effects of possible interscan effects suggest a limited 
effect of information bias.
To assess the microstructural integrity of the white matter we used diffusion 
tensor imaging, which is based on the diffusion of water molecules. However, as 
most applications on the diffusion tensor model have been based on regions with 
parallel white matter fibers, the use of diffusion tensor imaging in our study 
population might have led to misclassification, since the white matter architecture 
in older adults with SVD is more complex [384]. This might influence the 
interpretation of the microstructural integrity of the white matter, especially 
with respect to underlying pathophysiological mechanisms, because these 
associations have also been based on findings in parallel white matter fibers. The 
diffusion measures have been associated with, amongst others, axonal membrane 
integrity, demyelination, fiber density and coherence of fiber orientation in the 
white matter [387, 388], although the interpretation of underlying mechanisms 
remains complex and can differ along the spectrum of SVD severity. 
The identification of structural networks was based on DTI acquired at 1.5 Tesla 
and deterministic streamlining based on tensor reconstruction models [389, 390]. 
That is, streamlines were reconstructed by following the principal direction in 
each voxel, not taking into account multiple fiber orientations. Although this 
method is considered to provide reliable information on the major white matter 
tracts, this might have led to misclassification because it has difficulties with the 
identification of long distance fibers and the reconstruction of white matter tracts 
in a complex white matter architecture with crossing fibers due to noise and 
partial volume effects [384]. Although high resolution imaging and more advanced 
tractography methods are required to provide more detailed information about 
the white matter architecture, the consistency of our findings on impaired global 
efficiency in SVD and its relation with cognitive performance with other studies 
[53, 54, 295] indicate that our network analyses in participants with SVD are 
reliable. Another consideration in our network analyses is the selection of rich 
visually checked for segmentation errors by one trained rater blinded for clinical 
data, thereby optimizing the accuracy of measurements and minimizing the risk 
of misclassification. Both number and location of lacunes and microbleeds were 
rated manually on FLAIR/T1-weighted and T2*-weighted MRI scans according to 
the STRIVE criteria[5] by two trained raters blinded for clinical data with excellent 
inter- and intra-rater reliability [152], limiting the risk of information bias. 
Furthermore, brain volumes were calculated using the newest segmentation 
routines of SPM12 on T1-weighted images corrected for WMH to reduce the risk 
of misclassification. Besides, hippocampal volumes were calculated using subject 
templates as part of the longitudinal segmentation pipeline in Freesurfer 5.3. 
Moreover, all images were visually checked for artefacts and segmentation errors, 
reducing the risk of bias in volume calculations.
The assessment of progression of SVD markers over time, however, could have 
been biased, since the assessment of SVD markers has not been performed blinded 
to scanning date as to assess true WMH progression or regression and true incident 
or vanishing lacunes or microbleeds. Besides, neuroimaging analyses in participants 
with severe SVD (especially in combination with severe brain atrophy and large 
ventricles) are more vulnerable to measurement errors than analyses in healthy 
controls, especially because most standard atlases are based on healthy controls 
and registrations to these atlases are more difficult for participants with severe 
SVD than for participants with mild SVD. In addition, so-called partial volume 
effects (PVE) might have reinforced this potential bias, that is, NAWM voxels 
around the border of existing WMH or lacunes can contain a fraction of signal 
intensity from these WMH or lacunes that affects measurements in that voxel. 
Since participants with severe SVD are more prone to PVE than participants with 
mild SVD, this might have led to an overestimation of SVD, especially in 
participants with severe SVD.
A major source of potential bias in especially the longitudinal neuroimaging 
analyses within the RUN DMC study, is the upgrade of the MRI scanner and the 
slight adjustment of the FLAIR sequence between baseline and first follow-up. 
Changes in PVE between baseline and follow-up together with the reduced slice 
thickness of FLAIR images at follow-up might have led to erroneously higher rates 
of WMH progression and incident lacunes. We limited the risk of bias first by 
reslicing follow-up to baseline FLAIR images before rating lacunes and secondly by 
calculating WMH volumes for odd and even slices separately, which revealed 
similar results. Additionally, the scanner differences might also have lead to differences 
in co-registrations of the FLAIR images and WMH masks to MNI space between 
baseline and first and second follow-up images. However, we consider this unlikely 
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determinant and an outcome that is free of bias, does not necessarily imply that 
the outcome is caused by the determinant. Reverse causality refers to the possibility 
that the direction of cause-and-effect might be opposite of the common 
presumption.
One of the main strengths of the RUN DMC study, is the prospective design of the 
study with repeated neuroimaging and cognitive assessments. Where cross-sec-
tional studies can only examine associations between brain structures and 
cognitive performance and hence are limited in making inferences regarding 
causality, the longitudinal design of our study enables us to examine the change 
in neuroimaging markers in relation to the change in cognitive performance in 
order to provide more insights on temporal precedence between brain changes 
and cognitive impairments. Hence, confusion of cause and effect is unlikely.
Still, the prospective design of our study does not preclude reverse causality, since 
we performed three cross-sectional measurements and do not have additional 
information on levels of determinants and outcomes in the past or in between 
measurements. Especially in the studies on blood markers it was difficult to 
establish a temporal relationship, since blood samples were collected and analyzed 
at baseline only and we were unable to perform repeated plasma Aβ or serum NfL 
measurements. As a consequence, we could not assess the influence of changes in 
plasma Aβ or serum NfL levels over time on SVD markers. However, reverse 
causality is unlikely, because we performed repeated measurements of the 
outcome and assessed associations between blood markers at baseline and 
progression of SVD over time.
Generalizability of results 
External validity reflects the extent to which the results of a study can be 
generalized to populations beyond the study sample [385]. The RUN DMC study is 
a single-center hospital-based cohort study, including individuals between 50 and 
85 years of age without dementia at baseline, covering the whole spectrum of SVD. 
The prevalence of vascular risk factors and SVD markers on neuroimaging in our 
population is comparable to community-dwelling populations, where SVD 
markers were observed on neuroimaging in over 90% of individuals over 60 years 
of age [6]. We therefore believe that the results based on the RUN DMC study are 
generalizable to the older population. However, as the RUN DMC study is 
hospital-based rather than population-based and only includes older adults with 
SVD, the generalizability to individuals younger than 50 years and to healthy 
older adults without SVD might be limited.
club nodes. Our findings were based on a rich club defined from the eight nodes 
with highest degrees in healthy control subjects, which has been validated in 
several studies [375, 376]. Although these nodes were also among the highest 
ranked nodes in our study population, the rich club organization in participants 
was already disrupted at baseline due to their SVD [57], which might have 
influenced the results from our longitudinal analyses. However, classification of 
rich club nodes based on individual networks would also have caused bias, since 
participants with severe SVD would have fewer connections and less interconnected 
nodes, and we would have investigated different rich clubs across participants.
Confounding
Confounding occurs when the effect between the determinant and outcome is 
confused with the effect of an external factor that is associated with both the 
determinant and the outcome. In our studies, we dealt with confounding by 
adjusting for potential confounders in multivariate regression models to reveal 
the true association strengths between determinants and outcome. For example, 
age is an important confounder that we adjusted for in our studies, since age was 
significantly associated with all determinants and outcomes under study including 
all SVD markers, plasma Aβ and serum NfL levels and cognitive performance.
Of note is that the confounder should not be an intermediate factor in the causal 
pathway leading to the outcome variable [385]. Adjusting for an intermediate 
factor would result in an underestimation of effects, since part of the true effect is 
caused by the intermediate factor. However, whether to adjust for a certain 
intermediate factor highly depends on the research question. That is, in etiological 
questions, where one would want to unravel the underlying mechanisms of an 
outcome, one should not adjust for the intermediate factor as it underestimates 
the true association strength between determinant and outcome. In prognostic 
questions, on the other hand, one may choose to adjust for an intermediate factor 
as to estimate the independent effect of the determinant on the prognosis. For 
example, in Chapter 4 where we assessed the associations between plasma Aε levels 
with severity and progression of SVD, we additionally adjusted for hypertension. 
The purpose of adjusting here was to estimate the independent associations with 
SVD. The associations between plasma Aε levels and severity and progression of 
SVD were independent of hypertension, suggesting that the associations with SVD 
could not be attributed to the presence of hypertension alone.
Causal inference
Another topic that deserves consideration with respect to the interpretation of our 
results, is causal inference. That is, a precisely measured association between a 
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have been done so far, enabling us to elaborate on the factors involved in the 
origin of SVD, rather than of its progression.
Regression of cerebral small vessel disease 
Imaging assessments at three time-points also enabled us to identify regression of 
SVD markers followed by progression, in a cohort that on average showed 
progression (Chapter 3). SVD regression has also been described by a few previous 
studies with two imaging assessment, that reported a decline in WMH volume [28, 
59-62] or a decrease in number of lacunes [63, 64] or microbleeds [65, 66]. This is 
probably an underestimation of the real prevalence of SVD regression, since 
regression of SVD markers was often attributed to measurement error or classified 
as ‘no progression’, and because regression within a certain time window was 
possibly compensated by progression thereafter (or vice versa) and two imaging 
assessments do not allow disentangling of episodes with regression from those 
with progression. SVD regression might thus be a true phenomenon with clinical 
implications. This observation provides further evidence that SVD does not 
gradually evolve but is a dynamic process, with progression interrupted by 
regression in some.
The observed regression of SVD markers might have several explanations. SVD 
regression might depend on methodological issues or imaging artefacts, but 
might as well be the result of biological processes. Methodologically, it is possible 
that WMH regression within a certain time window is compensated by WMH 
progression thereafter (or vice versa) in a cohort that on average shows progression. 
WMH regression might therefore have been revealed in our study by adding a 
third neuroimaging assessment and could have been missed in studies using two 
neuroimaging assessments with a long interval. In addition, it is possible that, due 
to partial volume effects, SVD markers can be rated at baseline imaging but are 
not longer visible at follow-up imaging. Biologically, it might be that SVD 
regression is accompanied by brain atrophy and thereby lead to impaired clinical 
outcome, as we observed several lacunes that became incorporated into the 
ventricles (Chapter 3). However, brain atrophy in participants with SVD regression 
was comparable to the atrophy in participants with stable SVD (Chapter 8), 
making this hypothesis less likely. Alternatively, SVD regression might reflect 
reversibility of white matter damage (i.e. before permanent axonal injury or 
demyelination has occurred) and thereby account for recovery of clinical 
symptoms. Recently developed WMH might include areas of tissue edema and 
reduction in tissue edema at a later stage could then lead to reduced WMH volume, 
since the signal change on T2 or FLAIR is not just due to permanent myelin loss or 
axonal damage but may also be due to (reversible) shifts in water content [28]. 
General discussion of the main findings
Temporal dynamics of cerebral small vessel disease
A proper understanding of the time course of the disease is an important 
prerequisite to capture the complexity of underlying mechanisms and 
consequences of SVD. SVD progression so far has been considered a linear 
continuous process, without actual proof of concept. In this thesis, we assessed the 
temporal dynamics of SVD, using three neuroimaging assessments over a period 
of nine years. 
Non-linear progression
The use of three rather than two neuroimaging assessments allowed us to better 
study the time course of SVD progression.(Chapter 3). While the average 
progression in our study was comparable with other studies [67, 68, 82, 90, 97, 119, 
125, 130], the use of three imaging assessments now allowed us to show that SVD 
progression accelerated over time: incidence of lacunes and microbleeds was 
higher in the second compared to the first follow-up period and including a 
quadratic term for follow-up duration improved the model for WMH progression. 
Although we would need more than three time-points to further study exponential 
functions, our findings provide evidence for non-linear temporal dynamics of SVD 
progression and suggest that a quadratic course of SVD progression over time is 
plausible. Moreover, progression of SVD was predominantly seen in participants 
with moderate to severe baseline SVD, whereas participants with mild baseline 
SVD rarely showed progression, not even after nine years (Chapter 3). These 
findings do not support a hypothesized ceiling effect in which WMH progression 
reaches a certain threshold [3], as we also observed progression in those at high age 
and with severe SVD. The exponential progression of SVD can be explained by 
findings from our and previous studies, showing that, besides age, baseline lesion 
load may predict SVD progression [60-62, 97].
Our data show that SVD progression is a highly variable and exponential process, 
predominantly seen in participants with severe baseline SVD. However, at the 
same time, even the oldest participants with mild baseline SVD rarely show 
progression over a time course of nine years, indicating that SVD is a more complex 
and highly heterogeneous disease process than previously thought. The inter-indi-
vidual variability in SVD progression suggest heterogeneity in etiology of mild 
versus severe SVD and stresses the need for personalized treatment approaches. 
Still, we would require an even longer follow-up to exclude the possibility that all 
participants with mild baseline WMH would ultimately progress to severe WMH. 
Moreover, future studies should also focus on patients with a younger age than 
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increased efflux of Aβ into blood along with the Aβ concentration gradient. Our 
finding that plasma Aβ levels were elevated in participants with hypertension 
further supports this mechanism, since hypertension is thought to be a major 
cause of blood-brain-barrier breakdown [395]. Furthermore, some evidence exists 
of an exponential rather than a linear decrease in blood-brain-barrier function 
with higher age [391], which might explain the exponential course of SVD 
progression (Chapter 3). 
Proof of a causal role of blood-brain-barrier disruption in the pathogenesis of SVD 
also comes from a neuroimaging study in patients with lacunar stroke showing 
increased blood-brain-barrier permeability not only in regions of WMH but also in 
NAWM [393], although longitudinal studies investigating the conversion of these 
NAWM regions into WMH would be required to truly estimate a causal relationship. 
In addition, we observed associations of elevated baseline plasma Aβ levels with 
progression of SVD markers. Although these findings are suggestive of a causal 
relationship, future longitudinal studies using quantitative contrast-enhanced 
MRI – to visualize blood-brain-barrier permeability – are required to assess 
whether increased blood-brain-barrier permeability is involved in the progression 
of SVD.
Axonal damage
Further insights into the underlying mechanisms of SVD have been gained by the 
assessment of the microstructural integrity of the white matter. Impaired micro-
structural integrity in the normal appearing white matter, reflected by increased 
mean diffusivity (MD) and decreased fractional anisotropy (FA), preceded 
conversion into WMH and continued to decline over time (Chapter 4). This decline 
of microstructural integrity within the white matter implies an underlying 
disease process in the on conventional MRI normal appearing white matter, with 
gradual loss of microstructural integrity. These results are in line with previous 
longitudinal studies showing changes in baseline DTI measures that were related 
to incident WMH at follow-up [31, 32]. This confirms the hypothesis that WMH 
progression visible on conventional FLAIR imaging is only the “tip of the iceberg” 
with underlying loss of microstructural integrity that can only be visualized 
using more advanced neuroimaging techniques. Moreover, the observation of 
impaired microstructural integrity in remaining NAWM in participants with 
severe baseline SVD underlines that NAWM is not as normal one would expect 
from conventional MRI and might be an explanation for the observation that 
WMH progression was most pronounced in participants with severe SVD at 
baseline (Chapter 3).
After acute infarction the blood-brain barrier might be disturbed, causing leakage 
of cerebral fluid into the white matter, which may recover afterwards [140, 141]. 
Besides, it can be that lacunes collapsed into small lacunes that can be missed by 
brain imaging [64]. The disappearance of microbleeds may also be explained by 
clearance of hemosiderin-containing macrophages, if we consider the pathology of 
microbleeds as hemosiderin pigment accumulations in macrophages adjacent to 
ruptured atherosclerotic microvessels [66, 144]. Participants with SVD regression 
showed comparable cognitive decline compared to participants with stable SVD 
(Chapter 8), which might be supportive of the hypothesis that SVD regression 
reflects reversibility of white matter damage. These findings of comparable 
cognitive decline between participants with regression and stable SVD  might 
suggest that SVD regression has a relative benign cognitive outcome, although 
future studies are required to validate these findings and to assess the role of 
vascular risk factor control on SVD regression and possible recovery of clinical 
symptoms.
Together, these findings suggest a paradigm shift on how SVD progression should 
be considered: traditionally seen as a continuous progressive process, it should 
rather be considered a dynamic and highly heterogeneous process, sometimes 
interrupted by regression. The different progression profiles between participants 
with mild versus severe SVD might imply heterogeneity in etiology and cognitive 
consequences.
The etiology of cerebral small vessel disease
The underlying mechanisms of the development and progression of SVD are not 
yet fully understood. In this thesis, we used advanced neuroimaging techniques 
and biomarkers in blood to further elaborate on the underlying mechanisms of 
SVD. In this section, I will discuss three mechanisms that might contribute to the 
development and progression of SVD: disruption of the blood-brain-barrier, axonal 
damage and amyloid pathology.
Blood-brain-barrier disruption
Increasing evidence suggests that blood-brain-barrier disruption due to endothelial 
dysfunction might be an important factor in the pathogenesis of SVD [105, 160, 
342, 391-394]. That is, disruption of the blood-brain-barrier might lead to tissue 
damage and edema, which has been found to be among the pathological substrates 
of SVD on neuroimaging. Our findings of elevated plasma Aβ levels in participants 
with severe SVD (Chapter 5) would support a role of blood-brain-barrier disruption 
in SVD, since elevated Aβ levels in plasma might be caused by disruption of the 
blood-brain-barrier. That is, a more permeable blood-brain-barrier might lead to 
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Several mechanisms could explain the associations between plasma Aβ levels and 
SVD. Plasma Aβ might enhance endothelium-dependent vasoconstriction, leading 
to cerebral hypoperfusion, which in turn might result in WMH and lacunes 
[181-183]. Alternatively, an inverse relation could also explain the associations 
between plasma Aβ levels and SVD, i.e. that cerebral hypoperfusion – or reduced 
cerebral blood flow – promotes overproduction of Aβ and its secretion into the 
circulation [184], although the associations between plasma Aβ levels and 
progression of SVD markers over time support the first mechanism. Furthermore, 
amyloid has been shown to increase the permeability of the blood-brain-barrier 
[399], further supporting the notion that amyloid pathology might contribute to 
the pathogenesis of SVD. Besides, the associations between plasma Aβ and SVD 
might also be explained by mixed age-related pathologies, i.e. by interactions of 
SVD with Alzheimer’s type neurodegeneration. This hypothesis has been 
supported by previous studies reporting presence of WMH in AD patients [186, 
187]. Finally, it might also be that cerebrovascular and amyloid pathologies are 
caused by shared risk factors such as hypertension. We observed that plasma Aβ 
levels were elevated in participants with hypertension, which, in turn, was 
associated with SVD markers. Together with previously reported associations of 
plasma Aβ with hypertension [34, 36, 172, 173] and SVD markers [33-36, 176], these 
results suggest that amyloid pathology might also contribute to the development 
and progression of hypertension based SVD. 
Taken together, additional insights into the underlying mechanisms of SVD have 
been gained by both diffusion tensor imaging and blood biomarkers. Impaired 
microstructural integrity preceded conversion into WMH, suggesting an underlying 
disease process in on conventional MRI normal appearing white matter, with 
gradual loss of microstructural integrity. Inter-individual differences in micro-
structural integrity suggest heterogeneity of both NAWM and WMH, which might 
explain the exponential progression in participants with severe baseline SVD as 
well as the cognitive variability observed in patients with similar SVD severity. 
The combination of these diffusion measures with serum NfL and plasma Aβ 
provides evidence for blood-brain-barrier disruption, axonal damage and amyloid 
pathology as underlying mechanisms of SVD, though future studies are required 
to further elucidate the underlying pathophysiological mechanisms in the origin 
of SVD. 
Cognitive consequences of cerebral small vessel disease
The spectrum of cognitive deficits attributable to SVD is broad and cannot be fully 
explained by the severity and location of SVD markers. In this thesis, I elaborated 
on mechanisms that might explain the cognitive variability observed in patients 
The interpretation of impaired white matter microstructural integrity is 
challenging, especially with respect to underlying pathophysiological mechanisms. 
Alterations in diffusion measures have been associated with axonal membrane 
integrity and are often interpreted as impaired white matter integrity [387, 388], 
though recent studies have shown that diffusion alterations in SVD were mostly 
driven by increased extracellular free water [396]. In this thesis, we assessed the 
associations between neurofilament light chain (NfL), a blood marker for 
neuroaxonal damage, and diffusion measures both cross-sectionally (Chapter 6) 
and longitudinally (Chapter 7) in participants with SVD. The strong associations 
between NfL and mean diffusivity provide evidence for axonal damage as under- 
lying mechanism for diffusion alterations, though imaging-pathology combination 
studies are required to reveal the exact pathophysiological mechanisms.
Interestingly, baseline MD values in NAWM areas converting into WMH within 
five years were similar to MD values in WMH (Chapter 4), suggesting that additional 
mechanisms are involved in the final conversion of NAWM into WMH, e.g. 
inflammation or small acute infarctions. A role for inflammation in SVD has been 
suggested by previous studies indicating that inflammatory mediators might 
affect the permeability of the blood-brain barrier [397]. Evidence for acute WMH 
progression has been provided by a longitudinal neuroimaging study among five 
subjects with moderate to severe WMH with sixteen weekly MRI assessments, 
reporting nine small acute infarcts in three participants which approached the 
imaging characteristics of WMH in the weeks thereafter [398]. A follow-up of the 
RUN DMC study, the RUN DMC InTENse study, is designed to elaborate on the role 
of these small acute infarctions in the pathogenesis of SVD, using repeated MRI 
assessments monthly during ten consecutive months among participants with 
mild to severe SVD.
Amyloid pathology
To reveal further insights into the underlying mechanisms of SVD, we investigated 
the associations between plasma Aβ with both severity and progression of SVD 
markers. Our findings that elevated plasma Aβ levels were not only associated 
with severity of SVD cross-sectionally but also predicted the progression of SVD 
over time (Chapter 5), suggest that amyloid pathology might contribute to the 
development and progression of SVD. However, as plasma Aβ might only partly 
reflect amyloid pathology, quantitative measures of amyloid pathology using 
positron emission tomography (PET) are required to further elucidate the role of 
amyloid pathology in SVD.
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investigate a causal role of specific disruption of rich club connections in cognitive 
decline and dementia, we performed longitudinal mediation analyses on the 
associations between SVD markers, rich club organization and cognitive decline 
and dementia (Chapter 10). Interestingly, the decline in strength of peripheral 
connections, rather than rich club or feeder connections, was associated with 
cognitive decline and dementia. Although we are not aware of any studies 
investigating the preferential role of specific connections for cognitive function 
in elderly with SVD longitudinally, these results are in contrast to what we would 
expect based on the findings from several cross-sectional studies reporting an 
important role for rich club connections in cognitive processes [57, 58, 381]. There 
may be several explanations for this discrepancy. First, the selection of rich club 
nodes was based on node degree in healthy control subjects [375, 376], whereas the 
rich club organization in our study population was already disrupted at baseline 
due to their SVD [57], which might have influenced our results. In addition, it 
might be that initial disruptions of the rich club connections are followed by 
secondary disruptions of the feeder or peripheral connections and that 
impairments in peripheral connections only lead to clinical overt symptoms after 
a certain threshold of structural network disruption is reached [379]. Future 
longitudinal studies are required to ascertain the extrapolation of the concept of 
rich clubs to patients with SVD. 
SVD might also exert its effects on cognitive performance by affecting remote 
brain structures. That is, SVD might lead to global brain atrophy and consequent 
cognitive decline by inducing a cascade of events that spread from visible SVD 
markers to remote brain areas, possibly via axonal loss by anterograde or 
retrograde degeneration [4, 155]. Our findings that WMH progression was 
associated with subsequent white matter and total brain atrophy (Chapter 2), 
provide evidence for remote effects of SVD. These findings have been corroborated 
by others, who reported associations of SVD with brain atrophy and cortical 
thinning [49, 147]. In addition, these cortical changes were associated with 
cognitive decline and, moreover, mediated the associations between WMH and 
cognitive deficits. A cross-sectional study reported negative associations between 
WMH and cortical thickness [289], which in turn mediated the associations 
between WMH and cognitive deficits. Furthermore, several longitudinal studies 
showed that brain atrophy mediated the relationship between presence of WMH 
and cognitive decline [109, 291], providing evidence that SVD exerts its effect on 
cognition by affecting remote brain structures.
The variability in cognitive symptoms between patients with apparently similar 
degrees of SVD might also be explained by the presence of other neurodegenera-
with apparently similar SVD severity, thereby taking into account both local and 
remote effects.
From local to remote effects
Although SVD markers have a similar appearance on conventional neuroimaging, 
post-mortem histopathology studies have shown that these markers are in fact 
heterogeneous with respect to disease severity and etiology. Our findings that mi-
crostructural integrity was more impaired in participants with severe baseline 
SVD than in participants with mild baseline SVD, in all areas including WMH, 
confirm the hypothesis that SVD markers are heterogeneous (Chapter 4). This 
heterogeneity of microstructural integrity in WMH might explain the cognitive 
variability observed in participants with similar SVD severity. That is, participants 
with impaired WMH microstructural integrity might have more severe clinical 
symptoms compared with participants with the same degree of WMH, but with 
higher microstructural integrity in their WMH. This hypothesis was supported by 
findings in patients with SVD, showing that patients with severe loss of micro-
structural integrity within their WMH showed decreased cognitive performance 
and had higher risk of parkinsonian signs, independent of WMH volume [158, 159]. 
Growing evidence suggests that SVD exerts its clinical effects by disrupting brain 
networks, thereby affecting network efficiency and cognitive performance. Several 
studies demonstrated SVD-related disruptions in structural network connectivity 
in patients with SVD, reflected by decreased global efficiency [53, 54, 57, 294], 
which was related to increased cognitive impairment [53, 54, 289, 295, 297]. Our 
longitudinal findings that decline in global efficiency was associated with decline 
in cognitive performance and mediated the effects of WMH on dementia (Chapter 
10) provide further evidence on a causal role for network disruption in cognitive 
decline and dementia. This finding was corroborated by another neuroimaging 
study in patients with symptomatic SVD, reporting changes in network global 
efficiency that mediated the association of conventional MRI markers of SVD with 
cognitive decline and progression to dementia [378]. Additional insights into the 
extent and location of structural network disruption in SVD can be provided by 
so-called rich club analyses. Due to their central role in brain networks and high 
connectivity with other nodes, damage to rich club nodes or rich club connections 
might have a more widespread effect on network function compared with damage 
to peripheral nodes or peripheral connections in a network. Evidence for this 
hypothesis have been provided by several cross-sectional studies, reporting specific 
reductions in connections between rich club nodes in elderly with SVD, rather 
than a generalized reduction of the white matter connectivity, which mediated 
the associations between WMH volume and cognitive performance [57, 58, 381]. To 
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explain the heterogeneity in cognitive symptoms in patients with apparently 
similar SVD burden. To fully understand the spectrum of cognitive deficits in 
patients with SVD, one should also take into account the interaction of cerebrovas-
cular and neurodegenerative pathologies as well as the concept of brain resilience.
Clinical relevance
Biomarkers
The findings in this thesis are clinically relevant as differences in microstructural 
integrity between remaining NAWM and incident WMH suggest that it would be 
possible to predict which NAWM voxels will convert into WMH, based on baseline 
MRI values. Our observation that impaired microstructural integrity at baseline 
was associated with more extensive WMH progression over nine years, implies 
that measures of microstructural integrity can possibly be used as biomarker for 
WMH progression. Besides, the associations between serum NfL with neuroimaging 
markers of SVD, and especially with measures of microstructural integrity, 
implies that serum NfL might complement established MRI markers in assessing 
SVD burden. In addition, our findings that plasma Aβ levels were associated with 
both presence and progression of SVD markers, suggest that plasma Aβ might 
serve as inexpensive and non-invasive measure for identifying individuals with 
increased risk for progression of SVD. 
The longitudinal design of our study enabled us to elaborate on the directionality 
of associations. That is, we were able to examine baseline markers in relation to 
the severity and progression of SVD over time , thereby providing more insights 
on temporal precedence. Hence, measures of microstructural integrity, together 
with plasma Aβ and serum NfL levels, might serve as promising biomarkers for 
future SVD, possibly able to identify individuals at high risk for SVD progression, 
years before SVD can be detected on conventional MRI.
However, none of these markers is specific for SVD, since Aβ has also been 
associated with AD [404], and NfL with multiple sclerosis [37] and neurodegenera-
tive disorders [38], including AD [39] and frontotemporal dementia [40]. Since cere-
brovascular and neurodegenerative pathologies often co-occur in older 
individuals, plasma Aβ and serum NfL might offer the possibility to assess the 
combined effect of these pathologies on brain integrity. Perhaps, a combination of 
neuroimaging and blood markers would be able to increase the specificity, which 
would be an interesting angle for future studies.
tive pathologies, such as Alzheimer’s Disease (AD). Co-occurrence of both cerebro-
vascular and neurodegenerative pathologies has been reported previously, for 
example by studies reporting higher WMH volumes in patients with AD [400-403]. 
Our findings that memory decline could be best explained by the interaction of 
WMH with hippocampal atrophy, while the association between WMH and 
memory decline was not causally mediated by hippocampal atrophy (Chapter 9), 
suggest that WMH and hippocampal atrophy synergistically affect memory 
decline. In addition, several neuroimaging studies also reported a synergistic 
effect between WMH and markers indicative of AD pathology (e.g. hippocampal 
volume) on cognitive performance [334, 335], while others have suggested that 
cerebrovascular pathology and AD pathology negatively affect cognition 
independently of each other [327, 338]. Together, these findings indicate that 
cognitive decline in patients with SVD is a heterogeneous clinical phenotype to 
which different pathologies contribute. Future studies combining neuroimaging 
with pathology would be required to unravel the true pathophysiological 
mechanisms underlying cognitive deficits in SVD and should thereby take into 
account both cerebrovascular and neurodegenerative pathologies. 
Brain resilience
In the previous sections, I discussed mechanisms that might explain the spectrum 
of cognitive deficits observed in patients with SVD. Still, these mechanisms cannot 
fully explain the variation in cognitive deficits, as many individuals remain 
functionally independent despite a considerable burden of SVD. Conversely, an 
alternative approach might be to take into account brain resilience, which is the 
capacity to tolerate a certain degree of brain damage before clinical symptoms 
become manifest. That is, participants with larger brain volumes or higher levels 
of education might tolerate a greater burden of SVD pathology before cognitive 
symptoms arise than participants with smaller brain volumes or lower levels of 
education. This hypothesis was supported by studies reporting lower risk of 
dementia in patients with a larger brain volume [318] and slower rates of cognitive 
decline in participants with higher cognitive reserve [329], independently of SVD 
severity. Thus, by protecting against SVD-related cognitive deterioration via 
reserve and compensatory mechanisms, the concept of brain resilience might 
explain the variation of cognitive deficits observed in patients with apparently 
equal SVD severity.
To conclude, SVD markers with a rather homogeneous appearance on conventional 
neuroimaging are in fact highly heterogeneous, and might additionally affect 
brain tissue beyond the commonly recognized visible SVD by inducing a cascade 
of events that spread from the initial lesion to remote brain areas, which might 
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evidence of a stringent control of vascular risk factors according to current 
guidelines, until further data from randomized controlled trials are available. 
Future perspectives
Future studies are required to further unravel the etiology of SVD and the 
mechanisms by which SVD leads to cognitive deficits (Box). These studies should 
include advanced multimodal structural and functional MRI with high temporal 
and spatial resolution. To elaborate on the factors involved in the origin of SVD, 
the pathological correlates of neuroimaging markers of SVD should be further 
investigated and studies should include patients of a younger age than have been 
done thus far, preferably already from early adulthood. Moreover, studies with 
longitudinal designs are of utmost importance to elaborate on the directionality 
of associations and the sequence of events from local SVD towards remote effects 
eventually leading to widespread cognitive symptoms in patients with SVD. 
Furthermore, rather than solely focusing on vascular or Alzheimer’s dementia as 
isolated diseases, the field would benefit from a focus on the interaction of SVD 
pathology with other neurodegenerative pathologies.
Concluding remarks
Cerebral small vessel disease is highly heterogeneous, reflected in inter-individual 
variability in the temporal dynamics, etiology and cognitive consequences. SVD 
might exert its effects throughout the brain by inducing a cascade of events that 
spread from the visible SVD markers to remote brain areas, which might explain 
the variability in cognitive symptoms in patients with apparently similar SVD 
burden.
Personalized treatment 
Since SVD is considered the most important vascular contributor to cognitive 
decline and the development of dementia, it is important to identify those at risk 
as early as possible, preferably before irreversible damage has occurred. Our 
findings on inter-individual variability in SVD progression and underlying 
mechanisms are a major step forward in developing personalized treatment 
approaches. Those with severe SVD – already at baseline – had more microstruc-
tural white matter damage, even in the on conventional MRI normal appearing 
white matter, with subsequent exponential progression of their SVD. These 
findings may suggest that these patients are also at highest risk of developing 
cognitive decline or dementia. This may provide a window of opportunity to 
deploy intervention strategies, already before SVD becomes visible on conventional 
neuroimaging, to prevent or postpone cognitive symptoms. In order to facilitate 
personalized treatment, future studies should further elaborate on the inter-indi-
vidual differences in SVD and its cognitive consequences, especially aiming to 
identify patients at high risk of developing cognitive decline or dementia in early 
phases.
Treatment strategies of SVD should target risk factors or factors involved in the 
pathogenesis of SVD. Hypertension, diabetes mellitus, hypercholesterolemia, 
obesity, smoking, and lack of physical exercise, are major vascular risk factors for 
SVD and have been associated with an increased risk of cognitive impairment and 
dementia [14-26]. Since all these vascular risk factors are modifiable, either by 
medication or life-style interventions, they are important targets for treatment or 
prevention strategies. In addition, there is growing evidence for a causal role of 
blood-brain-barrier disruption due to endothelial dysfunction in the pathogenesis 
of SVD, suggesting that therapeutic strategies targeting vascular contributions to 
dementia may also be interested in targeting endothelial function. Furthermore, 
the concurrence of cerebrovascular pathologies with neurodegenerative 
pathologies in the development of cognitive decline and dementia implies that 
treatment should not be solely focused on targeting vascular contributions to 
dementia, but might rather require a multi-domain intervention. 
Thus far, randomized trials investigating  the effect of intervention of vascular 
risk factors on progression of SVD and cognitive decline have revealed mixed 
results [75, 161, 211, 405, 406]. Hence, future randomized trials are required, 
particularly focusing on multi-domain interventions in populations at high risk of 
SVD progression and developing dementia. Novel treatments might target the 
brains’ microvascular endothelium with endothelin antagonists or nitric oxide 
donors [161], although randomized controlled trials are required. For now, there is 
252 253
CHAPTER 13 DISCUSSION AND FUTURE PERSPECTIVES
13
Box  Next steps in the field
Research in early phases 
Studies on causes and consequences of SVD currently mainly focus on elderly individuals 
over 50 years of age. However, in order to improve our understanding on the causes of 
SVD, studies should also focus on patients from a younger age than have been done so 
far, enabling us to elaborate on the factors involved in the origin of SVD.
Longitudinal studies
Studies with longitudinal designs are of utmost importance to shed more light on the 
causality or directionality of associations and the sequence of events from local SVD 
towards global remote effects eventually leading to widespread cognitive symptoms in 
patients with SVD.
Standardized methods
Better SVD identification methods are needed that are both reliable and less time-
consuming. Ideally, robust standardized SVD segmentation should be developed to 
identically indentify SVD markers in various study populations. Besides, standardized 
methods for analyzing and reporting structural connectivity should be developed. This 
would enhance robustness and generalization of findings. 
Multimodal imaging
Multimodal imaging is required to assess various neuroimaging parameters such as T1, 
FLAIR, MD, FA, connectivity and perfusion contemporary in whole brain white and gray 
matter. The use of different imaging sequences will aid to assess coherence between 
different findings, e.g. correlations between SVD markers and structural or functional 
connectivity loss.
High field imaging 
Using high field strength MRI, one will become capable of directly visualizing small 
intracerebral arteries and veins, as well as the vascular wall of intracerebral arteries, 
perivascular spaces, and microvascular lesions including microbleeds and microinfarcts. 
Hence, future studies using high field imaging are required to offer new perspectives on 
underlying mechanisms of SVD.
High frequency scanning 
Our understanding of SVD is mainly based on cross-sectional data or longitudinal 
studies with typically inter-scan intervals of several years. Rather, longitudinal studies 
with much shorter inter-scan intervals of weeks or months might tremendously enhance 
our understanding of the sequence of events from focal SVD towards remote effects, 
thereby providing insights in SVD as a dynamic global brain disease.
Biomarker studies
There is a need for combining neuroimaging, including amyloid PET imaging, with 
biomarkers from serum and CSF, mainly to elaborate on both vascular and neurodegen-
erative pathologies in the brain, as this would shed light on how these pathologies 
interact in causing clinical symptoms.
Pathology studies
Future studies should also target the connection between neuroimaging findings and 
neuropathological changes. Revealing underlying pathological substrates of SVD 
markers would improve our understanding of the heterogeneity observed between and 
within neuroimaging markers of SVD.
Animal studies
The use of animal models (e.g. rodents) might enhance our understanding of the 
pathogenesis of SVD. Furthermore, animal models might be particularly useful to 
investigate potential biomarkers and therapeutic approaches for SVD. Particular 
attention should be paid on the translation of findings, as this is often hampered by the 
small proportion of white relative to gray matter in rodents compared to humans and 
the acute induction of risk factors. Instead, animal models should allow for a chronic 
development over a life-time course. 
Focus on mixed age-related pathologies
Future studies are required to shed more light into the longitudinal interactions between 
vascular, neurodegenerative and Alzheimer’s pathologies. Especially the interaction 
between SVD and these other factors needs to be further investigated, rather than solely 
focusing on “Vascular Dementia” or “Alzheimer’s Disease” who are clinical diagnoses 
likely representing mixtures of underlying pathologies, in order to fully understand the 
role of SVD in clinical presentation. 
Clinical trials
Clinical (intervention) trials are required to test whether (vascular) risk factor control, 
drug treatment and lifestyle modifications can prevent or minimize the transition of 
SVD into a global brain disease ultimately leading to widespread clinical symptoms.
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Schade aan de kleine bloedvaten in de hersenen wordt in het Engels ‘small vessel 
disease’ genoemd. De veronderstelde gevolgen van deze schade aan de kleine 
hersenvaatjes kunnen worden gezien op MRI scans als witte stofafwijkingen, 
lacunes (kleine herseninfarcten) en microbloedingen (kleine hersenbloedingen). 
Small vessel disease komt veel voor op latere leeftijd en is de belangrijkste 
vasculaire oorzaak voor cognitieve achteruitgang en dementie.
De studies in dit proefschrift zijn gebaseerd op de Radboud Universiteit Nijmegen 
Diffusie tensor en Magnetische resonantie beeldvorming Cohort (RUN DMC) 
studie, een prospectieve cohort studie bedoeld om de oorzaken en gevolgen van 
small vessel disease te onderzoeken. Hierin onderzochten we 503 mensen tussen 
de 50 en 85 jaar met small vessel disease, waarbij we op drie momenten over een 
periode van negen jaar (2006, 2011 en 2015) MRI scans hebben gemaakt en 
cognitief onderzoek hebben verricht. In dit proefschrift onderzocht ik eerst de 
verandering van small vessel disease in de tijd, om daarna verder in te gaan op 
onderliggende mechanismen en cognitieve gevolgen van small vessel disease. In 
dit hoofdstuk vat ik de belangrijkste bevindingen van mijn proefschrift samen.
Het dynamische beloop van small vessel disease in de tijd
In Deel II van dit proefschrift onderzocht ik het tijdsverloop van small vessel 
disease, met name omdat het in kaart brengen van het tijdsverloop van een ziekte 
zou kunnen helpen om de onderliggende mechanismen en klinische consequenties 
beter te begrijpen.
Hoofdstuk 2 bevat een literatuurstudie naar de toename en afname van small 
vessel disease. Hoewel small vessel disease in de loop der jaren gemiddeld meestal 
toeneemt, wordt afname van small vessel disease ook vaak beschreven. Deze 
afname werd meestal gerapporteerd als een meetfout of beschreven als ‘geen 
toename’, maar zou op basis van de resultaten van onze literatuurstudie eerder 
moeten worden beschouwd als een echt fenomeen. 
De dynamiek van small vessel disease binnen de RUN DMC studie heb ik beschreven 
in Hoofdstuk 3. In de meeste studies werd verandering van small vessel disease 
gemeten op twee tijdspunten, daarbij uitgaand van een lineaire toename. Middels 
het gebruik van drie MRI scans konden we deze hypothese voor het eerst 
daadwerkelijk testen. We vonden dat de toename van small vessel disease niet 
lineair verliep, maar exponentieel volgens een kwadratische curve. De toename 
was het grootst in deelnemers die op baseline al ernstige small vessel disease 
hadden; deelnemers met milde small vessel disease op baseline toonden nauwelijks 
progressie. Daarnaast zagen we dat deze gemiddelde toename in ongeveer een 
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zijn van axonale schade, suggereren deze bevindingen dat de verlaagde micro-
structurele integriteit wordt veroorzaakt door axonale schade. Verder was NfL in 
bloed ook geassocieerd met handelingssnelheid, het cognitieve domein dat het 
vaakst is aangedaan in mensen met small vessel disease. Deze bevindingen 
impliceren dat serum NfL een toevoeging kan zijn op de al bestaande MRI markers 
om de ernst van small vessel disease vast te stellen.
De associaties tussen serum NfL en toekomstige witte stof schade heb ik beschreven 
in Hoofdstuk 7. Serum NfL was geassocieerd met toekomstige witte stofafwijkin-
gen microstructurele integriteit en nieuwe lacunes. Verder was NfL ook 
geassocieerd met de handelingssnelheid negen jaar later. Deze bevindingen 
suggereren dat NfL een weerspiegeling is van de ernst en toename van small 
vessel disease, hoewel de prognostische waarde van NfL als vroege biomarker voor 
small vessel disease, vooral bovenop de al bestaande MRI markers, nog aangetoond 
moet worden.
De cognitieve consequenties van small vessel disease
In Deel IV van dit proefschrift beschreef ik de gevolgen van small vessel disease 
voor het cognitief functioneren. Vanaf zestig jaar of ouder heeft vrijwel iedereen 
in meer of mindere mate small vessel disease. Sommigen hebben daar geen last 
van; bij anderen leidt het tot cognitieve achteruitgang of dementie. Omdat de 
beschadiging van de kleinste hersenvaten overal in de hersenen kan optreden, 
kun je ook heel uiteenlopende symptomen verwachten. Voorheen werd small 
vessel disease vooral geassocieerd met trage handelingssnelheid, maar het 
spectrum van cognitieve problemen als gevolg van small vessel disease blijkt 
breder dan eerder gedacht. Deze cognitieve problemen kunnen niet alleen worden 
toegeschreven aan de ernst en locatie van MRI markers voor small vessel disease. 
In dit deel onderzocht ik daarom alternatieve verklaringen om de sterk 
uiteenlopende klinische verschijnselen van small vessel disease te beschrijven.
Hoofdstuk 8 bevat een literatuurstudie naar mechanismen voor cognitieve 
problemen in patiënten met small vessel disease. Hierin schep ik een nieuw kader 
voor de variatie in cognitieve problemen: lokale aanwezigheid van small vessel 
disease leidt tot globale verschijnselen. Nieuwe beeldvormende onderzoeken 
hebben aangetoond dat plaatselijke manifestaties van small vessel disease hun 
effect door de gehele hersenen kunnen hebben. De locatie waar de schade ontstaat, 
kan dus óók op andere locaties leiden tot verminderde functie – en dus tot andere 
ziekteverschijnselen leiden dan op grond van de locatie van zichtbare small vessel 
disease te verwachten zou zijn. 
vijfde van de deelnemers afgewisseld werd met afname van small vessel disease in 
een andere periode. In plaats van een continue lineair toenemend proces, zou 
small vessel disease dus moeten worden beschouwd als een zeer dynamisch proces, 
waarbij toename soms ook kan worden afgewisseld door afname.
De etiologie van small vessel disease
In Deel III van dit proefschrift onderzocht ik de onderliggende mechanismen van 
small vessel disease. Dat deed ik aan de hand van geavanceerde MRI methoden en 
aan de hand van markers in bloed.
In Hoofdstuk 4 onderzocht ik de kwaliteit van witte stof vóór het ontstaan van 
witte stofafwijkingen. Met een bepaalde MRI scan, de zogenaamde DTI scan, 
konden we de kwaliteit – ook wel genoemd: ‘microstructurele integriteit’ – van de 
witte stof bestuderen. We vonden dat de microstructurele integriteit van witte stof 
aangedaan was, zelfs jaren voor er afwijkingen te zien waren op MRI scans. De 
microstructurele integriteit was meer aangedaan in deelnemers met ernstige 
small vessel disease, in alle gebieden, inclusief de normaal lijkende witte stof en de 
witte stofafwijkingen. Deze heterogeniteit zou kunnen verklaren dat deelnemers 
met ernstige small vessel disease in de loop van de jaren aanzienlijk meer toename 
hebben dan degenen met slechts milde small vessel disease. Daarnaast zou deze 
heterogeniteit ook kunnen verklaren waarom patiënten met ogenschijnlijk 
eenzelfde hoeveelheid small vessel disease een grote variatie aan klinische 
symptomen laten zien.
Daarnaast heb ik in Hoofdstuk 5 onderzocht of de ernst van small vessel disease 
geassocieerd was met de concentraties van amyloid beta (Aβ) in bloed, een eiwit 
dat, naast vasculaire risicofactoren als hypertensie, een oorzaak van small vessel 
disease zou kunnen zijn. Hogere concentraties van Aβ in plasma waren geassocieerd 
met zowel de ernst als de toename van small vessel disease, hetgeen suggereert dat 
Aβ betrokken is bij de ontwikkeling van small vessel disease. Verder onderzoek is 
nodig om te bepalen of Aβ zou kunnen dienen als biomarker om al in een vroege 
fase mensen op te sporen met een hoog risico op toename van small vessel disease.
In Hoofdstuk 6 heb ik vervolgens onderzocht of small vessel disease geassocieerd 
was met de concentraties van neurofilament light chain (NfL) in bloed, een marker 
voor axonale schade (de witte stof banen bestaan uit axonen). NfL concentraties in 
serum waren verhoogd in deelnemers met small vessel disease ten opzichte van 
gezonde controles. Daarnaast was serum NfL geassocieerd met MRI markers voor 
small vessel disease, met name met de microstructurele integriteit zoals gemeten 
met DTI scans. Omdat verhoogde waarden van NFL in bloed een weerspiegeling 
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name in deelnemers met ernstige small vessel disease. Daarnaast vonden we dat 
de achteruitgang van de kwaliteit van perifere verbindingen, maar niet van de 
rich club verbindingen, geassocieerd was met achteruitgang van het cognitief 
functioneren. Bovendien hadden deelnemers met dementie een minder efficiënt 
hersennetwerk en verminderde kwaliteit van de perifere verbindingen dan 
deelnemers zonder dementie en was het effect van witte stofafwijkingen op 
dementie causaal gemedieerd door de globale efficiëntie en kwaliteit van de 
perifere verbindingen. Deze bevindingen impliceren dat verstoringen van hersen-
verbindingen een belangrijke rol speelt in het ontstaan van cognitieve 
achteruitgang en dementie in mensen met small vessel disease.
Conclusie
Small vessel disease is een heterogene ziekte, wat tot uiting komt in het dynamische 
tijdsverloop van small vessel disease, de onderliggende mechanismen en de 
variatie aan cognitieve problemen in mensen met small vessel disease. Met het 
nieuwe concept ‘lokale aanwezigheid, globale verschijnselen’ kunnen de 
cognitieve problemen als gevolg van small vessel disease beter worden begrepen: 
small vessel disease leidt niet alleen tot problemen door lokale hersenbeschadigin-
gen, maar kan door het beschadigen van hersenverbindingen ook leiden tot 
schade aan verder weg gelegen hersengebieden en via die weg leiden tot cognitieve 
problemen.
In Hoofdstuk 9 heb ik de gevolgen van afname van small vessel disease voor het 
cognitief functioneren beschreven. Eerder lieten we zien dat een op de vijf 
deelnemers naast toename ook afname van small vessel disease liet zien, maar de 
klinische gevolgen hiervan waren nog niet bekend. Enerzijds dachten we dat 
afname van small vessel disease gepaard zou gaan met atrofie van de hersenen en 
zo zou kunnen leiden tot meer cognitieve problemen. We vonden echter geen 
bewijs voor deze hypothese: afname van small vessel disease ging niet gepaard met 
globale atrofie van de hersenen. Anderzijds dachten we dat afname van small 
vessel disease een weerspiegeling kon zijn van omkeerbare witte stofschade en 
daarmee een relatief gunstig effect zou hebben op het cognitief functioneren. We 
vonden geen verschillen in cognitieve achteruitgang tussen deelnemers met 
afname van small vessel disease en deelnemers waarvan de hoeveelheid small 
vessel disease gelijk bleef. Daarnaast zagen we minder cognitieve achteruitgang in 
deelnemers met afname van witte stofafwijkingen dan in deelnemers met 
toename van witte stofafwijkingen en minder achteruitgang van handelingssnel-
heid in deelnemers met afname van lacunes dan in deelnemers met nieuwe 
lacunes, hoewel deze verschillen niet significant waren na correctie voor leeftijd. 
Verder onderzoek is nodig om de effecten van afname van small vessel disease op 
cognitieve achteruitgang vast te stellen.
In Hoofdstuk 10 zocht ik een verklaring voor de geheugenproblemen in patiënten 
met small vessel disease. Geheugenproblemen kunnen niet goed verklaard worden 
door de locatie van small vessel disease, maar worden vaak toegeschreven aan 
atrofie van de hippocampus. In dit hoofdstuk heb ik daarom de interactie tussen 
small vessel disease en hippocampusatrofie onderzocht. We konden de geheugen-
problemen in deelnemers met small vessel disease beter verklaren door de 
interactie van witte stofafwijkingen met hippocampusatrofie dan door deze 
variabelen apart. Daarnaast vonden we dat het effect van witte stofafwijkingen op 
geheugenachteruitgang niet causaal gemedieerd werd door hippocampusatrofie, 
hetgeen suggereert dat witte stofafwijkingen en hippocampusatrofie 
onafhankelijke processen zijn die samen een groter effect hebben op geheugen-
problemen dan allebei apart.
Tot slot heb ik de rol van achteruitgang van hersenverbindingen bij cognitieve 
problemen onderzocht in Hoofdstuk 11. Specifiek heb ik daarbij gekeken naar de 
‘centrale stations’ van de hersengebieden, de zogeheten ‘rich clubs’, en naar 
onderlinge verbindingen tussen deze gebieden. Dit netwerk van hersenverbindin-
gen wordt gezien als de spil van de communicatie in de hersenen en speelt een 
belangrijke rol in het cognitief functioneren. We zagen dat de kwaliteit van 
specifiek deze rich club verbindingen achteruit was gegaan na negen jaar, met 
Part VI
Appendices
265
LIST OF ABBREVIATIONS
List of abbreviations
Aβ = amyloid beta
AD = Alzheimer’s Disease
AIC = akaike information criterion
ANTs = advanced neuroimaging tools
APOE = apolipoprotein E
ARWMC = age-related white matter changes
AUC = area under the curve
B = Baseline
CAA = cerebral amyloid angiopathy 
CADASIL = cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
CAVIA = Cerebral Amyloid Angiopathy: Vascular Imaging and fluid markers of Amyloid deposition
CI = confidence interval
CSF = cerebrospinal fluid
CSFV = cerebrospinal fluid volume
DAN = dorsal attention network
DMN = default mode network
DTI = diffusion tensor imaging
DWI = diffusion-weighted imaging
ELISA = enzyme-linked colorimetric immunosorbent assay
FA = fractional anisotropy
FPCN = frontoparietal control network
FLAIR = fluid-attenuated inversion recovery
FSL = Functional Magnetic Resonance Imaging of the Brain (FMRIB) Software Library
FU = follow-up
GM = gray matter
GMV = gray matter volume
GRE = gradient recalled echo
HC = healthy controls
ICV = intracranial volume
IQR = interquartile range
MB = microbleed
MD = mean diffusivity
MMSE = Mini-Mental State Examination
MPRAGE = magnetization-prepared rapid gradient echo
MRI = magnetic resonance imaging
mRS = modified Rankin scale
NAWM = normal appearing white matter
NfL = neurofilament light chain
NIHSS = National Institutes of Health stroke scale
OR = odds ratio
PVE = partial volume effects
ROC = receiver operating characteristics
RUN DMC = Radboud University Nijmegen Diffusion tensor and Magnetic resonance imaging Cohort
SD = standard deviation
SPM = statistical parametric mapping
STRIVE = Standards for Reporting Vascular Changes on Neuroimaging
SVD = cerebral small vessel disease
TBV = total brain volume
TIA = transient ischemic attack
TBSS = tract-based spatial statistics 
WM = white matter
WMH = white matter hyperintensities
WMV = white matter volume
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WOORD VAN DE PARANIMFEN
Woord van de paranimfen
Esthers teamspirit, humor, harde werken, betrokkenheid, prestaties en energie 
hebben ervoor gezorgd dat er geen twijfel bestond om haar aan te nemen als 
3e  generatie RUN DMC’er. Deze kwaliteiten werden al snel zichtbaar tijdens haar 
 stage binnen de master neuroscience, waar ze zowel als persoonlijkheid uitblonk, 
maar ook in potentie in de meest ingewikkelde MRI-analyses. Hier is de basis  gelegd 
voor het huidige proefschrift over de cognitieve gevolgen van cerebral small 
vessel disease. 
Vol overgave stortte Esther zich, als opvolger van Ellen en Inge, samen met ‘team-
genoot’ Mayra op de dataverzameling, ook wel de ‘2e follow-up’. Er volgden vele 
koppen koffie tijdens de thuisbezoeken door het hele land. Dit zorgde voor meerdere 
memorabele momenten (zoals het ontmoeten van dé poes waar Esther en May-
ra over de telefoon al veel over hadden gehoord, ezeltjes naast het treinstation, 
de tekening van ‘het vissen’, het  huis met de vitrines, de buurtbussen en de appel-
taart). Dankzij Esthers social skills en engelengeduld zijn alle problemen tijdens 
de follow-up overwonnen, ondanks verdwaalde deelnemers (teruggevonden op 
de polikliniek cardiologie) en planningsmisverstanden. Door haar goede zin, energie 
en humor, heeft niemand deze momenten als vervelend ervaren, en behoren deze 
herinneringen tot de leukste momenten!
Niet alleen in dataverzameling is Esther een natuurtalent, daarnaast blinkt zij uit 
in analytische kwaliteiten. Hard werken, goede planning, doorzettingsvermogen 
en een grote berg aan kunde leverden haar al heel snel de Young Investigator 
Award op in Barcelona. Hierna volgde een Junior Investigator Award in Boston. 
Na een eerste publicatie in Neurology volgden nog publicaties in Clinical Science, 
Stroke en Nature Reviews Neurology, zoals te lezen in dit proefschrift.
Lieve Esther, we zijn buitengewoon trots dat we jouw paranimfen mogen zijn. 
We hebben met veel plezier en bewondering met je samengewerkt. Jouw prestaties 
en persoonlijkheid zijn inmiddels ook door de Nederlandse overheid opgemerkt. 
Het geeft ons een goed en veilig gevoel dat jij jouw talenten gaat inzetten om ons 
land veiliger te maken.
Inge en Mayra
De paranimfen
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Daar is ie dan: mijn boekje! Het eindresultaat van bijna vier jaar onderzoek. Met name 
de interesse en betrokkenheid van velen van jullie heb ik als heel bijzonder en fijn 
ervaren en ik wil daar graag een aantal mensen speciaal voor bedanken.
Allereerst wil ik graag alle deelnemers van het RUN DMC onderzoek bedanken. 
Zonder u was dit boekje er nooit geweest! Het heeft me ontroerd hoe u soms hemel 
en aarde heeft bewogen om in 2015 nogmaals deel te kunnen nemen aan het 
onderzoek, waarbij we ook een aantal van u thuis hebben bezocht. Door u ben ik 
nog extra gaan beseffen hoe belangrijk en waardevol het onderzoek is dat we doen.
Frank-Erik, ik besef me dat ik van geluk mag spreken met een promotor als jij. Ik 
vond het heel fijn dat je zo betrokken was, zowel bij de follow-up als bij mij als 
persoon. En wat was je vaak snel met reacties op mails of commentaar op stukken! 
Dat je zelfs tijdens FC Barcelona mijn rebuttals bekeek! En dat je dan toch nog 
scherp en kritisch bleef. Wellicht moeten we nog eens onderzoeken of het aantal 
doelpunten van Messi daar nog invloed op heeft..? Jouw oratie was een van de 
hoogtepunten van afgelopen jaren. Ik heb veel geleerd van de manier waarop jij je 
boodschap kort maar krachtig over kunt brengen. Meer dan verdiend dat je nu 
professor bent en extra bijzonder dat je nu dan ook echt mijn promotor kunt zijn. 
Ik heb er bewondering voor hoe jij iedereen aan weet te steken met jouw 
bevlogenheid en enthousiasme. Met de etentjes tijdens het ESOC en de neurovas-
culaire borrels weet jij iedereen weer bij elkaar te brengen en ik vind het bijzonder 
om te zien hoe die groep elk jaar weer groter wordt. Ik hoop van harte dat jij en 
Amanda de goede traditie van de neurovasculaire borrels in juni nog lang in ere 
zullen houden!
Marcel, ik blijf het soms bijzonder vinden hoe jij de meest ingewikkelde discussies 
kunt afwisselen met de meest flauwe humor. Heerlijk hoe jij alles van epidemiolo-
gisch onderzoek tot netwerkanalyses en van significante relaties tot verklaarde 
varianties weet te relativeren. Bedankt dat je me hebt geïntroduceerd in het CAA 
onderzoek en dat ik mee mocht naar Boston; van presentaties, meetings en 
discussies tot walvissen spotten en etentjes met koksmutsen, ik denk daar met 
veel plezier aan terug! Dankzij jouw creatief bedachte acroniemen heb ik aan veel 
mensen mogen uitleggen wat voor CAVIA onderzoek ik deed… Dankjewel hè, 
Verbeek!
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hebben geholpen met de tweede follow-up in 2015. Heel fijn dat we zo vaak bij 
jullie mochten aankloppen als we nog iets wilden weten. Kim en Annemieke, met 
de opzet van de RUN DMC InTENse studie zijn jullie alweer de 4e generatie. Wat 
een karwei om bij 50 deelnemers maandelijks een MRI scan te maken, ik ben erg 
benieuwd naar jullie resultaten!
Graag wil ik ook iedereen bedanken die geholpen heeft met de uitvoering van het 
onderzoek en voor alle support achter de schermen. Paul Gaalman, bedankt voor 
je hulp met alle (maar liefst 296!) MRI scans. Zonder jouw hulp hadden we nooit zo 
veel deelnemers kunnen scannen voordat de scanner werd vervangen. Dank ook 
voor je humor en de goede anekdotes, ik vond het altijd weer gezellig in de kelder! 
Dames van de poli en het Donders, bedankt voor jullie hulp en het opvangen van 
de deelnemers. Vrijwilligers van de golfkarretjes, dank voor de vele ritten tussen 
de Neurologie en het Donders. Door jullie inzet hebben we de follow-up in zo’n 
korte tijd kunnen voltooien! Veel dank ook aan Angelique, Eva en alle secretaresses 
op de 5e dat ik voor alle grote en kleine vragen bij jullie aan mocht kloppen. David, 
jij hebt met je komst als bedrijfsleider bij de Neuro voor frisse energie gezorgd. 
Altijd gezellig om je tegen te komen bij de koffieautomaat.
Ik wil ook graag alle co-auteurs bedanken voor hun bijdrage aan de artikelen die 
in dit proefschrift staan. Zonder jullie ideeën, commentaren en suggesties had dit 
boekje er heel anders uit gezien! Loes, bedankt voor je hulp bij statistische analyses 
en vooral ook voor de gezelligheid in Cambridge, wat heb je een heerlijk gezin! 
Fijn om met een BMW’er van gedachten te kunnen wisselen en dank voor je vele 
adviezen. Ik vind het heel bijzonder dat je vandaag ook deel uitmaakt van mijn 
promotiecommissie. Karin, ik ben onder de indruk van de manier waarop jij 
discussies interessante wendingen weet te geven. Bedankt voor je adviezen en het 
kritisch opbouwend meedenken. Ewoud, je methodologische inbreng in de vasculaire 
meetings heb ik erg gewaardeerd. Het was fijn met je te kunnen discussiëren over 
de verschillen tussen etiologisch en prognostisch onderzoek. Edo en Floris, 
ondanks dat we geen stukken samen hebben geschreven, is jullie input wel 
degelijk van belang geweest voor de inhoud van dit boekje. Edo, ik weet nog goed 
dat je een aantal jaar geleden de neurovasculaire meetings binnenkwam met het 
motto: ‘Koekjes & thee, met Edo & FE’. Ik heb je wijze lessen (zoals van de wc-eend 
reclame) en je kritische maar positieve blik erg gewaardeerd. Floris, super leuk 
dat je naar Nijmegen bent gekomen! Altijd aanwezig bij borrels en met je creatieve 
ideeën ben je ook zeker een waardevolle toevoeging voor de vasculaire groep. Roy 
Kessels en Jurgen Claassen, bedankt voor jullie input tijdens de consensusmeet-
ings! Roy, ik heb veel geleerd van je kritische kijk op neuropsychologisch onderzoek 
en het was heel fijn dat je altijd bereid was om op een enthousiaste en opbouwende 
Anil, bedankt voor al je hulp met de ingewikkelde MRI analyses. Mixed feelings als 
jij de errors ook niet meteen kon oplossen: “Yes, Anil weet het ook niet meteen”, 
kort daarna gevolgd door: “Maar als Anil het al niet weet…”. Gelukkig wist je me 
altijd weer op weg te helpen, dank daarvoor!
Graag wil ik ook de leden van de manuscriptcommissie, Prof. dr. Olde Rikkert, 
Prof. dr. Wermer en Dr. Meijer, bedanken voor het beoordelen van mijn proefschrift.
Lieve paranimfen, ik voel me vereerd dat jullie vandaag naast mij staan. Precies 
zoals jullie dat de afgelopen jaren ook hebben gedaan. Het is dan ook niet meer 
dan logisch dat jullie mijn paranimfen zijn. 
 Lieve Inge, wat heb ik geluk gehad met jou als voorganger! Je hebt me wegwijs 
gemaakt in alle cognitieve testen en het was fijn om te weten dat ik altijd bij je aan 
mocht kloppen als ik toch nog vragen had. En met jou was het een stuk leuker om 
telkens weer de in totaal 1160 scans en segmentaties te controleren.. Super fijn dat 
je mij in de laatste fase van jouw onderzoek hebt betrokken, door het samen 
schrijven van jouw laatste en mijn eerste stuk. Dankzij jou heb ik echt een 
vliegende start kunnen maken en ik hoop dat ik op mijn beurt jouw verlof een 
klein beetje rustiger heb gemaakt :-). Maar nog meer wil ik je bedanken dat je zo’n 
fijne collega bent! Jij verzekerde me dat mijn data wel zou wachten tot ik me weer 
beter zou voelen en jij zorgde ervoor dat ik vaak heel hard kon lachen om alle on-
derzoeksfrustraties. Heel fijn om een klankbord te hebben en onze successen 
samen te vieren. Ik denk met veel plezier terug aan alle etentjes, borrels en de vele 
koffie- en theemomenten de afgelopen jaren en hoop dat er nog veel wijntjes 
zullen volgen! Ik ben heel trots dat jij vandaag als mijn paranimf naast me staat.
 Lieve Mayra, ik had me geen betere RUN DMC buddy kunnen wensen! Als ik 
dacht dat ik zelf al collegiaal was, heb jij dat nog eens met een factor 10 overtroffen. 
Zonder jouw vindingrijkheid, kritische blik, humor en daadkracht was de tweede 
follow-up van de RUN DMC studie nooit zo’n succes was geworden. Ik heb veel 
dierbare herinneringen aan alles wat we hebben meegemaakt tijdens de follow-up: 
deelnemers zoeken op de cardiologie, huisbezoeken in de weilanden, mooie 
tekeningen en ohja, wat fijn dat je naar de poes vraagt! Ik ben heel blij dat je ook 
vandaag naast me staat.
Veel dank aan het gehele RUN DMC team. De 1e generatie: Anouk, Karlijn en Rob, 
bedankt voor de bergen werk die jullie hebben verzet om alle 503 deelnemers in 
2006 te includeren in het RUN DMC onderzoek. Daar plukken we nog steeds elke 
dag de vruchten van! De 2e generatie: Inge, Ellen en Anil, bedankt voor alle moeite 
die jullie tijdens de eerste follow-up in 2011 hebben gedaan om de data zo 
zorgvuldig te verzamelen. Super bedankt dat jullie Mayra en mij zo goed op weg 
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kennen. Je bent een super fijne collega, altijd bereid om mee te denken en altijd in 
voor een borrel. Jij gaat het nog ver schoppen en ik weet zeker dat wij nog vaker 
biertjes gaan drinken! Merel, Lotte en Nienke, heel leuk dat ik nog zo lang met 
jullie onderzoek heb mogen doen. Ik heb echt een klik ervaren met jullie! Gaan we 
nog eens samen eten? Esther, kort maar krachtig, zullen we maar zeggen! Jammer 
dat we niet langer samen onderzoek hebben gedaan, de wijntjes en jouw humor 
smaakten naar meer ;-) Sabine, dank voor het havermoutkoekjes-recept! Mayte, ik 
heb echt met je gelachen! Er rust echt een vloek op ons en etentjes, waarschijnlijk 
ooit begonnen door die Franse “Lunch is over!” mevrouw tijdens mijn eerste 
congres in Nice, toen we na onze enerverende postersessie niet eens meer mochten 
genieten van ons welverdiende broodje brie... Dat etentje gaat er nog komen!
Speciale dank ook aan alle anderen van de vasculaire groep: Renate, Pauline, 
Noortje, Nathalie, Karin Kanselaar, Saskia, Sharon, Annet, Janneke, Frank, Joyce, 
Lieke, Selma, Jamie, Myrna, Wei en anderen, bedankt voor jullie input tijdens de 
vasculaire meetings en de gezelligheid tijdens de congressen in Nice, Glasgow, 
Barcelona, Boston, Amsterdam, Praag en Gothenburg. De villa’s waren echt een 
groot succes! In gedachten ben ik in Milaan nog steeds een beetje bij jullie..!
Aruna! Waar ik eerst dacht dat het na onze studententijd niet meer beter kon, heb 
ik het idee dat onze vriendschap na 10 jaar alleen maar hechter is geworden. Lieve 
Chantal, Imke, Jade, Jasmijn, Jonneke, Lindsey en Maud, jullie zijn me erg dierbaar 
en ik prijs me erg gelukkig met vriendinnen als jullie. Ik hoop dat we later als 
gerimpelde omaatjes nog steeds samen wijntjes zullen drinken. Aiuto!
LIEFerds, ook jullie kunnen hier natuurlijk niet ontbreken! Ik weet nog als de dag 
van gisteren hoe jullie mijn tweelingzusje in het complot hebben betrokken om 
me bij LIEF te vragen. Sindsdien zijn er vele borrels en weekenden verstreken en 
elke keer kijk ik er weer naar uit om bij te kletsen. Ik ervaar jullie betrokkenheid 
en oprechte interesse als heel fijn en bijzonder en ik hoop dan ook dat er nog veel 
gezellige kerstdiners zullen volgen!
Waterpolo is altijd een welkome afleiding geweest! Femke, Lois, Naomi, Laura, 
Babette, Kim, Lisan, Marit, Natasja, Renee, Floor, Maaike, Lynne en anderen, 
bedankt voor de gezelligheid in en om het water. Fem, altijd gezellig om weer bij 
te kletsen. Bart, Thijs, Eveline, Daniel, Lisan, Femke en Coen, de Kriekjes in Gent 
waren wat mij betreft zeker voor herhaling vatbaar! Naoom, jij hebt me de 
afgelopen jaren veel tijd en stress bespaard. Super bedankt voor je hulp!
manier mee te denken over de cognitieve testen en analyses. Dank dat je ook deel 
uit wil maken van de promotiecommissie. Jurgen, ik vond het leuk om met je 
samen te werken en een kijkje te nemen bij je geheugenpoli: een eyeopener en erg 
inspirerend, bedankt! David Norris, many thanks for your critical feedback and 
suggestions with respect to the neuroimaging analyses. It has been of major help. 
Bram Platel, bedankt voor de hulp vanuit de radiologie. Mohsen, many thanks for 
your help with the segmentations as well as for creating all figures and videos. Bea, 
vooral dankzij jouw geduldige uitleg ben ik niet totaal verdwaald geraakt in het 
biomarker-onderzoek met alle verschillende technieken en eiwitten. Door je 
nuchtere en kritische blik is het fijn om met je van gedachten te wisselen. Ik heb 
goede herinneringen aan het CAA congres in Boston met jou en Lieke! Iris, Hugo 
Vanderstichele en Eric Stoops, bedankt voor jullie hulp bij de plasma Aβ bepalingen. 
Anna, heel fijn dat ik het plasma Aβ stokje met een gerust hart aan jou kan 
overdragen. Nils Peters, it was only recently that we started collaborating. It was a 
pleasure meeting you and many thanks for your efforts! Marco Düring, many 
thanks for all discussions, both on small vessel disease and on cultural differences 
between the Dutch and the Germans. It was a pleasure meeting you! Eline, ik vond 
het heel leuk om overdag samen MRI scans te maken en ’s avonds met LIEF te 
borrelen. Bedankt voor je hulp bij de dataverzameling en de hippocampus- 
segmentaties. Ik vond het leuk om te zien dat je zo enthousiast werd van het 
onderzoek! Sjacky, bedankt voor je enthousiasme! Je hebt in korte tijd veel werk 
verzet en het was leuk om je er bij te hebben. Jan Willem, bedankt voor je bereidheid 
om te sparren over de analyses in R. Jij hebt echt een waardevolle gave om hele 
moeilijke dingen heel makkelijk uit te leggen, super fijn! Hugh Markus, thank you 
for the opportunity to work together in Cambridge. Jonathan, a special thanks to 
you for your help with all statistical analyses. Your nerdiness, enthusiasm and 
ideas are truly unlimited. I wish you all the best in your further career. Just one 
more question… :-) 
Lieve kamergenootjes, zonder jullie waren de afgelopen jaren op de 5e nooit zo 
gezellig geweest! Tessa, Kim, Mayte, Merel, Lotte, Nienke, Hanneke, Bonnie, Carlijn, 
Sabine, Marthe, Annemieke, Esther en Anna, bedankt voor de gezelligheid op de 
5e, voor alle theemomentjes en de gesprekken bij de koffieautomaat, dat ik af en 
toe ook mijn (onderzoeks)frustraties bij jullie kwijt mocht, en voor de leuke borrels 
en etentjes. 
Tessa, bedankt voor de gezellige theemomenten en je luisterend oor. Ik vond het 
heel leuk om ons promotietraject samen te doorlopen en heel fijn om het bijna 
tegelijk af te kunnen ronden. Ik vind het een hele eer dat ik jouw paranimf mag 
zijn! Ik wens je heel veel geluk toe in Amsterdam. Kim, waar ik jou eerst vooral 
kende als ‘zusje van’, heb ik jou tijdens je stage ook van een andere kant leren 
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we na bedtijd alsnog genoeg tijd hadden om bij te kletsen, alsof we elkaar de hele 
dag nog niet gezien hadden ;-) In Rome hebben we de tijd van ons leven gehad en 
nog steeds vind ik het echt heerlijk om samen wijntjes te drinken en honderduit 
te kletsen. Jij begrijpt me als geen ander en met niemand anders kan ik de ene 
keer een bloemkoolgesprek voeren en de andere keer mijn levensissues bespreken. 
Ik ben heel trots op je. Loveyou! 
Lieve papa en mama, ik ben jullie heel dankbaar voor de veilige thuishaven en de 
talloze kansen die jullie altijd hebben geboden. Dat heeft ervoor gezorgd dat ik 
vroeger altijd al het nieuwsgierig aagje uit kon hangen en dat ik nu nog steeds wat 
vaker een sprong in het diepe durf te wagen. Jullie hebben me geleerd te denken 
in mogelijkheden, dat met hard werken en een beetje creativiteit bijna alles 
mogelijk is. Het is fijn om te weten dat de deur bij jullie altijd open staat. Dank 
jullie wel!
Liefste vriendje! Mijn laatste woord van dank is aan jou, omdat je nog niet half 
weet hoe veel fijner en leuker je de afgelopen jaren voor mij hebt gemaakt. Jij helpt 
me relativeren als ik me overal druk om maak en zorgt voor rust als ik een 
onrustig hoofd heb. Ik ben je heel dankbaar voor de spiegel die je me vaak hebt 
voorgehouden. Er is niks leuker dan lekker gek doen en grappen met jou. Jij bent 
lief! 1000!
Menno en Saskia, ook jullie wil ik graag bedanken. Wat een lieverds zijn jullie! 
Wat een eer om jullie bruiloft van zo dichtbij mee te maken en wat heb ik genoten 
van onze vakantie in Frankrijk. Dank jullie wel voor jullie betrokkenheid en 
berichtjes. Ik wens jullie heel veel geluk met jullie knappe zoon Leo!
Lieve Im, wat ben ik blij met een vriendin als jij! Eigenlijk heb ik er met jou gewoon 
een derde zus bij, want wij lijken stiekem echt heel veel op elkaar. Daarnaast ben jij 
het levende n=1 bewijs dat telepathie daadwerkelijk bestaat; op de een of andere 
manier weet jij altijd precies wanneer je mij een berichtje moet sturen. Ik ben heel 
trots op je en vind het echt super lief dat je speciaal uit München bent gekomen 
om er vandaag bij te zijn. Zo gaan we onze tweemaandelijkse bezoekjes nog bijna 
halen ook!
Oma & Opa Luijckx, u vormt een prachtig voorbeeld voor mij. Ik heb dierbare 
herinneringen aan de etentjes en aan alle kerstdiners die “nu echt voor de laatste 
keer” in Restaurant De Braak waren. Ik vind het heel bijzonder dat u vandaag bij 
mijn promotie aanwezig kunt zijn.
Opa van Leijsen, ik heb veel goede herinneringen aan de Shetland pony’s. Ook van 
uw 90e verjaardag in de oude boerderij heb ik erg genoten. Ik kom zeker nog eens 
langs op de skeelers!
Jokelien en Fred, ik meen het echt als ik zeg dat ik me geen betere schoonouders 
had kunnen wensen. Wat een warm welkom in de familie. En wat is het fijn dat 
jullie zo meeleven. Dus doe voorzichtig, niet de chauffeur afleiden, we hebben 
maar één jokfred… Ewout, hippe Amsterdammer! Jouw discipline en passie voor 
wielrennen zijn bewonderenswaardig. Dankjewel voor je oprechte interesse. 
Sjoerd, wat een humor heb jij! Ik hoop dat ik nog heel vaak onder de tafel mag 
liggen door die goede grappen van jou.
Lieve Susan, mijn kleine zusje ben je al lang niet meer. Het fijne aan zusjes zijn, 
is dat je elkaar niet dagelijks hoeft te spreken om te weten dat je op elkaar kunt 
bouwen. Het is elke keer weer gezellig om bij te kletsen en ik weet dat je er altijd 
zult zijn als het nodig is. Je bent echt een lieverd en ik mag van geluk spreken met 
een zusje als jij. Ik hoop dat ik later ook zo’n goede fysio krijg :) Ik ben echt super 
trots op je! 
Lieve Miriam, het blijft bijzonder om een tweelingzusje en vriendin in één te 
hebben! Als kind waren we altijd al twee handen op één buik. Als kleine peuter 
sprong ik bij jou in de wieg en later zorgden we er met ons “Ahum, ahum” voor dat 
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Parkinson Center Nijmegen (ParC)
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• Maarten J. Nijkrake. Improving the quality of allied health care in Parkinson’s disease through 
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29 November 2010
• Rick C.G. Helmich. Cerebral reorganization in Parkinson’s disease. Radboud University Nijmegen, 
24 May 2011
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• Charlotte A. Haaxma. New perspectives on preclinical and early stage Parkinson’s disease. Radboud 
University Nijmegen, 6 December 2011
• Johanna G. Kalf. Drooling and dysphagia in Parkinson’s disease. Radboud University Nijmegen, 22 
December 2011
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• Marjolein B. Aerts. Improving diagnostic accuracy in parkinsonism. Radboud University Nijmegen, 27 
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• Maartje Louter. Sleep in Parkinson’s disease. A focus on nocturnal movements. Radboud University 
Nijmegen, 13 February 2015
• Frederick Anton Meijer. Clinical Application of Brain MRI in Parkinsonism: From Basic to Advanced 
Imaging, Radboud University Nijmegen, 23 June 2015
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Radboud University Nijmegen, 2 September 2015
• Martijn van der Eijk. Patient-centered care in Parkinson’s disease. Radboud University Nijmegen, 1 
December 2015
• Ingrid Sturkenboom. Occupational therapy for people with Parkinson’s disease: towards evidence-in-
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• Merel M. van Gilst. Sleep benefit in Parkinson’s disease. Radboud University Nijmegen, 13 April 2016
• Arno M. Janssen. Transcranial magnetic stimulation - measuring and modeling in health and disease. 
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Non-Parkinsonian disorders of movement
• Sacha Vermeer. Clinical and genetic characterization of autosomal recessive cerebellarataxias. Radboud 
University Nijmegen, 5 April 2012
• Susanne T. de Bot. Hereditary spastic paraplegias in the Netherlands. Radboud University Nijmegen, 20 
December 2013
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logical insights. Radboud University Nijmegen, 7 January 2014
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• Britt S Hofland. Investigating the role of the cerebellum in idiopathic focal dystonia, 22 March 2018
Neuromuscular disorders of movement
• Mireille van Beekvelt. Quantitative near infrared spectroscopy (NIRS) in human skeletal muscle. 
Radboud University Nijmegen, 24 April 2002
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University Nijmegen, 21 September 2005
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January 2010
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• M. Minis. Sustainability of work for persons with neuromuscular diseases. Radboud University 
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